14
|
MGC5466+Wnt5A+KIAA0476+ITPR1+TCF2
|
mRNA
|
Humans
|
Differentially Expressed in Recurrent Cancer
|
Prognostic
|
Recurrence Vs No Recurrence
|
p<0.0001
|
Tissue
|
15067324
|
15
|
MGC5466+CHAF1A+CDS2+IER3
|
mRNA
|
Humans
|
Differentially Expressed in Recurrent Cancer
|
Prognostic
|
Recurrence Vs No Recurrence
|
p<0.0001
|
Tissue
|
15067324
|
16
|
PPFIA3+COPEB+FOS+JUNB+ZFP36
|
mRNA
|
Humans
|
Differentially Expressed in Recurrent Cancer
|
Prognostic
|
Recurrence Vs No Recurrence
|
p=0.001
|
Tissue
|
15067324
|
17
|
MGC5466+Wnt5A+KIAA0476+ITPR1+TCF2+CHAF1A+CDS2+IER3+PPFIA3+COPEB+FOS+JUNB+ZFP36
|
mRNA
|
Humans
|
Differentially Expressed in Recurrent Cancer
|
Prognostic
|
Recurrence Vs No Recurrence
|
p<0.0001
|
Tissue
|
15067324
|
18
|
Insulin Like Growth Factor-1 (IGF-1)
|
Protein
|
Mice
|
Downregulated in SPI (soy protein isolate) diet: [Control: (223 ±61ng/ml; SPI Diet: 349 ±40 ng/ml )
|
Prognostic
|
PCa Mice fed Control Diet Vs PCa Mice fed soy protein isolate Diet
|
p<0.05
|
Serum
|
10460196
|
23
|
XLKD1/LYVE1+CGA+ F2R/PAR1+ BCL-G
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Patients with Relapse Vs Without Relapse
|
p<0.05
|
Tissue
|
14654526
|
24
|
Caveolin-1
|
Protein
|
Humans
|
Upregulated in African American Men (AA: 39% vs WA: 17%)
|
Prognostic
|
African Americans vs White American men with Prostate Cancer
|
p=0.0048
|
Tissue
|
10999725
|
27
|
BCL-2
|
Protein
|
Humans
|
Upregulated in High Gleason Score
|
Prognostic
|
High (8-10) vs Low (2-4) Gleason Score
|
p<0.001
|
Tissue
|
11500787
|
28
|
Insulin
|
Protein
|
Humans
|
Upregulated in High Risk Group
|
Prognostic
|
High vs (Medium and Low) Risk
|
p= 0.05
|
Serum
|
11757030
|
34
|
Triiodothyronine
|
Protein
|
Humans
|
Upregulated in High Risk Group
|
Prognostic
|
High vs Moderate Risk Group
|
p=0.041
|
Serum
|
12497024
|
35
|
Triiodothyronine
|
Protein
|
Humans
|
Upregulated in High Risk Group
|
Prognostic
|
High vs Low Risk Group
|
p=0.013
|
Serum
|
12497024
|
38
|
Annexin 1
|
Protein
|
Humans
|
Downregulated in Metastatic hormone refractory PCa (2.23 fold)
|
Prognostic
|
Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer
|
p<0.001
|
Tissue
|
12507908
|
39
|
Annexin 2
|
Protein
|
Humans
|
Downregulated in Metastatic hormone refractory PCa (1.51 fold)
|
Prognostic
|
Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer
|
p=0.009
|
Tissue
|
12507908
|
40
|
Annexin 4
|
Protein
|
Humans
|
Downregulated in Metastatic hormone refractory PCa (1.3 fold)
|
Prognostic
|
Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer
|
p=0.001
|
Tissue
|
12507908
|
41
|
Annexin 7
|
Protein
|
Humans
|
Downregulated in Metastatic hormone refractory PCa (1.42 fold)
|
Prognostic
|
Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer
|
p<0.001
|
Tissue
|
12507908
|
42
|
Annexin 11
|
Protein
|
Humans
|
Downregulated in Metastatic hormone refractory PCa (1.81 fold)
|
Prognostic
|
Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer
|
p<0.001
|
Tissue
|
12507908
|
44
|
Fatty Acid Synthase (FAS)
|
mRNA
|
Humans
|
Upregulated in Metastatic PCa (12 fold) [Mean Value: GS7 :149.2 Vs Metastatic: 1960.8]
|
Prognostic
|
Gleason Score 7 Vs Metastatic Tumor
|
p<0.00000029
|
Tissue
|
12939396
|
48
|
phosphorylated Akt (pAkt)
|
Protein
|
Humans
|
Upregulated in PSA failures (PSA Failure: [222.18±33.9 vs PSA Non-Failure: 108.79±104.57)
|
Prognostic
|
PSA failure versus PSA non failure
|
p<0.001
|
Tissue
|
15289328
|
49
|
phosphorylated Akt (pAkt) + phosphorylated ERK (extracellular signal-regulated kinase) (pERK)
|
Protein
|
Humans
|
pAKT: Upregulated in PSA failures; pERK: Downregulated in PSA failures
|
Prognostic
|
PSA failure versus PSA non failure
|
NA
|
Tissue
|
15289328
|
60
|
BCL-2
|
Protein
|
Humans
|
Upregulated in PCa Patients: PSA >10 ng/ml
|
Prognostic
|
PSA ≤10 ng/ml Vs PSA >10 ng/ml
|
p<0.01
|
Tissue
|
15655565
|
61
|
COX-2
|
Protein
|
Humans
|
Upregulated in PCa Patients: PSA >10 ng/ml
|
Prognostic
|
PSA ≤10 ng/ml Vs PSA >10 ng/ml
|
p<0.01
|
Tissue
|
15655565
|
62
|
BCL-2
|
Protein
|
Humans
|
Upregulated in Patients with relapse
|
Prognostic
|
PCa Relapse Vs No Relapse
|
p<0.01
|
Tissue
|
15655565
|
63
|
COX-2
|
Protein
|
Humans
|
Upregulated in Patients with relapse
|
Prognostic
|
PCa Relapse Vs No Relapse
|
p<0.01
|
Tissue
|
15655565
|
95
|
E-cadherin
|
Protein
|
Humans
|
Upregulated in Metastatic PCa: (Localised PCa: 9.46; Metastatic PCa: 27.49)
|
Prognostic
|
Localised PCa Vs Metastatic PCa
|
p<0.001
|
Serum
|
15870707
|
96
|
E-cadherin
|
Protein
|
Humans
|
Iincreased risk of late biochemical failure with high expression
|
Prognostic
|
Biochemical Faliure Vs No Biochemical Faliure
|
p<0.05
|
Serum
|
15870707
|
102
|
Methylation status of GSTP1
|
mRNA
|
Humans
|
Hypermethylated in Patients who relapsed
|
Prognostic
|
Time to Progression
|
p<0.03
|
Tissue
|
16322291
|
103
|
Methylation status of GSTP1
|
mRNA
|
Humans
|
Hypermethylated in Patients who relapsed
|
Prognostic
|
Time to Progression
|
P = 0.004
|
Tissue
|
16322291
|
104
|
Methylation status of APC
|
mRNA
|
Humans
|
Hypermethylated in Patients who relapsed
|
Prognostic
|
Time to Progression
|
P = 0.004
|
Tissue
|
16322291
|
105
|
Methylation status of GSTP1
|
mRNA
|
Humans
|
Hypermethylated in Patients who relapsed
|
Prognostic
|
Time to Progression
|
P = 0.01
|
Tissue
|
16322291
|
106
|
Methylation status of Cyclin D2 + APC
|
mRNA
|
Humans
|
Hypermethylated in Patients who relapsed
|
Prognostic
|
Time to Progression
|
0.01
|
Tissue
|
16322291
|
114
|
PCDH7, NRXN3, TPTE/ PTEN2, EPHA3, TSPY, HGF, PKIA, PRLR, NR2F1, TNS, MET, CALN1, ADAM-TS3, NPL4, MYO3A, GNA11, GAGEB1/PA GE1, AKAP9, TCF4, MYLK, KLK2, HOXA10, DDR2, EGF, TEM8, XAGE-1, GAS2.
|
mRNA
|
Humans
|
Upregulated (Log2 fold change: 2-7.9 fold)
|
Prognostic
|
Androgen Independent PCa Vs Androgen Dependent PCa
|
NA
|
Cell Lines
|
17977648
|
115
|
ANGPT2, THBS1, CCL5, PTK6, CXCL11, S100P, PSMD5, CDKN2B, PEG3, HTATIP2, CXCL2, RND1, NK4, ACPP, ICAM1, FOSL2, SFN, PLAT, INHBE, CDKN1C, TP73, SOCS2, BMPR1B, CCL2, VIM, SPRY2, CXCL10, LCN2, AKAP12, KLF4, ATF3, FBN1, TWIST1, ALCAM, MSX2, LOX, BTG1, SOCS1, PPP3CA, PPP3CA
|
mRNA
|
Humans
|
Downregulated (Log2 fold change: 1.3-7.8 fold)
|
Prognostic
|
Androgen Independent PCa Vs Androgen Dependent PCa
|
NA
|
Cell Lines
|
17977648
|
117
|
ααCTX
|
Protein
|
Humans
|
Upregulated in Bone Metastatis PCa
|
Prognostic
|
Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer
|
p<0.05
|
Urine
|
16434583
|
118
|
ββCTX
|
Protein
|
Humans
|
Upregulated in Bone Metastatis PCa
|
Prognostic
|
Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer
|
p<0.05
|
Urine
|
16434583
|
119
|
NTx
|
Protein
|
Humans
|
Upregulated in Bone Metastatis PCa
|
Prognostic
|
Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer
|
p<0.05
|
Urine
|
16434583
|
120
|
ICTP
|
Protein
|
Humans
|
Upregulated in Bone Metastatis PCa
|
Prognostic
|
Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer
|
p<0.05
|
Serum
|
16434583
|
121
|
BSAP
|
Protein
|
Humans
|
Upregulated in Bone Metastatis PCa
|
Prognostic
|
Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer
|
p<0.05
|
Serum
|
16434583
|
122
|
TRAP5b
|
Protein
|
Humans
|
Upregulated in Bone Metastatis PCa
|
Prognostic
|
Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer
|
p<0.05
|
Serum
|
16434583
|
125
|
Neuropeptide Y (NPY)
|
Protein
|
Humans
|
Upregulated in Gleason Pattern 4
|
Prognostic
|
Gleason Pattern 3 Vs Gleason Pattern 4
|
p=0.042
|
Tissue
|
16614113
|
126
|
Neuropeptide Y (NPY)
|
Protein
|
Humans
|
Upregulated in Gleason Pattern 5
|
Prognostic
|
Gleason Pattern 4 Vs Gleason Pattern 5
|
p=0.037
|
Tissue
|
16614113
|
127
|
Neuropeptide Y (NPY)
|
Protein
|
Humans
|
Increased expression with increase in relapse
|
Prognostic
|
Relapse Vs No Relapse after Radical Prosteactomy
|
p=0.037
|
Tissue
|
16614113
|
130
|
Macrophage Inhibitory Cytokine-1 (MIC-1)
|
Protein
|
Humans
|
Increased expression with increase in relapse
|
Prognostic
|
Relapse Vs No Relapse after Radical Prosteactomy
|
p=0.037
|
Tissue
|
16614113
|
133
|
PTGS2
|
Other
|
Humans
|
Increased expression with increase in relapse
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p = 0.0395
|
Serum
|
17764114
|
134
|
Fusion Status of TMPRSS2-ERG
|
mRNA
|
Humans
|
Fusion of the genes in Positive Biopsy PCa
|
Prognostic
|
Positive Vs Negative Biopsies for PCa
|
NA
|
Urine
|
17785564
|
135
|
PCA3
|
mRNA
|
Humans
|
Upregulated in Positive Biopsy PCa
|
Prognostic
|
Positive Vs Negative Biopsies for PCa
|
NA
|
Urine
|
17785564
|
139
|
CCNE2+CDC6+FBP1+HOXC6+MKI67+MYBL2+PTTG1+DTL+UBE2C+WNT5A+ALCAM+AZGP1+CCK+MYLK+PPAP2B+PROK1
|
mRNA
|
Humans
|
Increased GEX Score with relapse
|
Prognostic
|
Relapse Vs No Relapse
|
p=0.007
|
Tissue
|
17459658
|
215
|
Endothelial cell-specific molecule 1; Protein tyrosine phosphatase receptor type-Q, CD24 antigen; Gap junction membrane channel protein alpha 1; Transmembrane 4 superfamily member 3; Serpine2; Activated leukocyte cell adhesion molecule; Fibromodulin; Plasminogen activator inhibitor 2 type A; Kelch repeat and BTB (POZ) domain containing 10 (krp1); Preproenkephalin, related sequence; Sialophorin; Thymosin beta-4; Glutamate receptor interacting protein 1; Synuclein, gamma; Hypoxanthine guanine phosphoribosyl transferase; Phosphoribosyl pyrophosphate synthetase 1; Phosphoribosyl pyrophosphate synthetase 2; UDP-Gal:betaGlcNAc beta1,4-galactosyltransferase, polypeptide 6; Dual specificity phosphatase 5; Cytochrome P450, family 3, subfamily a, polypeptide 13; 3-hydroxy-3-methylglutaryl-Coenzyme A reductase ; Branched chain keto acid dehydrogenase E1, beta polypeptide; Cytochrome P450, subfamily 24; Plasminogen activator, urokinase; Caveolin 1; Cyclin D1; High mobility group AT-hook 1; Cxxc5; HNF-3/forkhead homolog-1; Fatty acid binding protein 4, adipocyte; Fatty acid binding protein 5, epidermal; Rabin 3; Phospholipase C, delta 4; Decay-accelarating factor; Coagulation factor II (thrombin) receptor-like 1; Nerve growth factor receptor associated protein 1; Asparagine synthetase; Dual specificity phosphatase 6; Protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), beta isoform; Protein tyrosine phosphatase, receptor type, N1; UDP glycosyltransferase 1 family polypeptide A2; Adenosine monophosphate deaminase 3; Stearoyl-Coenzyme A desaturase 1; Hypothetical LOC290595 (LOC290595), mRNA; Similar to Tubulin alpha-4 chain (Alpha-tubulin 4) (LOC316531), mRNA; Similar to chromosome 14 open reading frame 50 (LOC299153), mRNA; Guanine nucleotide binding protein beta 4 subunit mRNA, partial cds;
|
mRNA
|
Rat
|
Upregulated (Endothelial cell-specific molecule 1 (26.5 fold); Protein tyrosine phosphatase receptor type Q (19.72 fold); CD24 antigen (15.56 fold); Gap junction membrane channel protein alpha 1 (10.53 fold); Transmembrane 4 superfamily member 3 (10.4 fold); Serpine2 (8.61 fold); Activated leukocyte cell adhesion molecule (6.65 fold) ; Fibromodulin (2.62 fold); Plasminogen activator inhibitor 2 type A (2.11 fold); Kelch repeat and BTB (POZ) domain containing 10 (krp1) (36.21 fold); Preproenkephalin, related sequence (24.63 fold); Sialophorin1 (24.14 fold); Thymosin beta-4 (19.82 fold) ; Glutamate receptor interacting protein 1 (8.4 fold) ; Synuclein, gamma (6.62 fold); Hypoxanthine guanine phosphoribosyl transferase (11.45 fold); Phosphoribosyl pyrophosphate synthetase 1 (8.25 fold) ; Phosphoribosyl pyrophosphate synthetase 2 (5.37 fold); UDP-Gal:betaGlcNAc beta1,4-galactosyltransferase, polypeptide 6 (3.4 fold); Dual specificity phosphatase 5 (2.35 fold); Cytochrome P450, family 3, subfamily a, polypeptide 13 (14.28 fold); 3-hydroxy-3-methylglutaryl-Coenzyme A reductase (3.49 fold) ; Branched chain keto acid dehydrogenase E1, beta polypeptide (2.14 fold); Cytochrome P450, subfamily 24 (2.11 fold); Plasminogen activator, urokinase (4.68 fold); Caveolin 1 (31.05 fold) ; Cyclin D1 (7.95 fold); High mobility group AT-hook 1 (15.41 fold) ; Cxxc5 (4.25 fold); HNF-3/forkhead homolog-1 (3.08 fold); Fatty acid binding protein 4, adipocyte (34.02 fold); Fatty acid binding protein 5, epidermal (15.38 fold) ; Rabin 3 (6.46 fold); Phospholipase C, delta 4 (2.64 fold); Decay-accelarating factor (4.02 fold); Coagulation factor II (thrombin) receptor-like 1 (4.96 fold); Nerve growth factor receptor associated protein 1 (8.75 fold); Asparagine synthetase (14.65 fold); Dual specificity phosphatase 6 (11.08 fold); Protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), beta isoform (2.31 fold) ; Protein tyrosine phosphatase, receptor type, N1 (2.22 fold); UDP glycosyltransferase 1 family polypeptide A21 (5.93 fold); Adenosine monophosphate deaminase 3 (2.14 fold); Stearoyl-Coenzyme A desaturase 1 (25.92 fold); Hypothetical LOC290595 (LOC290595), mRNA (8.46 fold); Similar to Tubulin alpha-4 chain (Alpha-tubulin 4) (LOC316531), mRNA (4.76 fold); Similar to chromosome 14 open reading frame 50 (LOC299153), mRNA (3.58 fold); Guanine nucleotide binding protein beta 4 subunit mRNA, partial cds (3.38 fold);
|
Prognostic
|
MAT-LyLu Vs G Cell Lines
|
p<0.005
|
Cell Lines
|
17713630
|
216
|
Procollagen, type XII, alpha 1; Glycoprotein Ib (platelet), beta polypeptide; Macrophage stimulating 1 (hepatocyte growth factor-like); Alpha-2-macroglobulin; Hyaluronan and proteoglycan link protein 1; Glycoprotein 38; Decorin; Vascular cell adhesion molecule 1; Clusterin; Elastin; Biglycan; Selenoprotein P, plasma, 1; T-cell receptor gamma chain; Myxovirus (influenza virus) resistance 2; Major histocompatibility complex, class II, DM alpha; MHC class Ib RT1.S3; RT1 class Ib, locus Aw2; Similar to interferon regulatory factor 7 (LOC293624), mRNA; Late gestation lung protein 1; Transgelin; Ectonucleoside triphosphate diphosphohydrolase 2; Dual specificity phosphatase 1; Cytochrome b-245, alpha polypeptide; 3-alpha-hydroxysteroid dehydrogenase; Cathepsin S; Alanyl (membrane) aminopeptidase; Dipeptidase 1 (renal); Caspase 1; B-cell translocation gene 3; CD 81 antigen; Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA; Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA; LIM homeobox protein 2; Lectin, galactose binding, soluble 9; apolipoprotein E; Ubiquitin carboxy-terminal hydrolase L1; Parvalbumin; Purkinje cell protein 4; Carboxylesterase 1; O-6-methylguanine-DNA methyltransferase; UDP glycosyltransferase 1 family, polypeptide A6; Endothelial differentiation, sphingolipid G-protein-coupled 29415 -2.27 0.003533 receptor, 5; Growth hormone receptor; Insulin-like growth factor 1; Insulin-like growth factor binding protein 5; Peripherin 1; Arginosuccinate synthetase; Lactate dehydrogenase B; Calcium/calmodulin-dependent serine protein kinase; Aminolevulinic acid synthase 1; 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2; Alcohol Dehydrogenase 1; Phosphodiesterase 3B; Similar to kelch domain containing 3; testis intracellular 363192 -2.17 0.03046 mediator protein (LOC363192), mRNA; Similar to cornichon-like protein (LOC361705), mRNA; Similar to RNA-binding protein with multiple splicing 361161 -2.81 0.024735 (RBP-MS) (LOC361161), mRNA; Similar to CLN6 protein (LOC315746), mRNA; Reticulocalbin 3; Similar to CG31613-PA (LOC364716), mRNA;
|
mRNA
|
Rat
|
Downregulated (Procollagen, type XII, alpha 1 (2.18 fold); Glycoprotein Ib (platelet), beta polypeptide (2.5 fold); Macrophage stimulating 1 (hepatocyte growth factor-like) (2.61 fold); Alpha-2-macroglobulin (3.8 fold); Hyaluronan and proteoglycan link protein 1 (3.82 fold); Glycoprotein 38 (3.87 fold); Decorin (5.74 fold); Vascular cell adhesion molecule 1 (7.82 fold); Clusterin (8.84 fold); Elastin (12.76 fold); Biglycan (13.23 fold); Selenoprotein P, plasma, 1 (23.08 fold); T-cell receptor gamma chain (2.2 fold); Myxovirus (influenza virus) resistance 2 (2.22 fold) ; Major histocompatibility complex, class II, DM alpha (2.37 fold); MHC class Ib RT1.S3 (4.8 fold) ; RT1 class Ib , locus Aw2 (5.18 fold); Similar to interferon regulatory factor 7 (LOC293624), mRNA (6.14 fold); Late gestation lung protein 1 (2.26 fold); Transgelin (5.72); Ectonucleoside triphosphate diphosphohydrolase 2 (2.7 fold); Dual specificity phosphatase 1 (2.3 fold); Cytochrome b-245, alpha polypeptide (3.64 fold); 3-alpha-hydroxysteroid dehydrogenase (4.86 fold); Cathepsin S (2.33 fold); Alanyl (membrane) aminopeptidase (3.18 fold); Dipeptidase 1 (renal) (6.82 fold); Caspase 1 (11.12 fold); B-cell translocation gene 3 (17.35 fold); CD 81 antigen (36 fold); Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA (2.28 fold); Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA (2.62 fold); LIM homeobox protein 2 (5.43 fold); Lectin, galactose binding, soluble 9 (2.46 fold); apolipoprotein E (29.52 fold); Ubiquitin carboxy-terminal hydrolase L1 (16.29 fold); Parvalbumin (3.85 fold); Purkinje cell protein 4 (6.82 fold); Carboxylesterase 1 (2.16 fold); O-6-methylguanine-DNA methyltransferase (4.62 fold); UDP glycosyltransferase 1 family, polypeptide A6 (3.25 fold); Endothelial differentiation, sphingolipid G-protein-coupled 29415 -2.27 0.003533 receptor, 5 (2.27 fold); Growth hormone receptor (3.12 fold); Insulin-like growth factor 1 (4.85 fold); Insulin-like growth factor binding protein 5 (5.25 fold); Peripherin 1 (7.17 fold); Arginosuccinate synthetase (12.75 fold); Lactate dehydrogenase B (15.07 fold); Calcium/calmodulin-dependent serine protein kinase (4.13 fold); Aminolevulinic acid synthase 1 (2.39 fold); 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (3.17 fold); Alcohol Dehydrogenase 1 (6.38 fold); Phosphodiesterase 3B (4.76 fold); Similar to kelch domain containing 3 testis intracellular 363192 -2.17 0.03046 mediator protein (LOC363192), mRNA (2.17 fold); Similar to cornichon-like protein (LOC361705), mRNA (2.35 fold); Similar to RNA-binding protein with multiple splicing 361161 -2.81 0.024735 (RBP-MS) (LOC361161), mRNA (2.81 fold); Similar to CLN6 protein (LOC315746), mRNA (3.68 fold); Reticulocalbin 3 (3.94 fold); Similar to CG31613-PA (LOC364716), mRNA (8.61 fold);
|
Prognostic
|
MAT-LyLu Vs G Cell Lines
|
p<0.005
|
Cell Lines
|
17713630
|
217
|
Kelch repeat and BTB (POZ) domain containing 10 (krp1)
|
mRNA
|
Rat
|
Upregulated in MAT-LyLu (48 fold)
|
Prognostic
|
MAT-LyLu Vs G Cell Lines
|
p=0.01816
|
Cell Lines
|
17713630
|
218
|
Endothelial cell-specific molecule 1
|
mRNA
|
Rat
|
Upregulated in MAT-LyLu (23 fold)
|
Prognostic
|
MAT-LyLu Vs G Cell Lines
|
p=0.00995283
|
Cell Lines
|
17713630
|
219
|
Caveolin 1
|
mRNA
|
Rat
|
Upregulated in MAT-LyLu (45 fold)
|
Prognostic
|
MAT-LyLu Vs G Cell Lines
|
p=0.0009527
|
Cell Lines
|
17713630
|
234
|
Metaclassifier: ENC1+GJB1+MYO6+AMACR+TSPAN13+PRKCBP+C20ORF74+DAPK1+IMAGE:396839 + ENC1
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Benign Prostate Vs Prostate Cancer
|
p<0.0005
|
Tissue
|
17460773
|
235
|
ARL6IP+MYH11
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Primary Vs Metastatic Prostate Cancer
|
NA
|
Tissue
|
17460773
|
248
|
PI3-K p85 α
|
mRNA
|
Humans
|
Downregulated in Gleason Score 7-10
|
Prognostic
|
Gleason Score 5-6 Vs Gleason Score 7-10
|
p<0.05
|
Tissue
|
18336616
|
249
|
ILK
|
mRNA
|
Humans
|
Downregulated in Gleason Score 7-11
|
Prognostic
|
Gleason Score 5-6 Vs Gleason Score 7-10
|
p<0.05
|
Tissue
|
18336616
|
250
|
PTEN
|
mRNA
|
Humans
|
Downregulated in Gleason Score 7-12
|
Prognostic
|
Gleason Score 5-6 Vs Gleason Score 7-10
|
p<0.05
|
Tissue
|
18336616
|
251
|
PHLPP
|
mRNA
|
Humans
|
Downregulated in Gleason Score 7-13
|
Prognostic
|
Gleason Score 5-6 Vs Gleason Score 7-10
|
p<0.05
|
Tissue
|
18336616
|
252
|
FOXO1A
|
mRNA
|
Humans
|
Downregulated in Gleason Score 7-14
|
Prognostic
|
Gleason Score 5-6 Vs Gleason Score 7-10
|
p<0.05
|
Tissue
|
18336616
|
254
|
C-reactive protein (CRP)
|
Protein
|
Humans
|
Increased in Overall Survival
|
Prognostic
|
Overall Survival Vs No Survival
|
p<0.0001
|
Plasma
|
18428198
|
255
|
C-reactive protein (CRP)
|
Protein
|
Humans
|
Increased in Overall Survival
|
Prognostic
|
PSA Decline Vs No PSA decline
|
p=0.0068
|
Plasma
|
18428198
|
258
|
NRP1
|
mRNA
|
Humans
|
Upregulated in Aggressive Prostate Cancer
|
Prognostic
|
Non Aggressive Vs Aggressive prostate cancer phenotype
|
p=0.007
|
Tissue
|
18347174
|
259
|
TOP2A
|
mRNA
|
Humans
|
Upregulated in Aggressive Prostate Cancer
|
Prognostic
|
Non Aggressive Vs Aggressive prostate cancer phenotype
|
p<0.0001
|
Tissue
|
18347174
|
260
|
RRM2
|
mRNA
|
Humans
|
Upregulated in Aggressive Prostate Cancer
|
Prognostic
|
Non Aggressive Vs Aggressive prostate cancer phenotype
|
p<0.0001
|
Tissue
|
18347174
|
261
|
KHRDSB3
|
mRNA
|
Humans
|
Upregulated in Aggressive Prostate Cancer
|
Prognostic
|
Non Aggressive Vs Aggressive prostate cancer phenotype
|
p=0.015
|
Tissue
|
18347174
|
262
|
SSTR1
|
mRNA
|
Humans
|
Upregulated in Aggressive Prostate Cancer
|
Prognostic
|
Non Aggressive Vs Aggressive prostate cancer phenotype
|
p=0.006
|
Tissue
|
18347174
|
276
|
Fusion Status of TMPRSS2:ERG
|
mRNA
|
Humans
|
Increased fusion in patients with biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence
|
p=0.0523
|
Tissue
|
18500259
|
277
|
Mutation of PTEN
|
mRNA
|
Humans
|
Deletion found in patients with Biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence
|
p=0.0009
|
Tissue
|
18500259
|
278
|
Fusion Status of TMPRSS2:ERG + PTEN deletion
|
mRNA
|
Humans
|
Fusion + Deletion
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence
|
p=0.001
|
Tissue
|
18500259
|
279
|
Fusion Status of TMPRSS2:ERG + PTEN deletion
|
mRNA
|
Humans
|
Fusion + Deletion
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence
|
p=0.036
|
Tissue
|
18500259
|
350
|
Transforming growth factor-β1 (TGF-β1)
|
Protein
|
Humans
|
Increased with Biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence in 5 years
|
p<0.001
|
Plasma
|
18559597
|
351
|
soluble IL-6 receptor (sIL-6R)
|
Protein
|
Humans
|
Increased with Biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence in 5 years
|
p<0.001
|
Plasma
|
18559597
|
352
|
IL-6
|
Protein
|
Humans
|
Increased with Biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence in 5 years
|
p<0.001
|
Plasma
|
18559597
|
353
|
Vascular endothelial growth factor (VEGF)
|
Protein
|
Humans
|
Increased with Biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence in 5 years
|
Univariate: p= 0.002; Multivariate: p=0.008
|
Plasma
|
18559597
|
354
|
Vascular cell adhesion molecule-1 (VCAM-1)
|
Protein
|
Humans
|
Increased with Biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence in 5 years
|
p<0.001
|
Plasma
|
18559597
|
355
|
Endoglin
|
Protein
|
Humans
|
Increased with Biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence in 5 years
|
Univariate: p<0.001Multivariate: p=0.002
|
Plasma
|
18559597
|
356
|
Urokinase-type plasminogen activator (uPA)
|
Protein
|
Humans
|
Increased with Biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence in 5 years
|
p<0.001
|
Plasma
|
18559597
|
357
|
uPA receptor (uPAR)
|
Protein
|
Humans
|
Increased with Biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence in 5 years
|
Univariate: p<0.001; Multivariate: p=0.05
|
Plasma
|
18559597
|
358
|
TGF-β1 + sIL-6R + IL-6 + VCAM-1 + VEGF + endoglin + uPA + PAI-1 + uPAR
|
Protein
|
Humans
|
Increased with Biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence in 5 years
|
NA
|
Plasma
|
18559597
|
359
|
TGF-β1 + sIL-6R + IL-6 + VCAM-1 + VEGF + endoglin + uPA
|
Protein
|
Humans
|
Increased with Biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence in 5 years
|
NA
|
Plasma
|
18559597
|
360
|
IL-8
|
Protein
|
Humans
|
Upregulated in Recurrent Group (Recurrent Group: 181.1 ± 89.3; Non Recurrent Group: 96.4 ± 85.6)
|
Prognostic
|
Reccurance Free Survival Vs Recurrance in 5 years
|
p<0.001
|
Tissue
|
18593988
|
361
|
Osteopontin
|
Protein
|
Humans
|
Upregulated in Recurrent Group (Recurrent Group: 203.2 ± 78.4; Non Recurrent Group: 127.76 ± 76.6)
|
Prognostic
|
Reccurance Free Survival Vs Recurrance in 5 years
|
p<0.001
|
Tissue
|
18593988
|
362
|
IL8 + Osteopontin
|
Protein
|
Humans
|
Upregulated in Recurrent Group
|
Prognostic
|
Reccurance Free Survival Vs Recurrance in 5 years
|
p<0.001
|
Tissue
|
18593988
|
365
|
CD31
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Progression Vs No Progression
|
p=0.009
|
Tissue
|
18767028
|
366
|
Ki67
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Progression Vs No Progression
|
p=0.003
|
Tissue
|
18767028
|
367
|
Her-2/neu
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Progression Vs No Progression
|
p=0.006
|
Tissue
|
18767028
|
368
|
CD31
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Progression Vs No Progression
|
p=0.001
|
Tissue
|
18767028
|
369
|
Ki67
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Progression Vs No Progression
|
p=0.03
|
Tissue
|
18767028
|
370
|
PCNA
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Progression Vs No Progression
|
p=0.03
|
Tissue
|
18767028
|
371
|
Her-2/neu
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Progression Vs No Progression
|
p=0.049
|
Tissue
|
18767028
|
372
|
CD31
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Progression Vs No Progression
|
p=0.028
|
Tissue
|
18767028
|
373
|
Her-2/neu
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Progression Vs No Progression
|
p=0.025
|
Tissue
|
18767028
|
374
|
Ki67
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Progression Vs No Progression
|
p=0.027
|
Tissue
|
18767028
|
375
|
Her-2/neu
|
Protein
|
Humans
|
Negative Staining in Patients with Progression Free Survival
|
Prognostic
|
Progression Free Survival Vs No Progression Survival
|
p=0.001
|
Tissue
|
18767043
|
376
|
Her-2/neu
|
Protein
|
Humans
|
Negative Staining in Patients with Metastatic Free Survival
|
Prognostic
|
Metastatic Vs Non Metastatic Prostate cancer
|
p=0.002
|
Tissue
|
18767043
|
377
|
Her-2/neu
|
Protein
|
Humans
|
Negative Staining in Patients with PCa Death Free Survival
|
Prognostic
|
PCa Specific Death Vs No PCa Specific Death
|
p=0.021
|
Tissue
|
18767043
|
385
|
TMPRSS2:ERG
|
mRNA
|
Humans
|
Fused in Prostate Cancer
|
Prognostic
|
(Benign Samples + Gleason sums < 7) Vs ≥ 7
|
p<0.05
|
Expressed Prostatic Secretion
|
18948370
|
394
|
Ornithine Decarboxylase (ODC) + Ornithine Decarboxylase antizyme (OAZ) +Adenosylmethionine Decarboxylase (AdoMetDC)+ Spermidine/Spermine N(1)-acetyltransferase (SSAT)+ histone H3 (H3)+ growth arrest specific gene (GAS1)+glyceraldehyde 3-phosphate dehydrogenase (GAPDH) + Clusterin (CLU)
|
mRNA
|
Humans
|
Downgregulated in PCa: (GAS1,SSAT, CLU, OAZ, GAPDH); Upregulated in PCa (H3, ODC)
|
Prognostic
|
Gleason Score <7 Vs Gleason Score ≥ 7
|
NA
|
Tissue
|
18974881
|
395
|
CCL4
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Biochemical Recurrence Vs No Recurrence
|
p=0.011
|
Tissue
|
19047106
|
396
|
CX3CL1
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Biochemical Recurrence Vs No Recurrence
|
p<0.0001
|
Tissue
|
19047106
|
397
|
CCL4
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Recurrence Free Survival Vs No Recurrence Free Survival
|
p=0.04
|
Tissue
|
19047106
|
398
|
CX3CL1
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Recurrence Free Survival Vs No Recurrence Free Survival
|
p<0.0001
|
Tissue
|
19047106
|
399
|
PSA+Surgical Margins+ seminal vesicle invasion+ Gleason Score+CX3CL1+CCL4+IL-15
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Biochemical Recurrence Vs No Recurrence
|
NA
|
Tissue
|
19047106
|
406
|
Androgen Receptor (AR)
|
mRNA
|
Humans
|
Upregulated in Hormone Refactory Prostate Cancer (11 fold)
|
Prognostic
|
Hormone Naive Vs Hormone Refractory Prostate Cancer
|
p<0.0001
|
Tissue
|
19117982
|
407
|
Androgen Receptor AR-V1
|
mRNA
|
Humans
|
Upregulated in Hormone Refactory Prostate Cancer (22 fold)
|
Prognostic
|
Hormone Naive Vs Hormone Refractory Prostate Cancer
|
p<0.0001
|
Tissue
|
19117982
|
408
|
Androgen Receptor AR-V7
|
mRNA
|
Humans
|
Upregulated in Hormone Refactory Prostate Cancer (20 fold)
|
Prognostic
|
Hormone Naive Vs Hormone Refractory Prostate Cancer
|
p<0.0001
|
Tissue
|
19117982
|
409
|
Androgen Receptor AR-V7
|
mRNA
|
Humans
|
Higher expression in patients with biochemical recurrence
|
Prognostic
|
PSA Recurrence Vs No PSA Recurrence
|
p=0.012
|
Tissue
|
19117982
|
410
|
Methylation Status of RARB2
|
Methylation
|
Humans
|
Methylated in Stage IV PCa
|
Prognostic
|
PCa stage I-III VS PCa Stage IV
|
p=0.027
|
Serum
|
19131636
|
411
|
Methylation Status of GSTP1
|
Methylation
|
Humans
|
Methylated in Stage IV PCa
|
Prognostic
|
PCA stage I-III VS PCA Stage IV
|
p=0.019
|
Serum
|
19131636
|
412
|
Methylation Status of GSTP1+RARB2
|
Methylation
|
Humans
|
Methylated in Stage IV PCa
|
Prognostic
|
PCA stage I-III VS PCA Stage IV
|
p=0.019
|
Serum
|
19131636
|
413
|
PSA +C4a lacking the C-terminal arginine (C4a des-Arg) + N-terminal fragment of PCI
|
Protein
|
Humans
|
Upregulated in PCa: [C4a lacking the C-terminal arginine (C4a des-Arg)];Downregulated in PCa: [N-terminal fragment of PCI]
|
Prognostic
|
Recurrence Vs No recurrence for 5 years
|
Training: p=0.012 Testing: p=0.011
|
Serum
|
19157448
|
417
|
Transforming growth factor-b1
|
Protein
|
Humans
|
Increased Expression with Biochemical Recurrence
|
Prognostic
|
Recurrence Vs No recurrence for 5 years
|
Univariate: p<0.001; Multivariate: p=0.003
|
Plasma
|
19229851
|
418
|
Interleukin-6 soluble receptor ((IL-6sR)
|
Protein
|
Humans
|
Increased Expression with Biochemical Recurrence
|
Prognostic
|
Recurrence Vs No recurrence for 5 years
|
Univariate: p<0.001; Multivariate: p=0.001
|
Plasma
|
19229851
|
419
|
Interleukin-6 (IL-6)
|
Protein
|
Humans
|
Increased Expression with Biochemical Recurrence
|
Prognostic
|
Recurrence Vs No recurrence for 5 years
|
Univariate: p<0.001
|
Plasma
|
19229851
|
420
|
Vascular cell adhesion molecular 1 (VCAM 1)
|
Protein
|
Humans
|
Increased Expression with Biochemical Recurrence
|
Prognostic
|
Recurrence Vs No recurrence for 5 years
|
p<0.001
|
Plasma
|
19229851
|
421
|
Vascular endothelial growth factor (VEGF)
|
Protein
|
Humans
|
Increased Expression with Biochemical Recurrence
|
Prognostic
|
Recurrence Vs No recurrence for 5 years
|
p=0.002
|
Plasma
|
19229851
|
422
|
Endoglin
|
Protein
|
Humans
|
Increased Expression with Biochemical Recurrence
|
Prognostic
|
Recurrence Vs No recurrence for 5 years
|
p<0.001
|
Plasma
|
19229851
|
423
|
Urokinase-type plasminogen activator (uPA)
|
Protein
|
Humans
|
Increased Expression with Biochemical Recurrence
|
Prognostic
|
Recurrence Vs No recurrence for 5 years
|
Univariate: p<0.001; Multivariate: p=0.036
|
Plasma
|
19229851
|
424
|
Urokinase-type plasminogen activator receptor (uPAR)
|
Protein
|
Humans
|
Increased Expression with Biochemical Recurrence
|
Prognostic
|
Recurrence Vs No recurrence for 5 years
|
p<0.001
|
Plasma
|
19229851
|
425
|
Gleason sum +TGFB1+ IL-6sR +VCAM1+uPA
|
Protein
|
Humans
|
Increased Expression with Biochemical Recurrence
|
Prognostic
|
Recurrence Vs No recurrence for 5 years
|
NA
|
Plasma
|
19229851
|
426
|
p53
|
Protein
|
Humans
|
Increased Expression with PCa Specific Death
|
Prognostic
|
Prostate Cancer Specific Survival Vs No Survival
|
Univariate: p<0.001; Multivariate: p=0.03;
|
Tissue
|
19239456
|
427
|
p53
|
Protein
|
Humans
|
Increased Expression with Overall Death
|
Prognostic
|
Overall Survival Vs No Survival
|
Univariate: p<0.001; Multivariate: p=0.001;
|
Tissue
|
19239456
|
428
|
p53
|
Protein
|
Humans
|
Increased Expression with PCa Specific Death
|
Prognostic
|
Prostate Cancer Specific Survival Vs No Survival
|
Univariate: p=0.01; Multivariate: p=0.01;
|
Tissue
|
19239456
|
429
|
p53
|
Protein
|
Humans
|
Increased Expression with Overall Death
|
Prognostic
|
Overall Survival Vs No Survival
|
Univariate: p=0.001; Multivariate: p=0.004;
|
Tissue
|
19239456
|
431
|
TMPRSS2
|
mRNA
|
Humans
|
Upregulated (Clinical Stage 1&2: 3.43 ± 0.62 ; Vs Clinical Stage 3: 5.45 ± 0.92)
|
Prognostic
|
Clincal Stage (1-2) Vs Clinical Stage 3
|
p=0.02
|
Tissue
|
19242826
|
432
|
TMPRSS2
|
mRNA
|
Humans
|
Upregulated (GS<6 4.64 ± 0.35 vs GS>6: 8.34 ± 1.53)
|
Prognostic
|
Gleason Score ≤6, Vs Gleason Score>6
|
p=0.008
|
Tissue
|
19242826
|
433
|
TMPRSS2
|
mRNA
|
Humans
|
Upregulated (Tumor Grade 1-2: 2.35 ± 1.45 vs Tumor Grade 3: 3.41 ± 2.31)
|
Prognostic
|
Tumor Grade (1-2) Vs Tumor Grade 3
|
p=0.016
|
Tissue
|
19242826
|
435
|
KLK11
|
mRNA
|
Humans
|
Upregulated (CS: (1-2) 6.05 ± 1.34 vs CS 3: 3.93 ± 0.45)
|
Prognostic
|
Clincal Stage (1-2) Vs Clinical Stage 3
|
p=0.009
|
Tissue
|
19242826
|
436
|
KLK11
|
mRNA
|
Humans
|
Upregulated (GS<6 4.64 ± 0.35 vs GS>6: 8.34 ± 1.53)
|
Prognostic
|
Gleason Score ≤6, Vs Gleason Score>6
|
p=0.01
|
Tissue
|
19242826
|
437
|
KLK11
|
mRNA
|
Humans
|
Upregulated (Tumor Grade 1-2 : 2.35 ± 1.45 vs Tumor Grade 3: 3.41 ± 2.31)
|
Prognostic
|
Tumor Grade (1-2) Vs Tumor Grade 3
|
p=0.006
|
Tissue
|
19242826
|
439
|
Methylation Status of: Ventral anterior homeobox 1 (VAX1); Homeobox D3 (HOXD3); CAP-GLY domain containing linker protein family (CLIP4); Calcium channel, voltage dependent, T-type, alpha 1G 2.0 subunit (CACNA1G) ; Glycoprotein V (GP5); Somatostatin receptor 1 (SSTR1); Methylthioadenosine phosporylase (MTAP); NK2 homeobox 2 (NKX2-2); Homeobox C11 (HOXC11); Ladybird homeobox 1 (LBX1); Motor neuron and pancreas homeobox 1 (MNX1); Glutamate receptor, metabotropic 1 (GRM1); LIM homeobox 9 (LHX9); Microtubule-associated protein tau (MAPT); Galactosidase, beta 1-like (GLB1L)
|
Methylation
|
Humans
|
Hypermethylated in Progression (PP4): [Ventral anterior homeobox 1 (VAX1) (2.7 fold); Homeobox D3 (HOXD3) (2.3 fold); CAP-GLY domain containing linker protein family (CLIP4) (2.1 fold); Calcium channel, voltage dependent, T-type, alpha 1G 2.0 subunit (CACNA1G) (2.0 fold); Glycoprotein V (GP5) (1.9 fold); Somatostatin receptor 1 (SSTR1) (1.8 fold); Methylthioadenosine phosporylase (MTAP) (1.8 fold); NK2 homeobox 2 (NKX2-2) (1.7 fold); Homeobox C11 (HOXC11) (1.6 fold); Ladybird homeobox 1 (LBX1) (1.6 fold); Motor neuron and pancreas homeobox 1 (MNX1) (1.6 fold); Glutamate receptor, metabotropic 1 (GRM1) (1.6 fold); LIM homeobox 9 (LHX9) (1.6 fold); Microtubule-associated protein tau (MAPT) (1.5 fold); Galactosidase, beta 1-like (GLB1L) (1.5 fold)]
|
Prognostic
|
Gleason Score 6 (Pure pattern 3) vs Gleason Score 8 (Pure Pattern 4)
|
p<0.05
|
Tissue
|
19283074
|
440
|
Ki-67
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Cause Specific Survival Vs No Survival
|
p<0.001
|
Tissue
|
19293807
|
441
|
Ki-67
|
Protein
|
Humans
|
Differentially Expressed [Cause Specific Survial (Δχ2 = 24.6) and overall survival (Δχ2 = 20.5)]
|
Prognostic
|
Overall Survival Vs No Survival
|
p<0.001
|
Tissue
|
19293807
|
442
|
ACPP; AD-017; AMIGO2; APPBP2; ASNS; ATAD2; ATP6V0E; ATXN1; AURKB; B3GALT4; BANK1; BCAP29; BIRC5; BM039 (CENPN); BRE; BUB1; BUB1B; C18orf10; C1orf9; C22orf18 (CENPM); C5orf13; C6orf111; C6orf210; C9orf116; C9orf127; CATSPER2; CCNA2; CCNB1; CCNB2; CCNE2; CD24; CDC16; CDC2; CDC20; CDC25C; CDC6; CDC7; CDKN3; CENPA; CENPC1; CENPF; CHEK1; CHEK1; CITED2; CITED2; CLUL1; COH1; CPT2; CRADD; CTSL2; CYFIP2; DEPDC1; DGKA; DMXL1; DSCR1L1; EFNB2; ESPL1; F2R; FEN1; FLJ10036; FLJ10534; FLJ22624; GABARAPL1; GALNT7; GFPT1; GGA2; GTSE1; GTSE1; H2AFX; H2AFY; HCAP-G; HCAP-G; HECA; HMGB2; HMMR; HMMR; HPS1; IL13RA1; INSIG1; KIAA0999; KIAA1608; KIF14; KIF20A; KIF4A KLK2; KLK2; KLK3; KNS2; KNTC2; LAMB2; LMAN1; LOC54103; MAC30; MALT1; MAPK8IP1; MCM5 ; MID1; MLF1IP; MLLT3; MTHFD2; MTMR1; MYCBP2; MYH10; MYRIP; NAP1L3; NAV3; NEK2; NEK2 NLGN1; NUSAP1; OIP5; OSR2; PBEF1; PCLO; PDE9A; PDIR; PER3; PIK3R1;PINK1; PIR51; PLCB4; PLK1; PMAIP1; PMS2L11; PMSCL1; PRC1; PRKWNK1; PTBP1; PTBP2; PTCD1 ; PTPN13; PTPRR; RAB3B; RACGAP1; RBM30; RFC3; RRM1 ; RRM2; RRM2; SAS; SDC2 ; SDC2 ; SDC4; SEC6L1; SHCBP1 ; SI; SLC29A1; SLC7A6; SMARCA2; SMC4L1; SMC4L1; SOCS2; SOD2; SOS1; Spc25; SS18; STC2; STK3; STK6 ; TM4SF1; TMPO; TNFRSF10B ; TNFSF13; TNFSF12-TNFSF13; TWE-PRIL; TOPK; TPBG; TPX2; TRIB1; TTC3; TUBA3; TYMS; UAP1; UBE3B; USP3; VEGF; ZNF175; ZNF292; ZNF45; ZWINT
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Metastatic Vs Localised Prostate Cancer
|
p=0.0000121714
|
Cell Lines
|
19351846
|
443
|
ACPP; AD-017 ; AMIGO2; APPBP2; ASNS ; ATAD2; ATP6V0E; ATXN1; AURKB; B3GALT4; BANK1; BCAP29; BIRC5; BM039 (CENPN); BRE; BUB1; BUB1B; C18orf10 ; C1orf9; C22orf18 (CENPM) ; C5orf13; C6orf111 ; C6orf210; C9orf116 ; C9orf127; CATSPER2 ; CCNA2; CCNB1; CCNB2; CCNE2; CD24; CDC16; CDC2 ; CDC20; CDC25C ; CDC6 ; CDC7; CDKN3; CENPA; CENPC1; CENPF; CHEK1; CHEK1; CITED2; CITED2; CLUL1; COH1; CPT2; CRADD; CTSL2; CYFIP2; DEPDC1; DGKA; DMXL1; DSCR1L1 ; EFNB2 ; ESPL1; F2R; FEN1; FLJ10036; FLJ10534; FLJ22624; GABARAPL1 ; GALNT7; GFPT1 ; GGA2; GTSE1; GTSE1 ; H2AFX ; H2AFY; HCAP-G; HCAP-G ; HECA; HMGB2; HMMR ; HMMR; HPS1; IL13RA1; INSIG1; KIAA0999; KIAA1608; KIF14; KIF20A; KIF4A; KLK2 ; KLK2 ; KLK3; KNS2 KNTC2 LAMB2; LMAN1; LOC54103; MAC30; MALT1; MAPK8IP1; MCM5; MID1; MLF1IP; MLLT3; MTHFD2; MTMR1; MYCBP2; MYH10 MYRIP; NAP1L3; NAV3 ; NEK2; NEK2; NLGN1; NUSAP1; OIP5; OSR2; PBEF1; PCLO; PDE9A ; PDIR; PER3 ; PIK3R1 ; PINK1 ; PIR51; PLCB4; PLK1; PMAIP1; PMS2L11; PMSCL1; PRC1; PRKWNK1; PTBP1; PTBP2; PTCD1 ; PTPN13; PTPRR; RAB3B ; RACGAP1;RBM30; RFC3; RRM1; RRM2; RRM2; SAS ; SDC2; SDC2 ; SDC4; SEC6L1; SHCBP1; SI; SLC29A1; SLC7A6; SMARCA2; SMC4L1; SMC4L1; SOCS2; SOD2; SOS1; Spc25; SS18; STC2 ; STK3; STK6; TM4SF1 ; TMPO; TNFRSF10B; TNFSF13; TNFSF12-TNFSF13; TWE-PRIL; TOPK ; TPBG; TPX2; TRIB1 ; TTC3; TUBA3; TYMS; UAP1;UBE3B; USP3; VEGF; ZNF175; ZNF292; ZNF45; ZWINT
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Androgen Dependent Vs Androgen Independent Prostate Cancer
|
p=0.0056
|
Cell Lines
|
19351846
|
447
|
CTC (Circulating Tumor Cells)
|
Others
|
Humans
|
Increased expression in overall survival
|
Prognostic
|
Overall Survival Vs No Survival
|
p<0.001
|
Blood
|
19505924
|
448
|
Alkaline Phosphatase
|
Metabolites
|
Humans
|
Increased expression in overall survival
|
Prognostic
|
Overall Survival Vs No Survival
|
p<0.001
|
Blood
|
19505924
|
449
|
LDH
|
Metabolites
|
Humans
|
Increased expression in overall survival
|
Prognostic
|
Overall Survival Vs No Survival
|
p<0.001
|
Blood
|
19505924
|
450
|
Prostatic Acid Phosphatase (PAP)
|
Metabolites
|
Humans
|
Increased expression in overall survival
|
Prognostic
|
Overall Survival Vs No Survival
|
p<0.001
|
Blood
|
19505924
|
451
|
Total Acid Phosphatase (TAP)
|
Metabolites
|
Humans
|
Increased expression in overall survival
|
Prognostic
|
Overall Survival Vs No Survival
|
p<0.001
|
Blood
|
19505924
|
452
|
Albumin
|
Metabolites
|
Humans
|
Increased expression in overall survival
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.002
|
Blood
|
19505924
|
453
|
Hemoglobin
|
Metabolites
|
Humans
|
Increased expression in overall survival
|
Prognostic
|
Overall Survival Vs No Survival
|
p<0.001
|
Blood
|
19505924
|
460
|
IGF1
|
Protein
|
Humans
|
Higher concentrations in patients with decreased risk of advanced prostate cancer
|
Prognostic
|
Localised Vs Advanced Prostate Cancer
|
p<0.001
|
NA
|
19491931
|
461
|
IGFBP3
|
Protein
|
Humans
|
Higher concentrations in patients with decreased risk of advanced prostate cancer
|
Prognostic
|
Localised Vs Advanced Prostate Cancer
|
p=0.004
|
NA
|
19491931
|
468
|
DNA Ploidy - Diploid
|
Mutation
|
Humans
|
DIPLOID: 5 year disease free survival - (80.5% ); 10 year disease free survival - (72.9%)
|
Prognostic
|
5 and 10 years disease free survival Vs no survival
|
p<0.001
|
Tissue
|
19633362
|
469
|
DNA Ploidy - Tetraploid
|
Mutation
|
Humans
|
TETRAPLOID: 5 year disease free survival - (67.8% ); 10 year disease free survival - (61.6%)
|
Prognostic
|
5 and 10 years disease free survival Vs no survival
|
p<0.001
|
Tissue
|
19633362
|
470
|
DNA Ploidy - Aneploid
|
Mutation
|
Humans
|
ANUEPLOID: 5 year disease free survival - (49.5% ); 10 year disease free survival - (31.8%)
|
Prognostic
|
5 and 10 years disease free survival Vs no survival
|
p<0.001
|
Tissue
|
19633362
|
471
|
DNA Ploidy - Diploid
|
Mutation
|
Humans
|
DIPLOID: 5 year disease free survival - (88.7% ); 10 year disease free survival - (84.8%)
|
Prognostic
|
5 and 10 years disease free survival Vs no survival for Gleason Score=7
|
p<0.001
|
Tissue
|
19633362
|
472
|
DNA Ploidy - Tetraploid
|
Mutation
|
Humans
|
TETRAPLOID: 5 year disease free survival - (74.3% ); 10 year disease free survival - (64.7%)
|
Prognostic
|
5 and 10 years disease free survival Vs no survival for Gleason Score=7
|
p<0.001
|
Tissue
|
19633362
|
473
|
DNA Ploidy - Anueploid
|
Mutation
|
Humans
|
ANUEPLOID: 5 year disease free survival - (25.0% ); 10 year disease free survival - (0%)
|
Prognostic
|
5 and 10 years disease free survival Vs no survival for Gleason Score=7
|
p<0.001
|
Tissue
|
19633362
|
476
|
GLUT1
|
Protein
|
Humans
|
Increased expression in Biochemical Recurrence
|
Prognostic
|
PSA recurrence Vs No PSA recurrence
|
p=0.005
|
Tissue
|
19854473
|
477
|
PHD1 (prolyl-4-hydroxylases 1)
|
Protein
|
Humans
|
Increased expression in Biochemical Recurrence
|
Prognostic
|
PSA recurrence Vs No PSA recurrence
|
p <0.001
|
Cell Lines
|
19854473
|
479
|
Clusterin & Clusterin Density
|
Protein
|
Humans
|
Upregulated: Clusterin [(No Metastasis 131.1 ± 32.1) Vs (Metastasis: 151.3 ± 34.6 )]; Clusterin Density [(No Metastasis: 5.1 ± 2.3 ) Vs (Metastasis: 6.2 ± 2.7 )]
|
Prognostic
|
No Metastasis Vs Metastasis
|
p<0.001
|
Serum
|
19854485
|
480
|
Clusterin Density
|
Protein
|
Humans
|
Upregulated: Clusterin Density [(ExtraProstatic 6.2 ± 2.4) Vs (Organ-confined disease: 5.4 ± 2.2 )];
|
Prognostic
|
Organ-confined disease Vs Extraprostatic disease
|
p=0.033
|
Serum
|
19854485
|
481
|
Clusterin Density
|
Protein
|
Humans
|
Decreased expression in Patients with Biochemical Recurrence free Survival
|
Prognostic
|
Biochemical Recurrence Free Survival Vs No Survial
|
p=0.034
|
Serum
|
19854485
|
492
|
ezrin; lamin B1; succinate dehydrogenase complex, subunit A, flavoprotein precursor; succinate dehydrogenase complex, subunit A, flavoprotein precursor; acute morphine dependence related protein 2; methylcrotonoyl Coenzyme A carboxylase 2 (beta); 3-oxoacid CoA transferase 1 precursor; CCT2; CCT2; CCT2; keratin 8; lamin A/C transcript variant 1; Chain A, X-ray Structure Of The Human mitogen activated protein kinase kinase 2 (Mek2)in A Complex; Stomatin (EPB72)-like 2; Heterogeneous nuclear ribonucleoprotein C (C1/C2), hnRNP; Heterogeneous nuclear ribonucleoprotein C (C1/C2); SEC13 homologue (S. cerevisiae); HSPC124; Enoyl Coenzyme A hydratase 1, peroxisomal; Chain A, Structure Of Inositol Monophosphatase the Putative Target Of Lithium Therapy; cathepsin D preproprotein; chloride intracellular channel 4; endoplasmic reticulum protein 29 isoform 1 precursor; heat shock 27 kDa protein 1; Chain A, Native Human Lysosomal Beta-Hexosaminidase Isoform B; thioredoxin peroxidase, peroxiredoxin 4; Chain A, Human Glyoxalase I With Benzyl-Glutathione inhibitor; Chain A, Human Glyoxalase I With Benzyl-Glutathione inhibitor; hypothetical protein LOC79017; ATP synthase, H+ transporting, mitochondrial F0; Ferritin, light polypeptide; nonmetastatic cells 1, protein (NM23A) expressed in isoform a; keratin-10; ubiquitin-conjugating enzyme E2N; fatty acid binding protein 5 (psoriasis-associated);
|
Protein
|
Humans
|
Upregulated ratio in LNMPCA: ezrin [2.4]; lamin B1 [2.76]; succinate dehydrogenase complex, subunit A, flavoprotein precursor [2.22]; succinate dehydrogenase complex, subunit A, flavoprotein precursor [1.86]; acute morphine dependence related protein 2 [1.94]; methylcrotonoyl Coenzyme A carboxylase 2 (beta) [5.27]; 3-oxoacid CoA transferase 1 precursor [1.90]; CCT2 [2.74]; CCT2 [2.22]; CCT2 [1.82]; keratin 8 [4.19]; lamin A/C transcript variant 1 [3.66]; Chain A, X-ray Structure Of The Human mitogen activated protein kinase kinase 2 (Mek2)in A Complex [2.95]; Stomatin (EPB72)-like 2 [2.10]; Heterogeneous nuclear ribonucleoprotein C (C1/C2), hnRNP [2.25]; Heterogeneous nuclear ribonucleoprotein C (C1/C2) [2.01]; SEC13 homologue (S. cerevisiae) [2.62]; HSPC124 [4.70]; Enoyl Coenzyme A hydratase 1, peroxisomal [3.79]; Chain A, Structure Of Inositol Monophosphatase the Putative Target Of Lithium Therapy [2.39]; cathepsin D preproprotein [2.49]; chloride intracellular channel 4 [2.16]; endoplasmic reticulum protein 29 isoform 1 precursor [2.54]; heat shock 27 kDa protein 1 [3.47]; Chain A, Native Human Lysosomal Beta-Hexosaminidase Isoform B [4.62]; thioredoxin peroxidase, peroxiredoxin 4 [2.12]; Chain A, Human Glyoxalase I With Benzyl-Glutathione inhibitor [4.19]; Chain A, Human Glyoxalase I With Benzyl-Glutathione inhibitor [4.56]; hypothetical protein LOC79017 [3.15]; ATP synthase, H+ transporting, mitochondrial F0 [2.46]; Ferritin, light polypeptide [2.49]; nonmetastatic cells 1, protein (NM23A) expressed in isoform a [2.99]; keratin-10 [3.84]; ubiquitin-conjugating enzyme E2N [2.23]; fatty acid binding protein 5 (psoriasis-associated) [20.86];
|
Prognostic
|
Lymph Node Metastatic Prostate Cancer Vs Localised PCA
|
p<0.05
|
Tissue
|
19894759
|
493
|
collagen, type VI, alpha 1 precursor; vinculin isoform meta-VCL; FLNA protein; gelsolin isoform b; transferrin; transferrin; lamin A/C transcript variant 1; archain; Dihydropyrimidinase-like 3; mutant desmin; PREDICTED: similar to actin, alpha 1, skeletal muscle isoform 2; Chain A, human B lactate dehydrogenase complexed with NAD+ and Hydroxy-1,2,5-Oxadiazole-3-Carbox; splicing factor, arginine/ serine-rich 1 isoform 1; Unknown (protein for IMAGE:3906970); ubiquitin carboxy-terminal hydrolase L1; Chain A, Ligand-Free Human Glutathione S-Transferase M2–2; Chain A, Crystal Structure Of Human Glutathione S-Transferase P1-1 Complexed With (9r,10r)-9; regulatory myosin light chain long version; smooth muscle protein (SM22); haptoglobin-related protein precursor; smooth muscle protein (SM22); smooth muscle protein (SM22); Chain A, X-ray Crystal Structure Of Human Galectin-1;
|
Protein
|
Humans
|
Downregulated ratio in LNMPCA: collagen, type VI, alpha 1 precursor [2.15]; vinculin isoform meta-VCL [3.47]; FLNA protein [1.99]; gelsolin isoform b [2.15]; transferrin [2.04]; transferrin [2.15]; lamin A/C transcript variant 1 [2.06]; archain [1.63]; Dihydropyrimidinase-like 3 [1.86]; mutant desmin [2.38]; PREDICTED: similar to actin, alpha 1, skeletal muscle isoform 2 [2.89]; Chain A, human B lactate dehydrogenase complexed with NAD+ and Hydroxy-1,2,5-Oxadiazole-3-Carbox [2.68]; splicing factor, arginine/ serine-rich 1 isoform 1 [2.6]; Unknown (protein for IMAGE:3906970) [2.04]; ubiquitin carboxy-terminal hydrolase L1 [2.78]; Chain A, Ligand-Free Human Glutathione S-Transferase M2–2 [3.32]; Chain A, Crystal Structure Of Human Glutathione S-Transferase P1-1 Complexed With (9r,10r)-9 [2.85]; regulatory myosin light chain long version [4.25]; smooth muscle protein (SM22) [13.98]; haptoglobin-related protein precursor [6.16]; smooth muscle protein (SM22) [5.08]; smooth muscle protein (SM22) [3.30]; Chain A, X-ray Crystal Structure Of Human Galectin-1 [2.46];
|
Prognostic
|
Lymph Node Metastatic Prostate Cancer Vs Localised PCA
|
p<0.05
|
Tissue
|
19894759
|
496
|
e-FABP5
|
Protein
|
Humans
|
Upregulated in LNM PCa
|
Prognostic
|
Lymph Node Metastatic Prostate Cancer Vs Localised PCA
|
p<0.01
|
Serum
|
19894759
|
498
|
e-FABP5, MCCC2, PPA2, Ezrin, and SLP2
|
Protein
|
Humans
|
Upregulated in LNM PCa
|
Prognostic
|
Lymph Node Metastatic Prostate Cancer Vs Localised PCA
|
p<0.01
|
Tissue
|
19894759
|
499
|
SM22
|
Protein
|
Humans
|
Downregulated in LNM PCa
|
Prognostic
|
Lymph Node Metastatic Prostate Cancer Vs Localised PCA
|
p<0.01
|
Tissue
|
19894759
|
500
|
Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP)[Fixed
|
DNA (Gene)
|
Humans
|
Differentially Expressed
|
Prognostic
|
Biochemical recurrence (within 1 year ) Vs No recurrence (24 months)
|
NA
|
Tissue
|
20028763
|
501
|
Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) [Floating]
|
DNA (Gene)
|
Humans
|
Differentially Expressed
|
Prognostic
|
Biochemical recurrence (within 1 year ) Vs No recurrence (24 months)
|
NA
|
Tissue
|
20028763
|
502
|
Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) [Integrated]
|
DNA (Gene)
|
Humans
|
Differentially Expressed
|
Prognostic
|
Biochemical recurrence (within 1 year ) Vs No recurrence (24 months)
|
NA
|
Tissue
|
20028763
|
503
|
ANXA5; APLP2; COL1A2; CRIM1; ECHS1; HMGB1; MAP3K5; NGFRAP1; NPM1; NUB1; PDIA3; PLA2G2A; ROCK1; TEGT; TMEM16G; TMEM69; TRAF4; VCAN; VCP; VDAC1;
|
mRNA
|
Humans
|
Differentially Expressed: ANXA5 [1.47 fold]; APLP2 [1.22 fold]; COL1A2 [1.18 fold]; CRIM1 [1.20 fold]; ECHS1 [1.18 fold]; HMGB1 [1.40 fold]; MAP3K5 [1.35 fold]; NGFRAP1 [1.32 fold]; NPM1 [1.30 fold]; NUB1 [1.12 fold]; PDIA3 [1.43 fold]; PLA2G2A [1.75 fold]; ROCK1 [1.17 fold]; TEGT [1.32 fold]; TMEM16G [0.66 fold]; TMEM69 [1.08 fold]; TRAF4 [1.26 fold]; VCAN [1.31 fold]; VCP [1.18 fold]; VDAC1 [1.51 fold];
|
Prognostic
|
Gleason Score 6 Vs Gleason Score (8-10)
|
p<0.05
|
Tissue
|
20035634
|
504
|
ANXA5; APLP2; COL1A2; CRIM1; ECHS1; HMGB1; MAP3K5; NGFRAP1; NPM1; NUB1; PDIA3; PLA2G2A; ROCK1; TEGT; TMEM16G; TMEM69; TRAF4; VCAN; VCP; VDAC1;
|
mRNA
|
Humans
|
Differentially Expressed: ANXA5 [4.28 fold]; APLP2 [2.83 fold]; COL1A2 [2.02 fold]; CRIM1 [3.23 fold]; ECHS1 [1.89 fold]; HMGB1 [4.68 fold]; MAP3K5 [2.98 fold]; NGFRAP1 [3.95 fold]; NPM1 [3.07 fold]; NUB1 [1.62 fold]; PDIA3 [2.40 fold]; PLA2G2A [3.00 fold]; ROCK1 [9.76 fold]; TEGT [2.77 fold]; TMEM16G [0.35 fold]; TMEM69 [2.77 fold]; TRAF4 [2.59 fold]; VCAN [2.92 fold]; VCP [2.75 fold]; VDAC1 [5.41 fold];
|
Prognostic
|
Gleason Score 6 Vs Gleason Score (8-10)
|
p<0.05
|
Tissue
|
20035634
|
505
|
MAP3K5
|
mRNA
|
Humans
|
Upregulated in Gleason Score 8-10
|
Prognostic
|
Gleason Score 6 Vs Gleason Score (8-10)
|
qRT-PCR: p=0.0129
|
Tissue
|
20035634
|
506
|
PDIA3
|
mRNA
|
Humans
|
Upregulated in Gleason Score 8-10
|
Prognostic
|
Gleason Score 6 Vs Gleason Score (8-10)
|
qRT-PCR: p=0.00167
|
Tissue
|
20035634
|
511
|
TMPRSS2–ERG
|
mRNA
|
Humans
|
Fusion Positive in Recurrence
|
Prognostic
|
Biochemical recurrence Vs No recurrence
|
p=0.0000000354
|
Tissue
|
20068566
|
512
|
ERG expression in TMPRSS2–ERG
|
mRNA
|
Humans
|
Upregulated in Fusion (3.07-fold)
|
Prognostic
|
ERG Fusion Vs No Fusion
|
p=3.48E-11
|
Tissue
|
20068566
|
513
|
CSPG2+ WNT10B+E2F3+CDKN2A+TYMS+TGFB3+ALOX12+CD44+LAF4
|
mRNA
|
Humans
|
Upregulated with Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence Vs No recurrence
|
Univariate: p=0.0000002; Multivariate: p=0.0270
|
Tissue
|
20068566
|
514
|
Enhancer of Zeste 2 (EZH2)
|
mRNA
|
Humans
|
Overexpression leads to aggressive behaviour in Cell Lines
|
Prognostic
|
Overexpression Vs No Overexpression in Cell Lines
|
NA
|
Cell Lines
|
20087897
|
519
|
EGFR [SNP rs884419]
|
Mutation
|
Humans
|
AG And GG Phenotypes associated with decreased risk of recurrence
|
Prognostic
|
Biochemical recurrence Vs No recurrence
|
A/G Phenotype: p= 0.0018; G/G Phenotype: p = 0.0016
|
Tissue
|
20303520
|
523
|
hsa-miR-375-4373027; hsa-miR-9*-4395342; hsa-miR-141-4373137; hsa-miR-516a-3p-4373183; hsa-miR-629-4395547; hsa-miR-203-4373095; hsa-miR-429-4373203; hsa-miR-618-4380996; hsa-miR-212-4373087; hsa-miR-21-4373090; hsa-miR-545-4395378; hsa-miR-218-4373081; hsa-miR-422a-4395408; hsa-miR-656-4380920; hsa-miR-655-4381015; hsa-miR-29c-4395171; hsa-miR-200b-4395362; hsa-miR-200c-4395411; hsa-miR-502-5p-4373227;
|
miRNA
|
Humans
|
Upregulated in Metastatis (Log Fold Change): hsa-miR-375-4373027 [-4.3]; hsa-miR-9*-4395342 [-3.8]; hsa-miR-141-4373137 [-4.5]; hsa-miR-516a-3p-4373183 [-3.9]; hsa-miR-629-4395547 [-2.1]; hsa-miR-203-4373095 [-2.5]; hsa-miR-429-4373203 [-3.4]; hsa-miR-618-4380996 [-3.7]; hsa-miR-212-4373087 [-2.6]; hsa-miR-21-4373090 [-1.8]; hsa-miR-545-4395378 [-2.3]; hsa-miR-218-4373081 [-2.8]; hsa-miR-422a-4395408 [-2.1]; hsa-miR-656-4380920 [-2.8]; hsa-miR-655-4381015 [-2.4]; hsa-miR-29c-4395171 [-1.7]; hsa-miR-200b-4395362 [-3.1]; hsa-miR-200c-4395411 [-1.8]; hsa-miR-502-5p-4373227 [-3.1];
|
Prognostic
|
Localised Vs Metastatic Prostate Cancer
|
p<0.0098
|
Serum
|
20473869
|
524
|
miRNA-375, miRNA-141 and miRNA-200b
|
miRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Pathoglical Stage pt3 vs pt2
|
p<0.05
|
Serum
|
20473869
|
525
|
miRNA-375, miRNA-141 and miRNA-200b
|
miRNA
|
Humans
|
Upregulated
|
Prognostic
|
Gleason Score 6 Vs Gleason Score 7
|
p<0.05
|
Serum
|
20473869
|
526
|
miRNA-375
|
miRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Lymph Node Status: NO Vs N1
|
p<0.01
|
Serum
|
20473869
|
527
|
miRNA-141
|
miRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Lymph Node Status: NO Vs N1
|
p<0.05
|
Serum
|
20473869
|
528
|
miRNA-141
|
miRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Gleason Score >8 Vs Gleason Score 7
|
p<0.01
|
Serum
|
20473869
|
532
|
KLK15 (kallikrein-related peptidase)
|
Protein
|
Humans
|
High levels associated with shorter progression-free survival.
|
Prognostic
|
PSA recurrence Vs No PSA recurrence
|
Univariate: p = 0.002; Multivariate: p=0.037; StepWise Inclusion: p=0.032
|
Tissue
|
20473923
|
536
|
PSA (G/G Genotype)
|
Mutation
|
Humans
|
Increases risk of Gleason Score >=7 with G/G Genotype compared with the G/A & A/A genotype
|
Prognostic
|
Gleason ≤7 Vs Gleason Score >7
|
p= 0.0122
|
Blood
|
20632874
|
537
|
AR: (Short CAG)
|
Mutation
|
Humans
|
Increased RIsk of GS (4+3) with Short CAG Repeats
|
Prognostic
|
Gleason Score 7 (4+3) Vs Gleason Score 7 (3+4)
|
p = 0.045
|
Blood
|
20632874
|
540
|
MMP-9 %
|
Protein
|
Humans
|
Increased expression in Recurrence free survival
|
Prognostic
|
Biochemical Recurrence Vs No Recurrence
|
p=0.03
|
Tissue
|
20889560
|
541
|
MMP-9 intensity
|
Protein
|
Humans
|
Increased expression in Disease Specific Mortality
|
Prognostic
|
Disease Specific Mortality Vs No Mortality
|
p<0.001
|
Tissue
|
20889560
|
542
|
MMP-9 intensity
|
Protein
|
Humans
|
Increased expression in Overall Mortality
|
Prognostic
|
Overall Mortality Vs No Mortality
|
p<0.001
|
Tissue
|
20889560
|
557
|
Fructose-bisphosphate aldolase A; Isocitrate dehydrogenase; Citrate synthase; L-Lactate dehydrogenase A; ATP synthase gamma chain; Alpha-enolase; Phosphoglycerate mutase 1; Malate dehydrogenase; Core protein II; Transketolase; 60 kDa heat shock protein; Lamin A; Flotillin 1; Cytokeratin-1; Mimecan; 26S protease regulatory subunit 8; Annexin A2;
|
Protein
|
Humans
|
Upregulated (with Regulation Coefficient): Fructose-bisphosphate aldolase A [1.85]; Isocitrate dehydrogenase [1.79]; Citrate synthase [1.76]; L-Lactate dehydrogenase A [1.75]; ATP synthase gamma chain [1.7]; Alpha-enolase [1.67]; Phosphoglycerate mutase 1 [1.65]; Malate dehydrogenase [1.64]; Core protein II [1.61]; Transketolase [1.59]; 60 kDa heat shock protein [2.13]; Lamin A [2.08]; Flotillin 1 [1.85]; Cytokeratin-1 [1.65]; Mimecan [1.58]; 26S protease regulatory subunit 8 [1.47]; Annexin A2 [1.46];
|
Prognostic
|
Gleason Score 6 Vs Gleason Score 8 and above
|
p<0.05
|
Tissue
|
20977276
|
558
|
Prostatic acid phosphatase; Prostate-specific antigen;
|
Protein
|
Humans
|
Downregulated (with Regulation Coefficient): Prostatic acid phosphatase [-1.84]; Prostate-specific antigen [-3.04];
|
Prognostic
|
Gleason Score 6 Vs Gleason Score 8 and above
|
p<0.05
|
Tissue
|
20977276
|
560
|
Lamin A
|
Protein
|
Humans
|
Upregulated in GS 8 and above
|
Prognostic
|
Gleason Score 6 Vs Gleason Score 8 and above
|
p<0.05
|
Tissue
|
20977276
|
569
|
D-Dimer
|
Protein
|
Humans
|
Upregulated in Progressive Disease
|
Prognostic
|
progressive disease (PD) Vs nonprogressive disease (non-PD)
|
p<0.024
|
Blood
|
21088161
|
575
|
Kininogen-1+ Protein AMBP + Coagulation factor XIII B chain + Complement factor H + Gluthathione peroxidase 3
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Gleason Score 5 vs Gleason Score 7
|
NA
|
Serum
|
21166384
|
576
|
Protein AMBP; Haptoglobin (R chain) ; Pigment Epithelium-Derived Factor 207 Kininogen-1
|
Protein
|
Humans
|
Downregulated in Non Organ Confined: [Haptoglobin (R chain) ]; Upregulated in Non Organ Confined: [Protein AMBP; Pigment Epithelium-Derived Factor 207 Kininogen-1]
|
Prognostic
|
Organ Confined vs Non-Organ Confined
|
NA
|
Serum
|
21166384
|
578
|
Kininogen-1+ Protein AMBP + Coagulation factor XIII B chain + Complement factor H +Gluthathione peroxidase 3
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
Gleason Score 5 vs Gleason Score 7
|
NA
|
Serum
|
21166384
|
579
|
Protein AMBP; Haptoglobin (R chain) ; Pigment Epithelium-Derived Factor 207 Kininogen-1
|
Protein
|
Humans
|
Downregulated in Non Organ Confined: [Haptoglobin (R chain) ]; Upregulated in Non Organ Confined: [Protein AMBP; Pigment Epithelium-Derived Factor 207 Kininogen-1]
|
Prognostic
|
Organ Confined vs Non-Organ Confined
|
NA
|
Serum
|
21166384
|
583
|
β-microseminoprotein (MSMB)
|
Protein
|
Humans
|
increased expression with decreased biochemical recurrence-free survival
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.001
|
Tissue
|
21240253
|
584
|
SLCO1B1; SLCO1B3; SLCO2A1; SLCO3A1;
|
mRNA
|
Humans
|
Upregulated in CRPC metastases: SLCO1B1 (5.5 fold); SLCO1B3( 3.6 fold); SLCO2A1 (3.2 fold); SLCO3A1 (5.4 fold);
|
Prognostic
|
CRPC metastases versus untreated prostate cancer
|
p<0.053
|
Tissue
|
21266523
|
585
|
SLCO2B1 (SNP rs12422149)
|
Mutation
|
Humans
|
Increased risk in GA or AA type allele
|
Prognostic
|
Prostate Cancer Specific Mortality No No mortality
|
p<0.05
|
Blood
|
21266523
|
586
|
SLCO1B3 (SNP rs4149117)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Prostate Cancer Specific Mortality No No mortality
|
p<0.05
|
Blood
|
21266523
|
588
|
Annexin A4 (ANXA4); Apolipoprotein A-I (APOA1); ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B); Creatine kinase, brain (CKB); Desmin (DES); Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1); Fibrinogen γ chain (FGG); Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5); Heat shock 60 kDa protein 1 (chaperonin) (HSPD1); Prolyl 4-hydroxylase, β polypeptide (P4HB); Prohibitin (PHB); Serpin peptidase inhibitor, clade A (α-1 antiproteinase, antitrypsin), member 1) (SERPINA1);
|
Protein
|
Humans
|
Upregulated in Gleason Score 7(Fold Change) : Annexin A4 (ANXA4) [1.000]; Apolipoprotein A-I (APOA1) [2.691]; ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B) [7.440]; Creatine kinase, brain (CKB) [1.000]; Desmin (DES) [2.059]; Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1) [2.335]; Fibrinogen γ chain (FGG) [7.634]; Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5) [2.339]; Heat shock 60 kDa protein 1 (chaperonin) (HSPD1) [1.000]; Prolyl 4-hydroxylase, β polypeptide (P4HB) [11.540]; Prohibitin (PHB) [1.000]; Serpin peptidase inhibitor, clade A (α-1 antiproteinase, antitrypsin), member 1) (SERPINA1) [2.992];
|
Prognostic
|
Gleason Score 5 Vs Gleason Score 7
|
p<0.05
|
Tissue
|
21305254
|
589
|
Albumin (ALB); Rho GDP dissociation inhibitor (GDI) α (ARHGDIA); Keratin 18 (KRT18); Keratin 19 (KRT19); Keratin 8 (KRT8);
|
Protein
|
Humans
|
Downregulated in Gleason Score 7(Fold Change) : Albumin (ALB) [2.155]; Rho GDP dissociation inhibitor (GDI) α (ARHGDIA) [2.571]; Keratin 18 (KRT18) [3.322]; Keratin 19 (KRT19) [4.950]; Keratin 8 (KRT8) [4.950];
|
Prognostic
|
Gleason Score 5 Vs Gleason Score 7
|
p<0.05
|
Tissue
|
21305254
|
590
|
Albumin (ALB); Annexin A4 (ANXA4); Apolipoprotein A-I (APOA1); ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B); Fibrinogen γ chain (FGG);
|
Protein
|
Humans
|
Upregulated in Stage T3 (Fold Change) : Albumin (ALB) [2.684]; Annexin A4 (ANXA4) [1.000]; Apolipoprotein A-I (APOA1) [2.691]; ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B) [1.000]; Fibrinogen γ chain (FGG) [1.000];
|
Prognostic
|
Stage T2 Vs Stage T3
|
p<0.05
|
Tissue
|
21305254
|
591
|
Rho GDP dissociation inhibitor (GDI) α (ARHGDIA); Desmin (DES); Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1); Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5); Keratin 18 (KRT18); Keratin 19 (KRT19); Keratin 8 (KRT8);
|
Protein
|
Humans
|
Downregulated in Stage T3(Fold Change) : Rho GDP dissociation inhibitor (GDI) α (ARHGDIA) [2.165]; Desmin (DES) [8.929]; Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1) [7.407]; Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5) [1.613]; Keratin 18 (KRT18) [3.322]; Keratin 19 (KRT19) [4.950]; Keratin 8 (KRT8) [4.950];
|
Prognostic
|
Stage T2 Vs Stage T3
|
p<0.05
|
Tissue
|
21305254
|
601
|
vascular endothelial growth factor (VEGF)
|
Protein
|
Humans
|
Upregulated in Lymph Node Metastatis
|
Prognostic
|
Lymph Node Metastatis Posititve Lymph Node Metastatis Negative
|
p<0.001
|
Tissue
|
21367627
|
602
|
matrix metalloproteinase-9 (MMP-9)
|
Protein
|
Humans
|
Upregulated in Lymph Node Metastatis
|
Prognostic
|
Lymph Node Metastatis Posititve Lymph Node Metastatis Negative
|
p<0.001
|
Tissue
|
21367627
|
603
|
Stromal cell-derived factor-1 (SDF-1)
|
Protein
|
Humans
|
Upregulated in Lymph Node Metastatis
|
Prognostic
|
Lymph Node Metastatis Posititve Lymph Node Metastatis Negative
|
p<0.001
|
Tissue
|
21367627
|
604
|
Stromal cell-derived factor-1 (SDF-1)
|
Protein
|
Humans
|
Patients with low levels survived longer than those with high levels
|
Prognostic
|
Prostate Cancer Specific Survival VS No Survival
|
Univariate: p<0.001; Multivariate: p=0.017
|
Tissue
|
21367627
|
605
|
vascular endothelial growth factor (VEGF)
|
Protein
|
Humans
|
Patients with low levels survived longer than those with high levels
|
Prognostic
|
Prostate Cancer Specific Survival VS No Survival
|
Univariate: p<0.001; Multivariate: p<0.001
|
Tissue
|
21367627
|
606
|
matrix metalloproteinase-9 (MMP-9)
|
Protein
|
Humans
|
Patients with low levels survived longer than those with high levels
|
Prognostic
|
Prostate Cancer Specific Survival VS No Survival
|
p<0.001
|
Tissue
|
21367627
|
641
|
Ki-67
|
Protein
|
Humans
|
Upregulated in Black men
|
Prognostic
|
Prostate Cancer in Black Men Vs Prostate Cancer in White Men
|
Univariate: p=0.02; Multivariate: =0.002
|
Tissue
|
21519348
|
642
|
Norm AR (Androgen Receptor)
|
Protein
|
Humans
|
Upregulated in Black men
|
Prognostic
|
Prostate Cancer in Black Men Vs Prostate Cancer in White Men
|
Univariate: p=0.006; Multivariate: p=0.001
|
Tissue
|
21519348
|
643
|
Ki-67/lum
|
Protein
|
Humans
|
Upregulated in Black men
|
Prognostic
|
Prostate Cancer in Black Men Vs Prostate Cancer in White Men
|
p=0.022
|
Tissue
|
21519348
|
653
|
Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3) + Biopsy T-stage + Gleason Score
|
Protein
|
Humans
|
Downregulated in Patients with Gleason Score Upgradation
|
Prognostic
|
Gleason Score Upgradation Vs No Gleason Score Upgradation
|
p = 0.024
|
Serum
|
21520165
|
654
|
Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3) + Biopsy T-stage + Gleason Score
|
Protein
|
Humans
|
Downregulated in Patients with Gleason Score Upgradation
|
Prognostic
|
Gleason Score Upgradation Vs No Gleason Score Upgradation
|
NA
|
Serum
|
21520165
|
655
|
enhancer of zeste homologue 2 (EZH2)
|
Protein
|
Humans
|
Progression Vs No Progression
|
Prognostic
|
Progression Free Survival Vs No Progression Free Survival
|
p=0.004
|
Tissue
|
21592298
|
656
|
minichromosome maintenance protein 7 (MCM7)
|
Protein
|
Humans
|
Progression Vs No Progression
|
Prognostic
|
Progression Free Survival Vs No Progression Free Survival
|
p<0.001
|
Tissue
|
21592298
|
657
|
Ki-67
|
Protein
|
Humans
|
Increased expression in patients with Progression
|
Prognostic
|
Progression Free Survival Vs No Progression Free Survival
|
p<0.001
|
Tissue
|
21592298
|
665
|
MKI67 (Ki-67) + TOP2A (DNA topoisomerase II, alpha) + E2F1 (E2F transcription factor 1)
|
Genes
|
Humans
|
TOP2A, E2F1: Increased expression with earlier Biochemical Recurrence,
|
Prognostic
|
PSA Reccurence Vs No Recurrence for 8 years
|
p=0.001
|
Tissue
|
21629784
|
666
|
PSA+ Grade + Stage +MKI67 (Ki-67) + TOP2A (DNA topoisomerase II, alpha) + E2F1 (E2F transcription factor 1)
|
Genes
|
Humans
|
TOP2A, E2F1: Increased expression with earlier Biochemical Recurrence,
|
Prognostic
|
PSA Reccurence Vs No Recurrence for 8 years
|
p=0.005
|
Tissue
|
21629784
|
667
|
NA
|
miRNA
|
Humans
|
Downregulated in Bone Metastatis:
|
Prognostic
|
Primary vs Bone Metastatis
|
p<0.05
|
Tissue
|
21647377
|
668
|
NA
|
miRNA
|
Humans
|
Upregulated in Bone Metastatis:
|
Prognostic
|
Primary vs Bone Metastatis
|
p<0.05
|
Tissue
|
21647377
|
669
|
miR-143
|
miRNA
|
Humans
|
Downregulated in Bone Metastatis: 12.9 fold
|
Prognostic
|
Primary vs Bone Metastatis
|
p=0.012
|
Tissue
|
21647377
|
670
|
miR-145
|
miRNA
|
Humans
|
Downregulated in Bone Metastatis: 17.3 fold
|
Prognostic
|
Primary vs Bone Metastatis
|
p=0.014
|
Tissue
|
21647377
|
671
|
miR-143
|
miRNA
|
Humans
|
Downregulated in Bone Metastatis
|
Prognostic
|
Bone Metastatis Vs No Bone Metastasis
|
p=0.039
|
Tissue
|
21647377
|
672
|
miR-145
|
miRNA
|
Humans
|
Downregulated in Bone Metastatis
|
Prognostic
|
Bone Metastatis Vs No Bone Metastasis
|
p=0.041
|
Tissue
|
21647377
|
679
|
miR-141
|
miRNA
|
Humans
|
Upregulated with increasing PSA
|
Prognostic
|
progression Vs No Progression
|
p<0.001
|
Plasma
|
21723797
|
680
|
Circulating Tumor Cells
|
Others
|
Humans
|
Upregulated with increasing PSA
|
Prognostic
|
progression Vs No Progression
|
p=0.002
|
Plasma
|
21723797
|
681
|
Lactate Dehydrogenase (LDH)
|
Metabolites
|
Humans
|
Upregulated with increasing PSA
|
Prognostic
|
progression Vs No Progression
|
p= 0.014
|
Plasma
|
21723797
|
682
|
thrombospondin 1 (THBS1) + C-Reactive Prostien (CRP) + poliovirus receptor-related 1 (PVRL1) + memembrane metallo endopeptidase (MME) +ephrin- A5 (EFNA5)
|
Protein
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival (12 months)
|
NA
|
Serum
|
21741162
|
683
|
thrombospondin 1 (THBS1) + C-Reactive Prostien (CRP) + poliovirus receptor-related 1 (PVRL1) + memembrane metallo endopeptidase (MME) +ephrin- A5 (EFNA5)
|
Protein
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival (24 months)
|
NA
|
Serum
|
21741162
|
684
|
PVRL1 (poliovirus receptor-related 1); PRG4 (proteoglycan 4); AP (alkaline phosphatase); FSTL1 (follistatin-like 1); Albumin; CEACAM1 (carcinoembryonic antigen related cell adhesion molecule 1); ANPEP (alanyl (membrane) aminopeptidase); CRP (C-reactive protein); Hb (hemoglobin); CADM1a (cell adhesion molecule 1a); POSTN (periostin, osteoblast specific factor); CADM1b (cell adhesion molecule 1b); CP (ceruloplasmin); AZGP1 (alpha-2-glycoprotein 1, zinc-binding).
|
Protein
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
PVRL1 (poliovirus receptor-related 1) p= 0.002; CD10 p= 0.004; PRG4 (proteoglycan 4) p = 0.006; AP (alkaline phosphatase) p= 0.007; FSTL1 (follistatin-like 1) p= 0.01; Albumin p= 0.016; CEACAM1 (carcinoembryonic antigen related cell adhesion molecule 1) p = 0.018; ANPEP (alanyl (membrane) aminopeptidase) p=0.02; CRP (C-reactive protein) p= 0.02; Hb (hemoglobin) p=0.022; CADM1a (cell adhesion molecule 1a) p =0.03; POSTN (periostin, osteoblast specific factor) p=0.034; CADM1b (cell adhesion molecule 1b) p=0.035; CP (ceruloplasmin) p =0.046; AZGP1 (alpha-2-glycoprotein 1, zinc-binding) p =0.046.
|
Serum
|
21741162
|
687
|
miR-139-5p; miR-1; miR-133b; miR-133a; miR-143*; miR-145*; miR-143; miR-145; miR-27b, miR-221; miR-222; miR-378; miR-204; miR-141*; miR-32; let-7b; miR-183*, miR-301b; miR-106b; miR-93; miR-25; miR-183; miR-96; miR-425; miR-663
|
miRNA
|
Humans
|
NA
|
Prognostic
|
group I (good prognosis) from group II (poor prognosis)
|
p=0.0005
|
Tissue
|
21765474
|
695
|
AMACR
|
mRNA
|
Humans
|
Upregulated in locally advanced cancers
|
Prognostic
|
localized Vs locally advanced cancers
|
p= 0.044
|
Urine
|
21788966
|
696
|
EZH2
|
mRNA
|
Humans
|
Upregulated in locally advanced cancers
|
Prognostic
|
localized Vs locally advanced cancers
|
p= 0.022
|
Urine
|
21788966
|
697
|
EZH2
|
mRNA
|
Humans
|
Upregulated in Intermediate and further upregulated in High Risk Group
|
Prognostic
|
Low Vs Intermediate Vs High Risk Group
|
High vs low-risk group patients (P = 0.002), intermediate vs low risk group patients (P = 0.044)
|
Urine
|
21788966
|
698
|
PCAT-1
|
ncRNA
|
Humans
|
Upregulated in a subset of metastatic and high-grade localized (Gleason score ≥7) cancers
|
Prognostic
|
High grade tumor vs. low grade tumor/non-tumor
|
NA
|
Tissue
|
21804560
|
699
|
KBP4; CRKL; PDHB, PRDX3; HYPK; MYL6;KHSRP; ENO1; ANXA5 ; RPLP0; OSTF1; CFL1; TXNDC12 ; PFDN5 ; HRNR; COPS8 ;
|
Protein
|
Humans
|
Upregulated (Atleast 2 fold): [KHSRP; ENO1; ANXA5 ; RPLP0; OSTF1; CFL1; TXNDC12 ; PFDN5 ; HRNR; COPS8;]Downregulated (Atleast 0.5 fold): [KBP4; CRKL; PDHB, PRDX3; HYPK; MYL6;]
|
Prognostic
|
CD44+ Vs CD44- Cells
|
p<0.05
|
Cell Lines
|
21820414
|
700
|
Cofilin
|
Protein
|
Humans
|
Upregulated in CD44++ Cells
|
Prognostic
|
CD44+ Vs CD44- Cells
|
p<0.01
|
Cell Lines
|
21820414
|
701
|
Annexin A5
|
Protein
|
Humans
|
Upregulated in CD44++ Cells
|
Prognostic
|
CD44+ Vs CD44- Cells
|
p<0.05
|
Cell Lines
|
21820414
|
702
|
Methylation Status of (RARB or GSTP1 or RASSF1)
|
Methylation
|
Humans
|
Hypermethylated in Cancer
|
Prognostic
|
Methylation in Patients with PCa
|
NA
|
Urine
|
21822036
|
703
|
Methylation Status of RARB
|
Methylation
|
Humans
|
Hypermethylated in Cancer
|
Prognostic
|
Methylation in Patients with PCa
|
NA
|
Tissue
|
21822036
|
704
|
Methylation Status of RARB
|
Methylation
|
Humans
|
Hypermethylated in Gleason Score 7 (PMR>=50)
|
Prognostic
|
Gleason Score 6 Vs Gleason Score 7
|
p=0.01
|
Urine
|
21822036
|
713
|
α2-macroglobulin (α2M)
|
Protein
|
Humans
|
Downregulated with α2M deficiency (Without α2M deficiency: 252.45±125.07 Vs with α2M deficiency: 12.75±5.60)
|
Prognostic
|
PCa patients without α2M deficiency vs. PCa patients with α2M deficiency
|
p<0.01
|
Serum
|
21894431
|
714
|
C-reactive protein (CRP)
|
Protein
|
Humans
|
Downregulated with α2M deficiency (without α2M deficiency: 1534.6±1482.8 Vs with α2M deficiency: 173±90.3)
|
Prognostic
|
PCa patients without α2M deficiency vs. PCa patients with α2M deficiency
|
p<0.01
|
Serum
|
21894431
|
715
|
serum amyloid A (SAA)
|
Protein
|
Humans
|
Downregulated with α2M deficiency (without α2M deficiency: 54.7±44.5 Vs with α2M deficiency: 2.15±1.68)
|
Prognostic
|
PCa patients without α2M deficiency vs. PCa patients with α2M deficiency
|
p<0.01
|
Serum
|
21894431
|
716
|
interleukin-6 (IL-6)
|
Protein
|
Humans
|
Downregulated with α2M deficiency (without α2M deficiency: 46.50±40.65 Vs with α2M deficiency: 3.38±2.61)
|
Prognostic
|
PCa patients without α2M deficiency vs. PCa patients with α2M deficiency
|
p<0.01
|
Serum
|
21894431
|
720
|
Katanin p60
|
Protein
|
Humans
|
Upregulated in PCa
|
Prognostic
|
bone metastasis (Met) Vs No bone metastasis (controls)
|
p<0.05
|
Bone Marrow (Tissue)
|
21681775
|
752
|
CEP55
|
Protein
|
Humans
|
Upregulated in Patients with Recurrence
|
Prognostic
|
PSA Reccurence Vs No Recurrence
|
p<0.0001
|
Tissue
|
21917134
|
753
|
NUF2
|
Protein
|
Humans
|
Upregulated in Patients with Recurrence
|
Prognostic
|
PSA Reccurence Vs No Recurrence
|
p<0.0001
|
Tissue
|
21917134
|
754
|
PAGE4
|
Protein
|
Humans
|
Downregulated in Patients with Recurrence
|
Prognostic
|
PSA Reccurence Vs No Recurrence
|
p=0.0045
|
Tissue
|
21917134
|
755
|
CEP55
|
Protein
|
Humans
|
Upregulated with high Gleason Score
|
Prognostic
|
Gleason Score (≤6, (3+4), (4+3), 8-10)
|
For Hazrard Ratio: (p = 0.003)
|
Tissue
|
21917134
|
756
|
NUF2
|
Protein
|
Humans
|
Upregulated with high Gleason Score
|
Prognostic
|
Gleason Score (≤6, (3+4), (4+3), 8-10)
|
For Hazrard Ratio: (p = 0.002)
|
Tissue
|
21917134
|
757
|
PBK
|
Protein
|
Humans
|
Upregulated with high Gleason Score
|
Prognostic
|
Gleason Score (≤6, (3+4), (4+3), 8-10)
|
For Hazrard Ratio: (p = 0.001)
|
Tissue
|
21917134
|
758
|
TTK
|
Protein
|
Humans
|
Upregulated with high Gleason Score
|
Prognostic
|
f
|
For Hazrard Ratio: (p = 0.002)
|
Tissue
|
21917134
|
759
|
PAGE4
|
Protein
|
Humans
|
Downregulated with high Gleason Score
|
Prognostic
|
Gleason Score (≤6, (3+4), (4+3), 8-10)
|
For Hazrard Ratio: (p = 0.002)
|
Tissue
|
21917134
|
767
|
OPNa (osteopontin -a )
|
mRNA
|
Humans
|
Upregulated with high Gleason Score (Median for GS< 7: 0.35, Median for GS ≥ 7: 84.54)
|
Prognostic
|
Gleason Score <7 Vs Gleason Score ≥ 7
|
p= 0.006
|
Tissue
|
21963599
|
768
|
OPNb (osteopontin -b )
|
mRNA
|
Humans
|
Upregulated with high Gleason Score (Median for GS< 7: 3.54, Median for GS ≥ 7: 61.19)
|
Prognostic
|
Gleason Score <7 Vs Gleason Score ≥ 7
|
p = 0.003
|
Tissue
|
21963599
|
769
|
OPNa (osteopontin -a )
|
mRNA
|
Humans
|
Upregulated with high Gleason Score (Median for GS< 7: 112.06, Median for GS ≥ 7: 526.39)
|
Prognostic
|
Gleason Score <7 Vs Gleason Score ≥ 7
|
p= 0.001
|
Tissue
|
21963599
|
770
|
miR-7; miR-126; miR-144; miR-144*; miR-335*; miR-374a;miR-374a*; miR-28-3p; miR-542-3p
|
miRNA
|
Humans
|
Upregulated: [miR-7: (3.22 fold); miR-126: (14.45 fold); miR-144 (6.78 fold);miR-144* (12.98 fold); miR-335* (1.39 fold) ; miR-374a (2.43 fold) ; miR-374a (1.16 fold) ; miR-28-3p (1.69 fold); miR-542-3p (3.72 fold)]
|
Prognostic
|
Metastatic Vs Non Metastatic
|
p<0.001
|
Tissue
|
21980368
|
771
|
miR-7-1*; miR-126*; miR-335; miR-28-5p; miR-339-3p; miR-339-5p; miR-542-5p
|
miRNA
|
Humans
|
Downregulated: [miR-7-1* (8.88 fold); miR-126* (3.46b fold); miR-335 (2,42 fold); miR-28-5p (6.84 fold); miR-339-3p (-1.57 fold); miR-339-5p (5.26 fold); miR-542-5p (13.31 fold)]
|
Prognostic
|
Metastatic Vs Non Metastatic
|
p<0.001
|
Tissue
|
21980368
|
777
|
Thiobarbituric acid reactive substances (TBARS)
|
Protein
|
Humans
|
Upregulated in Localised and Bone Metastasis
|
Prognostic
|
Controls Vs Localised Vs Bone Metastasis
|
p<0.05
|
Plasma
|
21993000
|
778
|
Vitamin -C
|
Protein
|
Humans
|
Downregulated in Localised and Bone Metastasis
|
Prognostic
|
Controls Vs Localised Vs Bone Metastasis
|
p<0.05
|
Serum
|
21993000
|
779
|
Vitamin -E
|
Protein
|
Humans
|
Downregulated in Localised and Bone Metastasis
|
Prognostic
|
Controls Vs Localised Vs Bone Metastasis
|
p<0.05
|
Serum
|
21993000
|
780
|
Thiobarbituric acid reactive substances (TBARS)
|
Protein
|
Humans
|
Upregulated in PCA (without treatment,), PCA (with Treatment: Goserelin A), and PCA (with treatment : Cytoproterone A.)
|
Prognostic
|
Controls Vs PCA (No Treatment) Vs PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A)
|
p<0.05 (Controls Vs PCA (No Treatment) ) & Controls Vs PCA (with Treatment: Goserelin A) & Controls Vs PCA (with Treatment: Cytoproterone A) & PCA (No Treatment) Vs PCA (with Treatment: Cytoproterone A) & PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A)
|
Plasma
|
21993000
|
781
|
Vitamin -C
|
Protein
|
Humans
|
Downregulated in PCA (without treatment,), PCA (with Treatment: Goserelin A), and PCA (with treatment : Cytoproterone A.)
|
Prognostic
|
Controls Vs PCA (No Treatment) Vs PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A)
|
p<0.05 (Controls Vs PCA (No Treatment) ) & Controls Vs PCA (with Treatment: Goserelin A) & Controls Vs PCA (with Treatment: Cytoproterone A)
|
Serum
|
21993000
|
782
|
Vitamin -E
|
Protein
|
Humans
|
Downregulated in PCA (without treatment,), PCA (with Treatment: Goserelin A), and PCA (with treatment : Cytoproterone A.)
|
Prognostic
|
Controls Vs PCA (No Treatment) Vs PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A)
|
p<0.05 (Controls Vs PCA (No Treatment) ) & Controls Vs PCA (with Treatment: Goserelin A) & Controls Vs PCA (with Treatment: Cytoproterone A) & PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A) & PCA (with Treatment: Goserelin A) Vs PCA (with no Treatment)
|
Serum
|
21993000
|
783
|
Thiobarbituric acid reactive substances (TBARS)
|
Protein
|
Humans
|
Upregulated in PCA (GS<7, GS=7, GS>7)
|
Prognostic
|
Controls Vs GS<7 Vs GS =7 Vs GS>7
|
p<0.05 (Controls Vs GS<7) & (Controls Vs GS=7) & (Controls Vs GS>7)
|
Plasma
|
21993000
|
784
|
Vitamin -C
|
Protein
|
Humans
|
Upregulated in PCA (GS<7, GS=7, GS>7)
|
Prognostic
|
Controls Vs GS<7 Vs GS =7 Vs GS>8
|
p<0.05 (Controls Vs GS<7) & (Controls Vs GS=7) & (Controls Vs GS>7)
|
Serum
|
21993000
|
785
|
Vitamin -E
|
Protein
|
Humans
|
Upregulated in PCA (GS<7, GS=7, GS>7)
|
Prognostic
|
Controls Vs GS<7 Vs GS =7 Vs GS>9
|
p<0.05 (Controls Vs GS<7) & (Controls Vs GS=7) & (Controls Vs GS>7)
|
Serum
|
21993000
|
798
|
hsa-mir-375
|
miRNA
|
Humans
|
High expression associated with an increased risk of BCR
|
Prognostic
|
Biochemical Recurrenece
|
p = 0.002
|
Serum
|
22052531
|
799
|
hsa-mir-375
|
miRNA
|
Humans
|
High expression with reduced chances of relapse free survival
|
Prognostic
|
Biochemical Recurrenece
|
Univariate: p=0.0001; Multivariate: p=0.0260
|
Serum
|
22052531
|
800
|
PRKAR1A; LRRN3; PCDH17; TTN; LAIR2; RNASE3; CEACAM6; AZU1; HIST1H4C; PGLYRP1; CEACAM8; LCN2; MPO; CAMP; DEFA1;DEFA1; DEFA1; DEFA3; DEFA1; DEFA1; CTSG; DEFA4; ELA2;
|
mRNA
|
Humans
|
Downregulated (0.6-0.82 fold): [PRKAR1A; LRRN3; PCDH17; TTN;] ; Upregulated (0.6 - 1.36 fold): [LAIR2; RNASE3; CEACAM6; AZU1; HIST1H4C; PGLYRP1; CEACAM8; LCN2; MPO; CAMP; DEFA1e;DEFA1e; DEFA1e; DEFA3; DEFA1e; DEFA1e; CTSG; DEFA4; ELA2;]
|
Prognostic
|
Long-term survivors (survived for >900 days) Vs Short-Term survivors (died within 300 days) - prevaccination
|
p< 0.008
|
Blood
|
22071976
|
801
|
LTB; OLR1; CEACAM1; ARG1; MYL4; ALAS2; SLPI; SELENBP1; SNCA; AZU1; HMGXB4; RNASE3; HBQ1; MMP9; GYPE; SNCA; EPB42; HP; IFIT1L; BPI; CEACAM6; MPO; OLFM4; HBM; ALAS2; CEACAM8; CA1; HBD; LCN2; CTSG; DEFA1; CAMP; ELA2; DEFA4; DEFA3; DEFA1; DEFA1; DEFA1; DEFA1;
|
mRNA
|
Humans
|
Downregulated: [LTB (1.03 fold)] ; Upregulated (1.04- 2.87 fold): [OLR1; CEACAM1; ARG1; MYL4; ALAS2; SLPI; SELENBP1; SNCAe; AZU1; HMGXB4; RNASE3; HBQ1; MMP9; GYPE; SNCAe; EPB42; HP; IFIT1L; BPI; CEACAM6; MPO; OLFM4; HBM; ALAS2; CEACAM8; CA1; HBD; LCN2; CTSG; DEFA1e; CAMP; ELA2; DEFA4; DEFA3; DEFA1e; DEFA1e; DEFA1e; DEFA1e;]
|
Prognostic
|
Long-term survivors (survived for >900 days) Vs Short-Term survivors (died within 300 days) - Postvaccination
|
p< 0.008
|
Blood
|
22071976
|
803
|
LRRN3+PCDH17+HIST1H4C+PGLYRP1
|
mRNA
|
Humans
|
Downregulated: [LRRN3; PCDH17;] ; Upregulated: [HIST1H4C; PGLYRP1;]
|
Prognostic
|
Long-term survivors (survived for >900 days) Vs Short-Term survivors (died within 300 days) - prevaccination
|
p< 0.008
|
Blood
|
22071976
|
804
|
Methylation of GSTP1
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Prognostic
|
negative histology followed by a positive biopsy more than 24 months later
|
NA
|
Tissue
|
22077694
|
805
|
Methylation of APC
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Prognostic
|
negative histology followed by a positive biopsy more than 24 months later
|
P=0.012
|
Tissue
|
22077694
|
806
|
Methylation of GSTP1 + APC
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Prognostic
|
negative histology followed by a positive biopsy more than 24 months later
|
NA
|
Tissue
|
22077694
|
807
|
%p2PSA
|
Protein
|
Humans
|
Upregulated in Gleason Score ≥7
|
Prognostic
|
Gleason Score ≥7 and Gleason Score <7
|
p<0.0001
|
Blood
|
22078333
|
808
|
Prostate Helth Index (phi)
|
Protein
|
Humans
|
Upregulated in Gleason Score ≥7
|
Prognostic
|
Gleason Score ≥7 and Gleason Score <7
|
p<0.0001
|
Blood
|
22078333
|
809
|
%p2PSA
|
Protein
|
Humans
|
Upregulated with GS upgrading
|
Prognostic
|
Gleason sum upgrading from 6 to 7
|
p<0.0001
|
Blood
|
22078333
|
810
|
Prostate Helth Index (phi)
|
Protein
|
Humans
|
Upregulated with GS upgrading
|
Prognostic
|
Gleason sum upgrading from 6 to 7
|
p<0.0001
|
Blood
|
22078333
|
811
|
%p2PSA
|
Protein
|
Humans
|
Upregulated in Tumor Stage pt3
|
Prognostic
|
pathological stage pt2 Vs pathological stage pt3
|
p<0.0001
|
Blood
|
22078333
|
812
|
Prostate Helth Index (phi)
|
Protein
|
Humans
|
Upregulated in Tumor Stage pt3
|
Prognostic
|
pathological stage pt2 Vs pathological stage pt3
|
p<0.0001
|
Blood
|
22078333
|
813
|
TGFβ1 (transforming growth factor beta 1)
|
mRNA
|
Humans
|
Associated with Prostate cancer specific Survival
|
Prognostic
|
disease specific survival Vs no survival
|
p=0.0
|
Tissue
|
22113713
|
814
|
(IL-7) Interleukin-7
|
mRNA
|
Humans
|
Associated with Prostate cancer specific Survival
|
Prognostic
|
disease specific survival Vs no survival
|
p=0.03
|
Tissue
|
22113713
|
815
|
miRNA - 221 and miRNA-222
|
miRNA
|
Humans
|
Upregulated in aggressive Prostate Cancer (Aggressive: 20.1 ± 2.4; Non Aggressive: 3.4 ± 0.2)
|
Prognostic
|
Agressive Vs Non - Agressive Prostate Cancer
|
p=0.001
|
Tissue
|
22117988
|
816
|
ARHI
|
mRNA
|
Humans
|
Downregulated in aggressive Prostate Cancer (Aggressive:9.6 ± 1.2; Non Agressive: 8.3 ± 2.3 )
|
Prognostic
|
Agressive Vs Non - Agressive Prostate Cancer
|
p=0.001
|
Tissue
|
22117988
|
817
|
Interleukin-18 (IL-18)
|
Protein
|
Humans
|
Upregulated in BPH and Prostate cancer: [ Controls: 143.97 ± 2.29; BPH: 145.88 ± 1.93; TNM Stage 2: 229.54 ± 3.30; TNM Stage 3: 245.66 ± 4.05; TNM Stage 4: 251.64 ± 4.12]
|
Prognostic
|
Controls Vs BPH Vs TNM T2 stage Vs TNM T3 stage Vs TNM T4 stage
|
p<0.05 (Controls Vs TNM Stage 2,3 and 4 ; BPH Vs TNM Stage 2,3 and 4; TNM Stage 2 Vs TNM Stage 3,4]
|
Serum
|
22126577
|
818
|
Interleukin-10 (IL-10)
|
Protein
|
Humans
|
Upregulated in BPH and Prostate cancer: [ Controls: 2.08 ± 0.27; BPH: 2.15 ± 0.18; TNM Stage 2: 8.03 ± 0.49; TNM Stage 3: 13.06 ± 0.45; TNM Stage 4: 6.32 ± 0.29]
|
Prognostic
|
Controls Vs BPH Vs TNM T2 stage Vs TNM T3 stage Vs TNM T4 stage
|
p<0.05 (Controls Vs TNM Stage 2,3 and 4 ; BPH Vs TNM Stage 2,3 and 4; TNM Stage 2 Vs TNM Stage 3,4]
|
Serum
|
22126577
|
819
|
Interleukin-18 (IL-18)
|
Protein
|
Humans
|
Increased expression in patients with poor survival
|
Prognostic
|
Survival Vs No Survival
|
p<0.001
|
Serum
|
22126577
|
820
|
Interleukin-10 (IL-10)
|
Protein
|
Humans
|
Increased expression in patients with poor survival
|
Prognostic
|
Survival Vs No Survival
|
p<0.001
|
Serum
|
22126577
|
821
|
Methylation Status of AIM1
|
Methylation
|
Humans
|
Decreased hypermethylation in progression
|
Prognostic
|
Time To Progression
|
Univariate: p = 0.02 ; Multivariate: p = 0.05
|
Tissue
|
22127895
|
823
|
TDRD1
|
mRNA
|
Humans
|
Upregulated in TMPRSS2-ERG gene fusion (36 fold) compared to benign samples and TMPRSS2-ERG gene fusion compared to non fusion (23 fold).
|
Prognostic
|
Benign Vs TMPRSS2-ERG gene fusion Vs non-fusion
|
TMPRSS2-ERG positive tumors compared to normal (p = 1.77*10^-9) and fusion-negative samples (p = 1.51*10^-9)
|
Tissue
|
22142399
|
830
|
Secreted frizzled-related protein (SFRP)-2
|
Protein
|
Humans
|
Upregulated in Gleason Grade 5 (PCa: 3.16 ± 0.99; Control: 0.77±0.15)
|
Prognostic
|
Gleason Grade 3,4 Vs Gleason Grade 5
|
p<0.0001
|
Tissue
|
22175903
|
834
|
Mutation Status of StAR
|
Mutation
|
Humans
|
Allelic Loss in StAR in Recurrence
|
Prognostic
|
Biochemical Recurrenece (5 years)
|
p=0.00269
|
Tissue
|
22213075
|
835
|
Mutation Status of HSD17B2
|
Mutation
|
Humans
|
Allelic Loss in HSD17B2 in Recurrence
|
Prognostic
|
Biochemical Recurrenece (5 years)
|
p=0.031
|
Tissue
|
22213075
|
836
|
Mutation Status of StAR or HSD17B2
|
Mutation
|
Humans
|
Allelic Loss in atleast one (HSD17B2 or StaR) in Recurrence
|
Prognostic
|
Biochemical Recurrenece (5 years)
|
p=0.0028
|
Tissue
|
22213075
|
842
|
breast cancer antiestrogen resistance 1 (BCAR1)
|
Protein
|
Humans
|
Significantly associated with Biochemical Relapse
|
Prognostic
|
Biochemical Recurrence
|
p=0.02
|
Tissue
|
22241677
|
863
|
sphingosine-1-phosphate (S1P)
|
Protein
|
Humans
|
Downregulated in Stage 2 PCa than Stage 1 PCa
|
Prognostic
|
Stage 1 Vs Stage 2 prostate cancer
|
p<0.001
|
Plasma
|
22315056
|
864
|
sphingosine-1-phosphate (S1P)
|
Protein
|
Humans
|
Downregulated in Patients with No survival (No Survival: 5.11±0.75 Vs Survival: 7.02±0.22)
|
Prognostic
|
disease specific survival Vs no survival
|
p=0.0439
|
Plasma
|
22315056
|
866
|
Testosterone
|
Protein
|
Humans
|
Downregulated in Gleason Score 8-9
|
Prognostic
|
Gleason Sum 5 Vs Gleason Sum 8-9
|
p=0.0495
|
Plasma
|
22315056
|
867
|
Testosterone
|
Protein
|
Humans
|
Upregulated in Metastases
|
Prognostic
|
Metastases Vs No Metastases
|
p<0.0001
|
Plasma
|
22315056
|
873
|
cDNA FLJ51403 ; Elongation Factor 1A (EF-A1) ; Alpha 1B - glycoprotien; Complement component C7; Inter-alpha (Globulin) inhibitor H4; Kininogen 1; Plasma retinol-binding protien; cDNA FLJ77744; Complement C1r subcomponent-like Protein; Ficolin-3
|
Protein
|
Humans
|
Upregulated: [cDNA FLJ51403 (1.9 fold); Elongation Factor 1A (EF-A1) (1.8 fold); Alpha 1B - glycoprotien (1.1 fold) ; Complement component C7 (1.1 fold) ; Inter-alpha (Globulin) inhibitor H4;(1.1 fold)]; Downregulated: [Kininogen 1 (1.1 fold); Plasma retinol-binding protien (1.2 fold); cDNA FLJ77744 (1.4 fold); Complement C1r subcomponent-like Protein (1.4 fold); Ficolin-3 (1.4 fold)]
|
Prognostic
|
Non Progressing Vs Progressing Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
874
|
Inter-alpha-trypsin inhibitor heavy chain H3 + Antithrombin III
|
Protein
|
Humans
|
Upregulated [Inter-alpha-trypsin inhibitor heavy chain H3 (2.0 fold) + Antithrombin III (1.2 fold)]
|
Prognostic
|
Non Progressing Vs Progressing Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
875
|
Apliopoprotien A-IV + Complement Component 4B
|
Protein
|
Humans
|
Downregulated [Apliopoprotien A-IV (1.1 fold)+ Complement Component 4B (1.3 fold)]
|
Prognostic
|
Non Progressing Vs Progressing Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
876
|
Beta 2-Glycoprotein 1 + Somatomedin- B
|
Protein
|
Humans
|
Downregulated [Beta 2-Glycoprotien 1 (1.1 fold) + Somatomedin- B (1.2 fold)]
|
Prognostic
|
Non Progressing Vs Progressing Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
877
|
Alpha-2 HS-glycoprotien chain B + Afamin + Fibronectin 1
|
Protein
|
Humans
|
Downregulated [Alpha-2 HS-glycoprotien chain B (1.2 fold) + Afamin (1.5 fold)+ Fibronectin 1 (1.6 fold)]
|
Prognostic
|
Non Progressing Vs Progressing Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
878
|
Elongation Factor 1A (EFA1) ; Zinc-alpha-2-glycoprotien ; Complement Compnent C6; Hemopexin ; Vitamin D-binding protien; cDNA FLJ53698; Histidine-rich glycoprotien; Inter-alpha-trypsin inhibitor heavy chain H1; Inter-alpha-trypsin inhibitor heavy chain H2; N-acetlymuramoyl-L-alanine amidase; Thyroxine-binding globulin
|
Protein
|
Humans
|
Upregulated [Elongation Factor 1A (EFA1) (1.4 fold) ; Zinc-alpha-2-glycoprotien (1.3 fold) ; Complement Compnent C6 (1.2 fold); Hemopexin (1.2 fold); Vitamin D-binding protien (1.1 fold)];Downregulated [cDNA FLJ53698 (1.3 fold); Histidine-rich glycoprotien (1.3 fold); Inter-alpha-trypsin inhibitor heavy chain H1 (1.3 fold); Inter-alpha-trypsin inhibitor heavy chain H2 (1.4 fold); N-acetlymuramoyl-L-alanine amidase (1.4 fold); Thyroxine-binding globulin (1.5 fold)]
|
Prognostic
|
Progressing Vs Metastatic Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
879
|
Apliopoprotien A-IV + Complement Component 4B
|
Protein
|
Humans
|
Upregulated [Apliopoprotien A-IV (1.3 fold) + Complement Component 4B (1.4 fold)]
|
Prognostic
|
Progressing Vs Metastatic Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
880
|
Alpha-2 HS-glycoprotien chain B + Afamin + Fibronectin 1
|
Protein
|
Humans
|
Downregulated [Alpha-2 HS-glycoprotien chain B (1.9 fold) + Afamin (1.9 fold)+ Fibronectin 1 (2.1 fold)]
|
Prognostic
|
Progressing Vs Metastatic Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
881
|
cDNA FLJ54228 + Alpha-1-antichymotrypsin+ Complement component C9b+ cDNA FLJ58564 + Complement C5+Ceruloplasmin+cDNA FLJ55673
|
Protein
|
Humans
|
Upregulated [cDNA FLJ54228 (2.2 fold)+ Alpha-1-antichymotrypsin (1.8 fold)+ Complement component C9b (1.4 fold)+ cDNA FLJ58564 (1.3 fold) + Complement C5 (1.3 fold) +Ceruloplasmin (1.2 fold) +cDNA FLJ55673 (1.1 fold)]
|
Prognostic
|
Progressing Vs Metastatic Prostate Cancer
|
p ≤0.01
|
Serum
|
22355332
|
889
|
Methylation Status of TBX15
|
Methylation
|
Humans
|
Highly methylated in ERG positive fusion compared to ERG negative fusion
|
Prognostic
|
ERG positive fusion compared to ERG negative fusion in Prostate cancer
|
p<0.01
|
Tissue
|
22452941
|
890
|
Methylation Status of HOXD3
|
Methylation
|
Humans
|
Highly methylated in ERG positive fusion compared to ERG negative fusion
|
Prognostic
|
ERG positive fusion compared to ERG negative fusion in Prostate cancer
|
p<0.01
|
Tissue
|
22452941
|
891
|
Methylation Status of CYP26A1
|
Methylation
|
Humans
|
Highly methylated in ERG positive fusion compared to ERG negative fusion
|
Prognostic
|
ERG positive fusion compared to ERG negative fusion in Prostate cancer
|
p≤0.041
|
Tissue
|
22452941
|
892
|
Methylation Status of HOXD3
|
Methylation
|
Humans
|
Differentially Expressed
|
Prognostic
|
Pathological Stage (pT2 Vs pT3/pT4)
|
p=0.026
|
Tissue
|
22452941
|
893
|
Methylation Status of TBX15
|
Methylation
|
Humans
|
Differentially Expressed
|
Prognostic
|
Pathological Stage (pT2 Vs pT3/pT4)
|
p=0.010
|
Tissue
|
22452941
|
894
|
Methylation Status of HOXD3
|
Methylation
|
Humans
|
Differentially Expressed
|
Prognostic
|
Gleason score as ≤ 7 Vs 8 and above
|
p<0.001
|
Tissue
|
22452941
|
895
|
Methylation Status of TBX15 or HOXD3
|
Methylation
|
Humans
|
Differentially Expressed
|
Prognostic
|
Disease specific survival Vs no survival
|
p=0.044
|
Tissue
|
22452941
|
903
|
ERG
|
mRNA
|
Humans
|
Upregulated in TMPRSS2-ERG positive fusion cases
|
Prognostic
|
TMPRSS2-ERG positive fusion compared to TMPRSS2-ERG negative fusion in Prostate cancer
|
p<0.0001
|
Tissue
|
22505341
|
904
|
SPINK1
|
mRNA
|
Humans
|
Upregulated in TMPRSS2-ERG negative fusion cases
|
Prognostic
|
TMPRSS2-ERG positive fusion compared to TMPRSS2-ERG negative fusion in Prostate cancer
|
p=0.03
|
Tissue
|
22505341
|
905
|
ERG
|
mRNA
|
Humans
|
Upregulated in TERT positive cases
|
Prognostic
|
TERT positive compared to TERT negative in Prostate cancer
|
p=0.016
|
Tissue
|
22505341
|
906
|
Fusion status of TMPRSS2-ERG and TERT expression
|
mRNA
|
Humans
|
TMPRSS2–ERG and TERT-negative tumors had significantly lower rate of recurrence
|
Prognostic
|
Biochemical Recurrence Free Survival
|
p=0.025
|
Urine
|
22505341
|
912
|
Minichromosome Maintenance Complex Protein 2 (MCM2) product scores
|
Protein
|
Humans
|
Upregulated with Increasing Gleason Score
|
Prognostic
|
Gleason Score ≤6 Vs 7 Vs ≥8
|
p=0.002
|
Tissue
|
22554381
|
914
|
Ki-67
|
Protein
|
Humans
|
Upregulated with Increasing Gleason Score
|
Prognostic
|
Gleason Score ≤ 6 Vs 7 Vs ≥ 8
|
p=0.008
|
Tissue
|
22554381
|
915
|
Minichromosome Maintenance Complex Protein 2 (MCM2) product scores
|
Protein
|
Humans
|
High in Patients with BCR
|
Prognostic
|
Biochemical Recurrence (Group 1)
|
p=0.001
|
Tissue
|
22554381
|
916
|
Minichromosome Maintenance Complex Protein 2 (MCM2) product score OR ki-67 Product Score
|
Protein
|
Humans
|
High in Patients with BCR
|
Prognostic
|
Biochemical Recurrence (Group 1)
|
p=0.02
|
Tissue
|
22554381
|
917
|
Minichromosome Maintenance Complex Protein 2 (MCM2) product score AND ki-67 Product Score
|
Protein
|
Humans
|
High in Patients with BCR
|
Prognostic
|
Biochemical Recurrence (Group 1)
|
p=0.002
|
Tissue
|
22554381
|
922
|
Methylation Status Of ACTL6B; AEBP1; AMID; CD8A; CRIP1; FLJ30934; FLNC; FMOD; FOXE3; GAS7; GDPD5; HS3ST2; LOC349136; NEUROG1; PLTP; PTGER2; RASGRF2; RUNX3; SIX6; SLC9A3; SPSB4; SRD5A2; SUSD3; SYT10; TMEM74
|
Methylation
|
Humans
|
Hypermethlated in recurrent prostate cancer :
|
Prognostic
|
recurrent prostate cancer Vs nonrecurrent cancer
|
NA
|
Tissue
|
22589488
|
923
|
Methylation Status Of CHST7; LMX1B; RAFTLIN; RASGRF2; TNFRSF10D; ZNF135
|
Methylation
|
Humans
|
Methylated with Clinical Recurrence
|
Prognostic
|
clinical recurrence Vs biochemical recurrence
|
NA
|
Tissue
|
22589488
|
924
|
Methylation Status Of ALPL; AMPH; BCDIN3; BCL11B; BRD4; C18orf34; DCAMKL1; FGF5; FLJ42486; JAM2; LHX9; LOC283537; LRAT; PDE4B; POU3F3; PTGS2; RASGRF2; SLC27A6; SLC03A1; SPSB4; STAT3; SYN2; TACR3; TIRAP; WNT11
|
Methylation
|
Humans
|
Methylated with Systemic Recurrence
|
Prognostic
|
systemic recurrence Vs local recurrence
|
NA
|
Tissue
|
22589488
|
926
|
Methylation Status Of CRIP1; RUNX3; HS3ST2; FLNC; RASGRF2
|
Methylation
|
Humans
|
Methylated in PCA:
|
Prognostic
|
recurrent prostate cancer Vs nonrecurrent cancer
|
NA
|
Tissue
|
22589488
|
927
|
Methylation Status Of PHLDA3; RASGRF2; TNFRSF10D; ZNF135
|
Methylation
|
Humans
|
Hypermethlated in recurrent prostate cancer :
|
Prognostic
|
clinical recurrence Vs biochemical recurrence
|
NA
|
Tissue
|
22589488
|
928
|
Methylation Status Of BCL11B; POU3F3; RASGRF2
|
Methylation
|
Humans
|
Methylated with Clinical Recurrence
|
Prognostic
|
systemic recurrence Vs local recurrence
|
NA
|
Tissue
|
22589488
|
941
|
Mutation Status of KLK3 (-5429 T/G (rs2569733))
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical Recurrence Vs no Biochemical Recurrence (5 years)
|
Univariate Analysis: <0.01 ; Multivariate Analysis : p=0.013
|
Blood
|
22759231
|
942
|
Mutation Status of KLK2 (Arg250Trp (rs198977))
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical Recurrence Vs no Biochemical Recurrence (5 years)
|
Univariate Analysis: p=0.025 ; Multivariate Analysis : p=0.044
|
Blood
|
22759231
|
943
|
Mutation Status of SULT1A1, Arg213His (rs9282861)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical Recurrence Vs no Biochemical Recurrence (5 years)
|
Univariate Analysis: 0.014
|
Blood
|
22759231
|
944
|
Mutation Status of BGLAP, -198 T/C (rs1800247)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical Recurrence Vs no Biochemical Recurrence (5 years)
|
Univariate Analysis: <0.01 ; Multivariate Analysis : p=0.020
|
Blood
|
22759231
|
945
|
Mutation Status of KLK3 + KLK2 + SULT1A1 + BGLAP + Nonogram
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical Recurrence Vs no Biochemical Recurrence (5 years)
|
p<0.001
|
Blood
|
22759231
|
952
|
Mutation Status of LEPR (LEPR Gln223Arg)
|
Mutation
|
Humans
|
Increased Risk of High Grade PCa
|
Prognostic
|
LEPR Gln223Arg ( A Vs G mutation) in Patients with High Grade PCa
|
NA
|
NA
|
22792137
|
953
|
Mutation Status of SPP1 (SPP1-66 T>G)
|
Mutation
|
Humans
|
Increased Risk of High Grade PCa
|
Prognostic
|
SPP1 mutaion (SPP1- 66 T>G) in Patients with High Grade PCa
|
NA
|
NA
|
22792137
|
954
|
Mutation Status of IGF1R (IGF1R+3174 G>A)
|
Mutation
|
Humans
|
Increased Risk of High Grade PCa
|
Prognostic
|
IGF1R mutation (IGF1R+3174 G>A) in Patients with High Grade PCa
|
NA
|
NA
|
22792137
|
955
|
Mutation Status of IGFBP3 (IGFBP3-202 A>C)
|
Mutation
|
Humans
|
Increased Risk of High Grade PCa
|
Prognostic
|
IGFBP3 mutation (IGFBP3-202 A>C) in Patients with High Grade PCa
|
NA
|
NA
|
22792137
|
956
|
Mutation Status of FGF2 (FGF2+223 C>T)
|
Mutation
|
Humans
|
Increased Risk of High Grade PCa
|
Prognostic
|
FGF2 mutation (FGF2+223 C>T) in Patients with High Grade PCa
|
NA
|
NA
|
22792137
|
957
|
Mutation Status of IL6 (IL6-597 G>A)
|
Mutation
|
Humans
|
Increased Risk of High Grade PCa
|
Prognostic
|
IL6 mutation (IL6-597 G>A) in Patients with High Grade PCa
|
NA
|
NA
|
22792137
|
958
|
Mutation Status of LEPR (LEPR Gln223Arg)
|
Mutation
|
Humans
|
Increased Risk of High Grade PCa for Metastasis
|
Prognostic
|
LEPR Gln223Arg ( A Vs G mutation) in Patients with High Grade PCa With Metastasis
|
NA
|
NA
|
22792137
|
959
|
Mutation Status of SPP1 (SPP1-66 T>G)
|
Mutation
|
Humans
|
Increased Risk of High Grade PCa for Metastasis
|
Prognostic
|
SPP1 mutaion (SPP1- 66 T>G) in Patients with High Grade PCa With Metastasis
|
NA
|
NA
|
22792137
|
960
|
Mutation Status of FGF2 (FGF2+223 C>T)
|
Mutation
|
Humans
|
Increased Risk of High Grade PCa for Metastasis
|
Prognostic
|
FGF2 mutation (FGF2+223 C>T) in Patients with High Grade PCa With Metastasis
|
NA
|
NA
|
22792137
|
964
|
Soluble interleukin-6 Receptor (sIL-6R)
|
Protein
|
Humans
|
Upregulated in higher Gleason Score (Without Gleason Score Upgrading: 65.62±23.87 Vs With Gleason Score Upgrading: 94.63±33.31)
|
Prognostic
|
Gleason Score Upgrading Vs No Gleason Score Uprading
|
p=0.024
|
Serum
|
22866141
|
965
|
Soluble interleukin-6 Receptor / Interleukin-6 ((sIL-6R/IL-6)
|
Protein
|
Humans
|
Upregulated in higher Gleason Score (Without Gleason Score Upgrading: 9.23±5.78 Vs With Gleason Score Upgrading: 15.61±4.94)
|
Prognostic
|
Gleason Score Upgrading Vs No Gleason Score Uprading
|
p=0.011
|
Serum
|
22866141
|
968
|
GADD45B; CDKN1A; NLRP1; ERBB3; FMO5; SERINC2; AMFR; DPP4; PGC; YWHAE; EHF; TF; TNFSF10; EIF5A; TGM4;
|
mRNA
|
Humans
|
Upregulated in Relapse: [GADD45B (4.86 fold); CDKN1A (2.65 fold); NLRP1 (1.57 fold)]; Downregulated in Relapse: [ERBB3 (0.55 fold); FMO5 (0.55 fold); SERINC2 (0.43 fold); AMFR (0.41 fold); DPP4 (0.40 fold); PGC (0.38 fold); YWHAE (0.34 fold); EHF(0.33 fold); TF (0.33 fold); TNFSF10 (0.31 fold); EIF5A (0.15 fold); TGM4 (0.03 fold);]
|
Prognostic
|
Relpase Vs No Relapse
|
p<0.05
|
Tissue
|
22870216
|
969
|
hsa-miR-375; hsa-miR-96; hsa-miR-892b; hsa-miR-378; hsa-miR-302b; hsa-miR-548c-3p; hsa-miR-124; hsa-miR-141; hsa-miR-875-5p; hsa-miR-409-3p; hsa-miR-548a-3p; hsa-miR-623; hsa-miR-520d-5p; hsa-miR-489
|
miRNA
|
Humans
|
Upregulated in PCa: [hsa-miR-375 (8 fold); hsa-miR-96 (45.3 fold); hsa-miR-892b (9.9 fold); hsa-miR-378 (9.2 fold); hsa-miR-302b (45.3 fold); hsa-miR-548c-3p (2.8 fold); hsa-miR-124 (4.6 fold); hsa-miR-141 (6.5 fold); hsa-miR-875-5p (4.6 fold) ;hsa-miR-548a-3p (2.8 fold); hsa-miR-520d-5p (2.6 fold); hsa-miR-489 (7.5 fold)]; Downregulated in PCa: [ hsa-miR-409-3p (7 fold); hsa-miR-623 (2.6 fold); ]
|
Prognostic
|
LowRisk(LR) Vs Metastatic CRPC
|
p<0.0001
|
Serum
|
22887127
|
970
|
miR-375; miR-141; miR-378*;
|
miRNA
|
Humans
|
Upregulated in Primary Tumors: [miR-375 and miR-141]; Downregulated in Primary Tumors: [miR-378*]
|
Prognostic
|
Normal Vs Primary Tumor
|
p<0.0001
|
Tissue
|
22887127
|
971
|
miR-375; miR-141; miR-378*; miR-409-3p
|
miRNA
|
Humans
|
Upregulated in Low Risk PCa: [miR-375 ; miR-141]; Downregulated in Low Risk PCa: [miR-378*, miR-409-3p]
|
Prognostic
|
Normal Vs Low Risk Prostate Cancer
|
miR-375; miR-141; miR-378*[p<0.0001]; miR-409-3p [p=0.004]
|
Tissue
|
22887127
|
972
|
Prostate Specific Antigen (PSA)
|
Protein
|
Humans
|
Downregulated with Increased BMI: [BMI <23: 9.49±3.46 Vs BMI >25: 6.28±1.36]
|
Prognostic
|
BMI Group <23 Vs BMI Group >25
|
p=0.001
|
Serum
|
22901185
|
976
|
RhoC score
|
Protein
|
Humans
|
10-point increase in the RhoC score reduced the subsequent risk of PSA failure by about 6%
|
Prognostic
|
Time to PSA Failure
|
p=0.009
|
Tissue
|
22935975
|
977
|
RhoC score
|
Protein
|
Humans
|
Decreased in Cases
|
Prognostic
|
Time to PSA Failure
|
p=0.009
|
Tissue
|
22935975
|
979
|
ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; ABCC4-004; ALK-001; ATP1A1-002; NAMPT-006; NAMPT-007; RP11-627G23.1-004;
|
genes or ncRNA
|
Humans
|
Upregulated: C19orf46-002, RSRC2-017 get upregulated with fold change >1.2; Downregualted: Others get downregulated with Fold Change < 1.1
|
Prognostic
|
Metastatic Vs Primary
|
p<0.05
|
Tissue
|
22956952
|
981
|
ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; ABCC4-004; ALK-001; ATP1A1-002; NAMPT-006; NAMPT-007; RP11-627G23.1-004;
|
genes or ncRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical Recurrence
|
p<0.005
|
Tissue
|
22956952
|
982
|
EGFR
|
Protein
|
Humans
|
Overexpressed for Progression Free Survival
|
Prognostic
|
Progression Free Survival
|
p= 0.01
|
Tissue
|
22977195
|
983
|
EGFR
|
mRNA
|
Humans
|
Overexpressed for Progression Free Survival
|
Prognostic
|
Progression Free Survival
|
p= 0.005
|
Tissue
|
22977195
|
984
|
PTEN
|
Protein
|
Humans
|
Overexpressed for Progression Free Survival
|
Prognostic
|
Progression Free Survival
|
p= 0.02
|
Tissue
|
22977195
|
985
|
PTEN
|
mRNA
|
Humans
|
Overexpressed for Progression Free Survival
|
Prognostic
|
Progression Free Survival
|
p= 0.0003
|
Tissue
|
22977195
|
986
|
PTEN
|
mRNA
|
Humans
|
Overexpressed for Progression Free Survival
|
Prognostic
|
Overall Survival
|
p= 0.02
|
Tissue
|
22977195
|
987
|
EGFR + PTEN
|
mRNA
|
Humans
|
Overexpressed for Progression Free Survival
|
Prognostic
|
Progression Free Survival
|
NA
|
Tissue
|
22977195
|
990
|
FLIP
|
Protein
|
Humans
|
NA
|
Prognostic
|
PSA Failure Vs Non Failure
|
p<0.05
|
Tissue
|
23028678
|
991
|
Sp1
|
Protein
|
Humans
|
NA
|
Prognostic
|
PSA Failure Vs Non Failure
|
p<0.05
|
Tissue
|
23028678
|
992
|
Sp3
|
Protein
|
Humans
|
NA
|
Prognostic
|
PSA Failure Vs Non Failure
|
p<0.05
|
Tissue
|
23028678
|
993
|
FLIP + Sp1 + Sp3 + Gleason Score
|
Protein
|
Humans
|
NA
|
Prognostic
|
PSA Failure Vs Non Failure
|
p<0.05
|
Tissue
|
23028678
|
994
|
Ras-related GTP binding D (RRAGD) + polyglutamine binding protein 1 (PQBP1) +histone cluster 1, H2bg (HIST1H2BC)+ aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) +tripartite motif-containing 22 (TRIM22) + RNA binding protein with multiple splicing (RBPMS) + heat shock 22 kDa protein 8 (HSPB8)
|
mRNA
|
Humans
|
Upregulated: [histone cluster 1, H2bg (HIST1H2BC) (1.88 fold); polyglutamine binding protein 1 (PQBP1) (2.08 fold)]; Downregulated: [Ras-related GTP binding D (RRAGD) (0.45 fold); aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) (0.49 fold) ; tripartite motif-containing 22 (TRIM22) (0.54 fold) ; RNA binding protein with multiple splicing (RBPMS) (0.49 fold) + heat shock 22 kDa protein 8 (HSPB8) (0.44 fold)]
|
Prognostic
|
Biochemical relapse Vs No biochemical Relpase
|
p<0.002
|
Tissue
|
23028830
|
995
|
Ras-related GTP binding D (RRAGD) + polyglutamine binding protein 1 (PQBP1) +histone cluster 1, H2bg (HIST1H2BC)+ aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) +tripartite motif-containing 22 (TRIM22) + RNA binding protein with multiple splicing (RBPMS) + heat shock 22 kDa protein 8 (HSPB8) + Cell Type Hetrogenity + Gleason Score
|
mRNA
|
Humans
|
Upregulated: [histone cluster 1, H2bg (HIST1H2BC) (1.88 fold); polyglutamine binding protein 1 (PQBP1) (2.08 fold)]; Downregulated: [Ras-related GTP binding D (RRAGD) (0.45 fold); aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) (0.49 fold) ; tripartite motif-containing 22 (TRIM22) (0.54 fold) ; RNA binding protein with multiple splicing (RBPMS) (0.49 fold) + heat shock 22 kDa protein 8 (HSPB8) (0.44 fold)]
|
Prognostic
|
Biochemical relapse Vs No biochemical Relpase
|
p<0.002
|
Tissue
|
23028830
|
996
|
GPX1
|
mRNA
|
Humans
|
Upregulated in Metatstasis
|
Prognostic
|
Relpase Vs No Relapse
|
p<0.001
|
Blood
|
23046102
|
997
|
SOD2
|
mRNA
|
Humans
|
Upregulated in Metatstasis
|
Prognostic
|
Relpase Vs No Relapse
|
p=0.01
|
Blood
|
23046102
|
998
|
AR
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Relpase Vs No Relapse
|
p=0.001
|
Blood
|
23046102
|
999
|
Cyclin B
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Relpase Vs No Relapse
|
p=0.007
|
Blood
|
23046102
|
1000
|
bFGF
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Relpase Vs No Relapse
|
p=0.004
|
Blood
|
23046102
|
1001
|
2 or more out of (GPX1; SOD2; AR; Cyclin B; bFGF)
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Relpase Vs No Relapse
|
p<0.001
|
Blood
|
23046102
|
1002
|
ABL2+SEMA4D+ITGAL+C1QA+TIMP1+CDKN1A
|
mRNA
|
Humans
|
NA
|
Prognostic
|
low-risk group Vs high-risk group
|
p<0.05
|
Blood
|
23059047
|
1022
|
TMPRSS2-ERG (v-ets erythroblastosis virus E26 oncogene homolog) >= 10
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Gleason Score <7 Vs Gleason score ≥ 7
|
p<0.001
|
Urine
|
23201468
|
1023
|
TMPRSS2-ERG
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Tumor Stage (T3-T4)
|
p = 0.023
|
Urine
|
23201468
|
1024
|
Serum PSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
PCa Vs No PCA group
|
p<0.001
|
Serum
|
23201468
|
1025
|
Serum PSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
Gleason Score <7 Vs Gleason score ≥ 7
|
p = 0.003
|
Serum
|
23201468
|
1026
|
Serum PSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
Tumor Stage (T3-T4)
|
p = 0.002
|
Serum
|
23201468
|
1031
|
miR-30d
|
miRNA
|
Humans
|
Shorter Survival Time in High miRNA-30d group
|
Prognostic
|
Biochemical Recurrence
|
p = 0.026 (BCR); p =0.04 (Univariate); 0.003 (multivariate)
|
Tissue
|
23231923
|
1035
|
BMI1
|
Protein
|
Humans
|
Upregulated with Advanced Stage PCa (stage 2: 3.91±.60 Vs Stage 3: 8.55 ±1.95; Stage 4: 10.84 ± 2.44)
|
Prognostic
|
Stage 2 Vs Stage 3 Vs Stage 4 Prostate Cancer
|
p< 0.001
|
Serum
|
23308129
|
1040
|
Aminopeptidase N (APN)
|
Protein
|
Humans
|
NA
|
Prognostic
|
Recurrence Free Survival
|
Univariate: p=0.002; Mutlivariate: p=0.017
|
Tissue
|
23322201
|
1041
|
Aminopeptidase N (APN)
|
Protein
|
Humans
|
NA
|
Prognostic
|
Cancer Specific Survival
|
Univariate: p=0.017; Mutlivariate: p=0.049
|
Tissue
|
23322201
|
1045
|
Early Growth Response 1 (Egr1)
|
mRNA
|
Humans
|
Downregulated in Relapse (0.784 fold)
|
Prognostic
|
Relpase Vs No Relapse
|
p = 0.017
|
Tissue
|
23342084
|
1055
|
Circulating Tumor Cells (CTC)
|
Others
|
Humans
|
Upregulated in mRCPC (CTC count >=3)
|
Prognostic
|
Locally Advanced Prostate Cancer (LaPC) Vs Metastatic Disease
|
p < 0.001
|
Blood
|
23358719
|
1056
|
Circulating Tumor Cells (CTC)
|
Others
|
Humans
|
Upregulated in patients with Lower Overall Survival (CTC count >=3)
|
Prognostic
|
Overall Survival
|
p = 0.001
|
Blood
|
23358719
|
1064
|
miR-141
|
miRNA
|
Humans
|
Upregulated in Bone Metastasis
|
Prognostic
|
Patients with Bone Metastasis Vs No Bone Metastasis
|
p<0.001
|
Serum
|
23377530
|
1075
|
Methylation Status of APC
|
Methylation
|
Humans
|
Hypermethylated in early stages of PCa
|
Prognostic
|
Stage 1 & 2 Vs Stage 3 & 4
|
p<0.049
|
Tissue
|
23431474
|
1076
|
3-hydroxy-3-methylglutaryl coenzyme A synthase ( HMGCS2 ); aldehyde dehydrogenase 1 family, member A3 ( ALDH1A3 ); chromosome 6 open reading frame 115 ( C6orf115 ); hydroxysteroid (11-beta) dehydrogenase 2 ( HSD11B2 ); anterior gradient homolog 2 (Xenopus laevis) ( AGR2 ); S100 calcium binding protein P ( S100P ); dehydrogenase/reductase (SDR family) member 2 ( DHRS2 ); monoamine oxidase B ( MAOB ); thymidine phosphorylase ( TYMP ); monoamine oxidase A ( MAOA ); sequestosome 1 ( SQSTM1 ); tropomyosin 1 (alpha) ( TPM1 ); cathepsin D ( CTSD ); growth differentiation factor 15 ( GDF15 ); arginase, type II ( ARG2 ); glutaminase ( GLS ); arylacetamide deacetylase-like 1 ( AADACL1 ); aldehyde dehydrogenase 4 family, member A1 ( ALDH4A1 ); solute carrier family 12 (potassium/chloride transporters), member 7 ( SLC12A7 ); spermatogenesis associated, serine-rich 2-like ( SPATS2L ); N-acylsphingosine amidohydrolase (acid ceramidase) 1 ( ASAH1 ); calpain 2, (m/II) large subunit ( CAPN2 ); acyl-CoA thioesterase 9 ( ACOT9 ); keratin 18 ( KRT18 ); epoxide hydrolase 1, microsomal (xenobiotic) ( EPHX1 ); glutathione S-transferase kappa ( GSTK1 ); aldo-keto reductase family 1, member C2 ( AKR1C2 ); acyl-CoA synthetase long-chain family member 3 ( ACSL3 ); mannosidase, beta A, lysosomal ( MANBA ); vesicle-associated membrane protein 8 (endobrevin) ( VAMP8 ); retinol saturase (all-trans-retinol 13,14-reductase) ( RETSAT ); occludin ( OCLN ); sulfide dehydrogenase like ( SQRDL ); acyl-CoA dehydrogenase, C-2 to C-3 short chain ( ACADS ); microtubule associated monoxygenase, calponin and LIM domain containing 1 ( MICAL1 ); 3-hydroxyisobutyryl-CoA hydrolase ( HIBCH ); abhydrolase domain containing 11 ( ABHD11 ); acyl-CoA synthetase long-chain family member 4 ( ACSL4 ); superoxide dismutase 2, mitochondrial ( SOD2 ); fucosidase, alpha-L- 1, tissue ( FUCA1 ); sideroflexin 3 ( SFXN3 ); carnitine palmitoyltransferase 2 ( CPT2 );
|
Protein
|
Humans
|
Upregulated in LNCAP-SF [3-hydroxy-3-methylglutaryl coenzyme A synthase ( HMGCS2 ); ( 9.2394 fold) aldehyde dehydrogenase 1 family, member A3 ( ALDH1A3 ); ( 8.1484 fold) chromosome 6 open reading frame 115 ( C6orf115 ); ( 6.6899 fold) hydroxysteroid (11-beta) dehydrogenase 2 ( HSD11B2 ); ( 5.4227 fold) anterior gradient homolog 2 (Xenopus laevis) ( AGR2 ); ( 5.0377 fold) S100 calcium binding protein P ( S100P ); ( 4.92 fold) dehydrogenase/reductase (SDR family) member 2 ( DHRS2 ); ( 4.5974 fold) monoamine oxidase B ( MAOB ); ( 4.3792 fold) thymidine phosphorylase ( TYMP ); ( 3.8776 fold) monoamine oxidase A ( MAOA ); ( 3.8563 fold) sequestosome 1 ( SQSTM1 ); ( 3.8075 fold) tropomyosin 1 (alpha) ( TPM1 ); ( 3.5117 fold) cathepsin D ( CTSD ); ( 3.3074 fold) growth differentiation factor 15 ( GDF15 ); ( 3.2564 fold) arginase, type II ( ARG2 ); ( 3.2251 fold) glutaminase ( GLS ); ( 3.2099 fold) arylacetamide deacetylase-like 1 ( AADACL1 ); ( 3.1698 fold) aldehyde dehydrogenase 4 family, member A1 ( ALDH4A1 ); ( 3.0362 fold) solute carrier family 12 (potassium/chloride transporters), member 7 ( SLC12A7 ); ( 3.0201 fold) spermatogenesis associated, serine-rich 2-like ( SPATS2L ); ( 2.9743 fold) N-acylsphingosine amidohydrolase (acid ceramidase) 1 ( ASAH1 ); ( 2.9654 fold) calpain 2, (m/II) large subunit ( CAPN2 ); ( 2.9387 fold) acyl-CoA thioesterase 9 ( ACOT9 ); ( 2.9016 fold) keratin 18 ( KRT18 ); ( 2.8839 fold) epoxide hydrolase 1, microsomal (xenobiotic) ( EPHX1 ); ( 2.8828 fold) glutathione S-transferase kappa ( GSTK1 ); ( 2.8356 fold) aldo-keto reductase family 1, member C2 ( AKR1C2 ); ( 2.8239 fold) acyl-CoA synthetase long-chain family member 3 ( ACSL3 ); ( 2.8157 fold) mannosidase, beta A, lysosomal ( MANBA ); ( 2.813 fold) vesicle-associated membrane protein 8 (endobrevin) ( VAMP8 ); ( 2.7515 fold) retinol saturase (all-trans-retinol 13,14-reductase) ( RETSAT ); ( 2.7151 fold) occludin ( OCLN ); ( 2.7082 fold) sulfide dehydrogenase like ( SQRDL ); ( 2.7062 fold) acyl-CoA dehydrogenase, C-2 to C-3 short chain ( ACADS ); ( 2.6711 fold) microtubule associated monoxygenase, calponin and LIM domain containing 1 ( MICAL1 ); ( 2.6382 fold) 3-hydroxyisobutyryl-CoA hydrolase ( HIBCH ); ( 2.5805 fold) abhydrolase domain containing 11 ( ABHD11 ); ( 2.5752 fold) acyl-CoA synthetase long-chain family member 4 ( ACSL4 ); ( 2.5729 fold) superoxide dismutase 2, mitochondrial ( SOD2 ); ( 2.536 fold) fucosidase, alpha-L- 1, tissue ( FUCA1 ); ( 2.5286 fold) sideroflexin 3 ( SFXN3 ); ( 2.5136 fold) carnitine palmitoyltransferase 2 ( CPT2 ); ( 2.5117 fold)
|
Prognostic
|
LNCAP Cell Lines Vs LNCaP-SF (androgen independent)
|
NA
|
Cell Lines
|
23443136
|
1077
|
semenogelin I ( SEMG1 ); Cyclin-dependent kinase 1 ( CDC2 ); thymidine kinase 1, soluble ( TK1 ); semenogelin II ( SEMG2 ); barrier to autointegration factor 1 ( BANF1 ); cDNA FLJ16186 ( cDNA FLJ16186 ); polo-like kinase 1 ( PLK1 ); cyclin-dependent kinase 2 ( CDK2 ); insulin-like growth factor binding protein 2, 36kDa ( IGFBP2 ); stathmin 1 ( STMN1 ); ribonucleotide reductase M2 ( RRM2 ); S100 calcium binding protein A13 ( S100A13 ); GINS complex subunit 3 (Psf3 homolog) ( GINS3 ); neural cell adhesion molecule 2 ( NCAM2 ); thyroid hormone receptor interactor 13 ( TRIP13 ); ribonucleotide reductase M1 ( RRM1 ); nucleolar pre-rRNA processing protein ( ESF1 ); stathmin-like 2 ( STMN2 ); H3 histone, family 3A ( H3F3A ); GINS complex subunit 4 (Sld5 homolog) ( GINS4 ); H2A histone family, member Z ( H2AFZ ); DNA (cytosine-5-)-methyltransferase 1 ( DNMT1 ); ATPase family, AAA domain containing 2 ( ATAD2 ); SCD6 homolog B (S. cerevisiae) ( LSM14B ); chromosome 13 open reading frame 33 ( C13orf33 ); karyopherin alpha 2 (RAG cohort 1, importin alpha 1) ( KPNA2 ); Nuclear autoantigenic sperm protein (histone-binding) ( NASP ); acireductone dioxygenase 1 ( ADI1 ); histone cluster 1, H4a ( HIST1H4A ); lamin B1 ( LMNB1 ); 3-hydroxybutyrate dehydrogenase, type 2 ( BDH2 ); phosphorylase, glycogen, liver ( PYGL ); PDZ binding kinase ( PBK ); histone cluster 1, H1b ( HIST1H1B ); histone acetyltransferase 1 ( HAT1 ); Ras association (RalGDS/AF-6) domain family member 3 ( RASSF3 ); nitrogen fixation 1 homolog (S. cerevisiae) ( NFS1 ); programmed cell death 4 (neoplastic transformation inhibitor) ( PDCD4 ); H2A histone family, member Y ( H2AFY ); ligase I, DNA, ATP-dependent ( LIG1 ); structural maintenance of chromosomes 4 ( SMC4 ); topoisomerase (DNA) II beta 180kDa ( TOP2B ); nucleus accumbens associated 1, BEN and BTB (POZ) domain containing ( NACC1 ); structural maintenance of chromosomes 2 ( SMC2 ); DEAH (Asp-Glu-Ala-His) box polypeptide 36 ( DHX36 ); Metastasis-associated protein 1 ( MTA1 );
|
Protein
|
Humans
|
Downregulated in LNCAP-SF [semenogelin I ( SEMG1 ); ( 0.076735 fold) Cyclin-dependent kinase 1 ( CDC2 ); ( 0.081925 fold) thymidine kinase 1, soluble ( TK1 ); ( 0.083392 fold) semenogelin II ( SEMG2 ); ( 0.10883 fold) barrier to autointegration factor 1 ( BANF1 ); ( 0.17609 fold) cDNA FLJ16186 ( cDNA FLJ16186 ); ( 0.19531 fold) polo-like kinase 1 ( PLK1 ); ( 0.20362 fold) cyclin-dependent kinase 2 ( CDK2 ); ( 0.22407 fold) insulin-like growth factor binding protein 2, 36kDa ( IGFBP2 ); ( 0.22637 fold) stathmin 1 ( STMN1 ); ( 0.24713 fold) ribonucleotide reductase M2 ( RRM2 ); ( 0.25054 fold) S100 calcium binding protein A13 ( S100A13 ); ( 0.2628 fold) GINS complex subunit 3 (Psf3 homolog) ( GINS3 ); ( 0.26922 fold) neural cell adhesion molecule 2 ( NCAM2 ); ( 0.26951 fold) thyroid hormone receptor interactor 13 ( TRIP13 ); ( 0.27195 fold) ribonucleotide reductase M1 ( RRM1 ); ( 0.27289 fold) nucleolar pre-rRNA processing protein ( ESF1 ); ( 0.27757 fold) stathmin-like 2 ( STMN2 ); ( 0.28292 fold) H3 histone, family 3A ( H3F3A ); ( 0.28744 fold) GINS complex subunit 4 (Sld5 homolog) ( GINS4 ); ( 0.28965 fold) H2A histone family, member Z ( H2AFZ ); ( 0.2989 fold) DNA (cytosine-5-)-methyltransferase 1 ( DNMT1 ); ( 0.3037 fold) ATPase family, AAA domain containing 2 ( ATAD2 ); ( 0.30571 fold) SCD6 homolog B (S. cerevisiae) ( LSM14B ); ( 0.30649 fold) chromosome 13 open reading frame 33 ( C13orf33 ); ( 0.3127 fold) karyopherin alpha 2 (RAG cohort 1, importin alpha 1) ( KPNA2 ); ( 0.31541 fold) Nuclear autoantigenic sperm protein (histone-binding) ( NASP ); ( 0.32372 fold) acireductone dioxygenase 1 ( ADI1 ); ( 0.33027 fold) histone cluster 1, H4a ( HIST1H4A ); ( 0.33313 fold) lamin B1 ( LMNB1 ); ( 0.33412 fold) 3-hydroxybutyrate dehydrogenase, type 2 ( BDH2 ); ( 0.33637 fold) phosphorylase, glycogen, liver ( PYGL ); ( 0.33849 fold) PDZ binding kinase ( PBK ); ( 0.34986 fold) histone cluster 1, H1b ( HIST1H1B ); ( 0.35951 fold) histone acetyltransferase 1 ( HAT1 ); ( 0.36643 fold) Ras association (RalGDS/AF-6) domain family member 3 ( RASSF3 ); ( 0.37213 fold) nitrogen fixation 1 homolog (S. cerevisiae) ( NFS1 ); ( 0.37728 fold) programmed cell death 4 (neoplastic transformation inhibitor) ( PDCD4 ); ( 0.37993 fold) H2A histone family, member Y ( H2AFY ); ( 0.38303 fold) ligase I, DNA, ATP-dependent ( LIG1 ); ( 0.38796 fold) structural maintenance of chromosomes 4 ( SMC4 ); ( 0.38871 fold) topoisomerase (DNA) II beta 180kDa ( TOP2B ); ( 0.38889 fold) nucleus accumbens associated 1, BEN and BTB (POZ) domain containing ( NACC1 ); ( 0.39627 fold) structural maintenance of chromosomes 2 ( SMC2 ); ( 0.3968 fold) DEAH (Asp-Glu-Ala-His) box polypeptide 36 ( DHX36 ); ( 0.39825 fold) Metastasis-associated protein 1 ( MTA1 ); ( 0.39986 fold) ]
|
Prognostic
|
LNCAP Cell Lines Vs LNCaP-SF (androgen independent)
|
NA
|
Cell Lines
|
23443136
|
1079
|
PCA3
|
mRNA
|
Humans
|
Upregulated with High Gleason Score
|
Prognostic
|
Low Gleason Score Vs high Gleason Score (≥7)
|
p=0.02
|
Urine
|
23515404
|
1080
|
TMPRSS2:ERG
|
mRNA
|
Humans
|
Upregulated with High Gleason Score
|
Prognostic
|
Low Gleason Score Vs high Gleason Score (≥7)
|
p=0.02
|
Urine
|
23515404
|
1081
|
PCA3 + TMPRSS2:ERG
|
mRNA
|
Humans
|
Upregulated with High Gleason Score
|
Prognostic
|
Low Gleason Score Vs high Gleason Score (≥7)
|
NA
|
Urine
|
23515404
|
1084
|
PCA3 + TMPRSS2:ERG + PSA
|
mRNA
|
Humans
|
Upregulated with High Gleason Score
|
Prognostic
|
Low Gleason Score Vs high Gleason Score (≥7)
|
NA
|
Urine
|
23515404
|
1087
|
miR-183
|
miRNA
|
Humans
|
Upregulated in Prostate Cancer
|
Prognostic
|
Tumor Stage pT2 Vs pT3
|
p<0.05
|
Tissue
|
23538390
|
1088
|
miR-183
|
miRNA
|
Humans
|
Upregulated in Prostate Cancer
|
Prognostic
|
Overall Survival
|
p<0.05
|
Tissue
|
23538390
|
1091
|
miR-141
|
miRNA
|
Humans
|
Upregulated in metastatic castration-resistant PCa (mCRPC)
|
Prognostic
|
localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC)
|
p < 0.001
|
Plasma
|
23574937
|
1092
|
miR-375
|
miRNA
|
Humans
|
Upregulated in metastatic castration-resistant PCa (mCRPC)
|
Prognostic
|
localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC)
|
p < 0.001
|
Plasma
|
23574937
|
1093
|
miR-151-3p
|
miRNA
|
Humans
|
Upregulated in metastatic castration-resistant PCa (mCRPC)
|
Prognostic
|
localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC)
|
p < 0.001
|
Plasma
|
23574937
|
1094
|
miR-126
|
miRNA
|
Humans
|
Upregulated in metastatic castration-resistant PCa (mCRPC)
|
Prognostic
|
localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC)
|
p < 0.001
|
Plasma
|
23574937
|
1095
|
miR-16
|
miRNA
|
Humans
|
Downregulated in metastatic castration-resistant PCa (mCRPC)
|
Prognostic
|
localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC)
|
p < 0.001
|
Plasma
|
23574937
|
1096
|
miR-205
|
miRNA
|
Humans
|
Downregulated in metastatic castration-resistant PCa (mCRPC)
|
Prognostic
|
localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC)
|
p < 0.001
|
Plasma
|
23574937
|
1097
|
PSA + miR141 + mir-151-3p + mir-16
|
miRNA
|
Humans
|
Upregulated in metastatic castration-resistant PCa (mCRPC)
|
Prognostic
|
localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC)
|
p < 0.001
|
Plasma
|
23574937
|
1098
|
miR-423-3p
|
miRNA
|
Humans
|
Upregulated with High Gleason Score
|
Prognostic
|
Gleason Score < 7 Vs Gleason Score ≥ 8
|
p = 0.002
|
Plasma
|
23574937
|
1099
|
miR-205
|
miRNA
|
Humans
|
Downregulated with High Gleason Score
|
Prognostic
|
Gleason Score < 7 Vs Gleason Score ≥ 8
|
p = 0.004
|
Plasma
|
23574937
|
1100
|
miR-205
|
miRNA
|
Humans
|
Upregulated in Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence
|
p = 0.006
|
Plasma
|
23574937
|
1101
|
miR-423-3p
|
miRNA
|
Humans
|
Downregulated in Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence
|
p<0.001
|
Plasma
|
23574937
|
1102
|
miR-151-3p
|
miRNA
|
Humans
|
Downregulated in Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence
|
p<0.001
|
Plasma
|
23574937
|
1103
|
Apolipoprotein B
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.01
|
Serum
|
23582881
|
1104
|
Biotinidase
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p= 0.041
|
Serum
|
23582881
|
1105
|
Cell adhesion molecule 1
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p= 0.046
|
Serum
|
23582881
|
1106
|
Complement factor H
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p= 0.025
|
Serum
|
23582881
|
1107
|
Ceruloplasmin
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.041
|
Serum
|
23582881
|
1108
|
Carboxypeptidase M
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.001
|
Serum
|
23582881
|
1109
|
Intercellular adhesion molecule 1
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.041
|
Serum
|
23582881
|
1110
|
Galectin-3-binding protein
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.009
|
Serum
|
23582881
|
1111
|
Serum paraoxonase/arylesterase 1
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.011
|
Serum
|
23582881
|
1112
|
Poliovirus receptor-related protein 1
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.046
|
Serum
|
23582881
|
1113
|
Thrombospondin-1
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.022
|
Serum
|
23582881
|
1114
|
Transmembrane 9 superfamily member 3
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.037
|
Serum
|
23582881
|
1121
|
Asporin; Cartilage oligomeric matrix Protein (COMP); Versican; EMILIN 3;
|
Protein
|
Humans
|
Upregulated in Agressive Prostate Cancer (Fold Change); [Asporin (2.14 fold); Cartilage oligomeric matrix Protein (COMP) (100 fold) ; Versican (100 fold) ; EMILIN 3 ( 6 fold);
|
Prognostic
|
Agressive Vs Non Agressive Prostate Cancer
|
Asporin (p=0.00016) ; Cartilage oligomeric matrix Protein (COMP) (p = 0.00228) ; Versican ( 0.03367) ; EMILIN 3 (0.04983);
|
Tissue
|
23716368
|
1122
|
Acid ceramidase
|
Protein
|
Humans
|
Downregulated in Agressive Prostate Cancer 0.18 Fold
|
Prognostic
|
Agressive Vs Non Agressive Prostate Cancer
|
p = 0.04983
|
Tissue
|
23716368
|
1136
|
Aminoadipic acid
|
Metabolites
|
Humans
|
Increased in Patients with Recurrence
|
Prognostic
|
Recurrence Free Survival Vs No Recurrence Free Survival
|
p =0.031
|
Tissue
|
23737455
|
1137
|
Gluconic acid
|
Metabolites
|
Humans
|
Decreased in Patients with Recurrence
|
Prognostic
|
Recurrence Free Survival Vs No Recurrence Free Survival
|
p =0.036
|
Tissue
|
23737455
|
1138
|
Maltotriose
|
Metabolites
|
Humans
|
Decreased in Patients with Recurrence
|
Prognostic
|
Recurrence Free Survival Vs No Recurrence Free Survival
|
p =0.006
|
Tissue
|
23737455
|
1139
|
Aminoadipic acid
|
Metabolites
|
Humans
|
Increased in Patients with Recurrence
|
Prognostic
|
Recurrence Free Survival Vs No Recurrence Free Survival
|
p =0.048
|
Tissue
|
23737455
|
1141
|
let-7a; let-7b; let-7c, miR-515-3p; miR515-5p; miR-181b; miR-146b; miR-361
|
miRNA
|
Humans
|
Upregulated: [let-7a - 1.7 fold; let-7b 3.7 fold; let-7c 3.0 fold, miR-515-3p 3.2 fold; miR515-5p 3.2 fold;] Downregulated: [miR-181b 1.8 fold; miR-146b 1.7 fold; miR-361 1.7 fold]
|
Prognostic
|
Clinical progression free survival (CPFS) Vs. clinical failure (CF)
|
p<0.05
|
Tissue
|
23798998
|
1148
|
C-Reactive Protein (CRP)
|
Protein
|
Humans
|
Higher levels associated with shorter biochemical failure-free survival (Both for patients with Post- radical Prostatectomy and Definitive Radiotherapy)
|
Prognostic
|
Biochemical Failure Free survival
|
p = 0.009
|
Serum
|
23818401
|
1151
|
Histidine; Glycine; Alanine; Kynurenine; Glutamate; Glycerol 3-phosphate (G3P); Betaine; Pipecolate 2-methylbutyrylcarnitin; Isobar: 15-methylpalmitate; 2-methylpalmitate; Threonine; Cytidine 50-diphosphocholine; Valine; Myristoleate (14:1n5); S-adenosylhomocysteine (SAH); Phosphate; Choline; 2-aminobutyrate 2-hydroxypalmitate; Glycerol; Adenine; 2-hydroxystearate; Deoxycarnitine; Fumarate; Docosadienoate (22:2n6);
|
Metabolites
|
Humans
|
Increased with Upgraded Gleason Score
|
Prognostic
|
Gleason Score Upgrading [6 to 7 (3+4) to 7(4+3) to 8]
|
p<0.05
|
Tissue
|
23824564
|
1152
|
Adenosine 50 -diphosphate (ADP); Citrate; Palmitoyl-sphingomyelin;
|
Metabolites
|
Humans
|
Decreased with Upgraded Gleason Score
|
Prognostic
|
Gleason Score Upgrading [6 to 7 (3+4) to 7(4+3) to 8]
|
p<0.05
|
Tissue
|
23824564
|
1153
|
5,6-dihydrouracil +choline phosphate+ glycerol + methylpalmitate
|
Metabolites
|
Humans
|
Differentially Expressed
|
Prognostic
|
Organ Confined Vs Non Orgnan Confined
|
p<0.05
|
Tissue
|
23824564
|
1154
|
7-HOCA+ pregnen-diol disulfate +mannosyl tryptophan
|
Metabolites
|
Humans
|
Differentially Expressed
|
Prognostic
|
Progression Free Survival (5 years) Vs No Progression Free Survival (5 years)
|
p<0.05
|
Tissue
|
23824564
|
1155
|
LASP1 + IQGAP3+ NFIB+ S1PR4+ THBS2+ANO7+ PCDH7 + MYBPC1+ EPPK1+ TSBP+ PBX1+ NUSAP1+ ZWILCH+ UBE2C+ CAMK2N1+ RABGAP1+ PCAT-32 + GLYATL1P4/PCAT-80 + TNFRSF19
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Metastasis Vs No Metastasis
|
p<0.01
|
Tissue
|
23826159
|
1159
|
Peptide ID: [1004; 2663; 5650; 7228; 9483; 9504; 10193; 10442; 10471; 10502; 17993]
|
Protein
|
Humans
|
Upregulated in PCa [mean(case)/mean(control)]: Downregulated in PCa [mean(control)/mean (case)]: []
|
Prognostic
|
Localised Vs Advanced Prostate Cancer
|
p=0.0055
|
Plasma
|
23826311
|
1170
|
miR-141
|
miRNA
|
Humans
|
Upregulated in patients with Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p = 0.007
|
Serum
|
23846169
|
1171
|
miR-146b-3p
|
miRNA
|
Humans
|
Upregulated in patients with Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p = 0.008
|
Serum
|
23846169
|
1172
|
miR-194
|
miRNA
|
Humans
|
Upregulated in patients with Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p = 0.044
|
Serum
|
23846169
|
1173
|
miR-146b-3p
|
miRNA
|
Humans
|
Upregulated in patients with Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p = 0.02
|
Serum
|
23846169
|
1174
|
miR-194
|
miRNA
|
Humans
|
Upregulated in patients with Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p = 0.029
|
Serum
|
23846169
|
1178
|
SLCO2B1 rs12422149 (GG allele)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Time to Progression
|
p =0.028
|
Blood
|
23896625
|
1184
|
Bone Sialoprotein
|
Protein
|
Humans
|
Upregulated in Bone Metastatis (BM: 38.7 ±19.3; NBM: 9.1 ± 5.8)
|
Prognostic
|
Bone Metastatis Vs No Bone Metastatis
|
p<0.05
|
Tissue
|
23904377
|
1185
|
Methylation Status of AOX1 (High vs. Low)
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
1186
|
Methylation Status of AOX1 (as continous variable)
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
1187
|
Methylation Status of C1orf114 (as continous variable)
|
Methylation
|
Humans
|
Lower Methylation in Patients with Longer Survival
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
1188
|
Methylation Status of C1orf114 (High vs. Low)
|
Methylation
|
Humans
|
Lower Methylation in Patients with Longer Survival
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
1189
|
Methylation Status of GAS6 (as continous variable)
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
1190
|
Methylation Status of GSTP1
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
1191
|
Methylation Status of HAPLN3 (as continous variable)
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
1192
|
Methylation Status of HAPLN3 (High vs. Low)
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
1193
|
Methylation Status of KLF8 (High vs. Low)
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
1194
|
Methylation Status of KLF8 (as continuous variable)
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
1195
|
Methylation Status of MOB3B
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
1196
|
Methylation Status of AOX1/C1orf114/HAPLN3
|
Methylation
|
Humans
|
Lower Methylation in Patients with Longer Survival
|
Prognostic
|
Biochemical recurrence
|
NA
|
Tissue
|
23918943
|
1197
|
Methylation Status of AOX1/C1orf114/HAPLN3
|
Methylation
|
Humans
|
Lower Methylation in Patients with Longer Survival
|
Prognostic
|
Biochemical recurrence
|
NA
|
Tissue
|
23918943
|
1208
|
RNASEL [D541E variant: GG]
|
Mutation
|
Humans
|
Expressed in patients with High Risk of PCa
|
Prognostic
|
High Risk with GG phenotype Vs High Risk with (TG and TT phenotype)
|
p≤ 0.001
|
Blood
|
24046815
|
1209
|
RNASEL [R462Q variant: AA]
|
Mutation
|
Humans
|
Expressed in patients with High Risk of PCa
|
Prognostic
|
High Risk with AA phenotype Vs High Risk with (AA and GA phenotype)
|
p≤ 0.001
|
Blood
|
24046815
|
1210
|
Copy Number Variation: Deletion of 2p24.3
|
Mutation
|
Humans
|
Deletion found in Hispanic patients with High Risk PCa
|
Prognostic
|
High Risk Vs Low Risk
|
p = 0.007
|
Blood
|
24054869
|
1218
|
Methylation Status of APC
|
Methylation
|
Humans
|
Hypermethylated in patients with Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.02
|
Tissue
|
24086370
|
1219
|
Methylation Status of GSTP1
|
Methylation
|
Humans
|
Hypermethylated in patients with Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.02
|
Serum
|
24086370
|
1220
|
Semaphorin 4F (SF4)
|
mRNA
|
Humans
|
Upregulated (high levels) had increased risk of biochemical recurrence
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p = 0.0002
|
Tissue
|
24097862
|
1223
|
Prostate Specific Membrane Antigen (PSMA)
|
Protein
|
Humans
|
Upregulted in Lethal PCa
|
Prognostic
|
Lethal Vs Non Lethal Prostate Cancer
|
p< 0.01
|
Tissue
|
24130224
|
1232
|
N-terminal propeptide of collagen type I (PINP)
|
Protein
|
Humans
|
Upregulated in Bone Metastatis
|
Prognostic
|
Bone Metastatis Vs No Bone Metastatis
|
P < 0.001
|
Serum
|
24179387
|
1239
|
cutaneous fatty acid-binding protein (C-FABP)
|
Protein
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Low Vs Moderate Vs High Gleason Score
|
p<0.05
|
Tissue
|
24189640
|
1244
|
N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 )
|
Protein
|
Humans
|
Upregulated with High Tumor Stage
|
Prognostic
|
Tumor Stage pT2 Vs pT3 Vs pT4
|
p= 0.004
|
Tissue
|
24240687
|
1245
|
N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 )
|
Protein
|
Humans
|
Upregulated with High Gleason Score
|
Prognostic
|
Gleason Score 3 Vs 4 Vs 5
|
p=0.028
|
Tissue
|
24240687
|
1246
|
N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 )
|
Protein
|
Humans
|
Increased in Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: p = 0.0038; Multivariate: p =0.036
|
Tissue
|
24240687
|
1249
|
Lactate Dehydrogenase [LDH]
|
Protein
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
Univariate: p < 0.001; Multivariate: p =0.023
|
Blood
|
24255071
|
1250
|
Lactate Dehydrogenase [LDH]
|
Protein
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
Univariate: p = 0.006
|
Blood
|
24255071
|
1253
|
Osteopontin (OPN)
|
Protein
|
Humans
|
Upregulated in PCa: [Localised PCa: 613.6; Metastaic PCa: 1024]
|
Prognostic
|
Localised Vs Metastatic Prostate Cancer
|
p = 0.003
|
Urine
|
24266816
|
1254
|
Forkhead Box A1 [FOXA1]
|
mRNA
|
Humans
|
Increased in shorter time to Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p = 0.028
|
Tissue
|
24292680
|
1256
|
Discs Large Homolog 7 [DLG7]
|
mRNA
|
Humans
|
Upregulated in PCa (log 2 PCa/Normal): []
|
Prognostic
|
Progression Vs No Progression
|
NA
|
Tissue
|
24349376
|
1260
|
Claudin 7
|
mRNA
|
Humans
|
Downregulated in DU145 and PC-3
|
Prognostic
|
DU145, PC-3 Vs CAHPV-10
|
DU145 (p=0.02); PC-3 (p<0.001)
|
Cell Lines
|
24358122
|
1262
|
α-catenin
|
mRNA
|
Humans
|
Downregulated in DU145 and PC-3
|
Prognostic
|
DU145, PC-3 Vs CAHPV-10
|
p<0.001
|
Cell Lines
|
24358122
|
1264
|
β-catenin
|
mRNA
|
Humans
|
Upregulated in DU145 and PC-3
|
Prognostic
|
DU145, PC-3 Vs CAHPV-10
|
DU145 (p=0.006); PC-3 (p=0.001)
|
Cell Lines
|
24358122
|
1268
|
Claudin 7
|
Protein
|
Humans
|
Downregulated in CAHPV-10
|
Prognostic
|
CAHPV-10 Vs PC-3
|
p < 0.01
|
Cell Lines
|
24358122
|
1271
|
ITGA3; ITGB1; TLN1; VCL; ITGA1; FLNC;
|
Protein
|
Humans
|
Differentially Expressed
|
Prognostic
|
LNCaP Cell Lines Vs PC-3 Cell Lines
|
p<0.05
|
Cell Lines
|
24371517
|
1288
|
F3
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.001
|
Tissue
|
24394557
|
1289
|
WNT5B
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.004
|
Tissue
|
24394557
|
1290
|
VGLL3
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p<0.0001
|
Tissue
|
24394557
|
1291
|
c-MAF-a
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.008
|
Tissue
|
24394557
|
1292
|
CTGF
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.008
|
Tissue
|
24394557
|
1293
|
AMACR
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.009
|
Tissue
|
24394557
|
1294
|
MUC1
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.025
|
Tissue
|
24394557
|
1295
|
F3
|
mRNA
|
Humans
|
NA
|
Prognostic
|
PCa Specific Survival Vs No PCa Specific Survival
|
p<0.0001
|
Tissue
|
24394557
|
1296
|
WNT5B
|
mRNA
|
Humans
|
NA
|
Prognostic
|
PCa Specific Survival Vs No PCa Specific Survival
|
p<0.0001
|
Tissue
|
24394557
|
1297
|
VGLL3
|
mRNA
|
Humans
|
NA
|
Prognostic
|
PCa Specific Survival Vs No PCa Specific Survival
|
p=0.014
|
Tissue
|
24394557
|
1298
|
c-MAF-a
|
mRNA
|
Humans
|
NA
|
Prognostic
|
PCa Specific Survival Vs No PCa Specific Survival
|
p=0.036
|
Tissue
|
24394557
|
1299
|
CTGF
|
mRNA
|
Humans
|
NA
|
Prognostic
|
PCa Specific Survival Vs No PCa Specific Survival
|
p=0.023
|
Tissue
|
24394557
|
1300
|
IGFBP3
|
mRNA
|
Humans
|
NA
|
Prognostic
|
PCa Specific Survival Vs No PCa Specific Survival
|
p=0.013
|
Tissue
|
24394557
|
1301
|
c-MAF-b
|
mRNA
|
Humans
|
NA
|
Prognostic
|
PCa Specific Survival Vs No PCa Specific Survival
|
p=0.019
|
Tissue
|
24394557
|
1302
|
EZH2
|
mRNA
|
Humans
|
NA
|
Prognostic
|
PCa Specific Survival Vs No PCa Specific Survival
|
p=0.018
|
Tissue
|
24394557
|
1303
|
AMACR
|
mRNA
|
Humans
|
NA
|
Prognostic
|
PCa Specific Survival Vs No PCa Specific Survival
|
p=0.049
|
Tissue
|
24394557
|
1304
|
VGLL3 + IGFBP3 + F3
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
Univariate: [p<0.0001;] Multivariate:[Group2: p=0.013 Group 1: p<0.0001]
|
Tissue
|
24394557
|
1305
|
Clinical Parameters + VGLL3 + IGFBP3 + F3
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
NA
|
Tissue
|
24394557
|
1306
|
VGLL3 + IGFBP3 + F3
|
mRNA
|
Humans
|
NA
|
Prognostic
|
PCa Specific Survival Vs No PCa Specific Survival
|
Group2: [Univariate: p= 0.002; Multivariate: 0.030]; Group 1: p<0.0001
|
Tissue
|
24394557
|
1307
|
Clinical Parameters + VGLL3 + IGFBP3 + F3
|
mRNA
|
Humans
|
NA
|
Prognostic
|
PCa Specific Survival Vs No PCa Specific Survival
|
NA
|
Tissue
|
24394557
|
1308
|
C2orf43 [SNP: rs13385191]
|
Mutation
|
Humans
|
Decreased risk of PCa Specific Mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.05
|
Blood
|
24411283
|
1309
|
PDLIM5 [SNP: rs17021918]
|
Mutation
|
Humans
|
Decreased risk of PCa Specific Mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.01
|
Blood
|
24411283
|
1310
|
JAZF1 [SNP: rs10486567]
|
Mutation
|
Humans
|
Decreased risk of PCa Specific Mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.001
|
Blood
|
24411283
|
1311
|
LMTK2 [SNP: rs6465657]
|
Mutation
|
Humans
|
Decreased risk of PCa Specific Mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.02
|
Blood
|
24411283
|
1312
|
MSMB [SNP: rs10993994]
|
Mutation
|
Humans
|
Decreased risk of PCa Specific Mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.02
|
Blood
|
24411283
|
1313
|
SNP: rs7127900
|
Mutation
|
Humans
|
Decreased risk of PCa Specific Mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.01
|
Blood
|
24411283
|
1314
|
SNP: rs11672691
|
Mutation
|
Humans
|
Increased risk of PCa Specific Mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.007
|
Blood
|
24411283
|
1315
|
KLK3 [SNP: rs2735839]
|
Mutation
|
Humans
|
Decreased risk of PCa Specific Mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.002
|
Blood
|
24411283
|
1316
|
FRK [SNP: rs171866: AA versus gg/gA]
|
Mutation
|
Humans
|
Increased risk of Progression
|
Prognostic
|
Progression Vs No Progression During ADT
|
p=0.015
|
Blood
|
24448834
|
1317
|
DAB2 [SNP: rs268091: GC/CC versus GG]
|
Mutation
|
Humans
|
Increased risk of Progression
|
Prognostic
|
PCa Specific Mortality Vs No Mortality During ADT
|
p=0.012
|
Blood
|
24448834
|
1318
|
DAB2 [SNP: rs268091: CC versus GG/GC]
|
Mutation
|
Humans
|
Increased risk of Progression
|
Prognostic
|
PCa Specific Mortality Vs No Mortality During ADT
|
p=0.031
|
Blood
|
24448834
|
1319
|
EXOC4: [SNP: rs1149558: TT versus CC/CT]
|
Mutation
|
Humans
|
Increased risk of Progression
|
Prognostic
|
PCa Specific Mortality Vs No Mortality During ADT
|
p=0.014
|
Blood
|
24448834
|
1320
|
EXOC4: [SNP: rs1149558: TT versus CC/CT]
|
Mutation
|
Humans
|
Increased risk of Progression
|
Prognostic
|
All Cause Mortality Vs No Mortality during ADT
|
p=0.005
|
Blood
|
24448834
|
1325
|
Monoclonal Antibody MIB-1 [Ki-67]
|
Protein
|
Humans
|
Increased with increased risk of death
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p<0.001
|
Tissue
|
24486077
|
1326
|
Monoclonal Antibody MIB-1 [Ki-67]
|
Protein
|
Humans
|
Increased with increased risk of death
|
Prognostic
|
Progression Vs No Progression
|
p<0.001
|
Tissue
|
24486077
|
1332
|
UAP1+ PDLIM5+ IMPDH2+ HSPD1+ PCA3+ TMPRSS2+ ERG+ GAPDH+ B2M+age+sPSA level
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Gleason Score <7 Vs Gleason Score ≥ 7
|
NA
|
Urine + Plasma
|
24512523
|
1338
|
PCAT18
|
LncRNA
|
Humans
|
Upregulated in metastatic Prostatic Cancer
|
Prognostic
|
Localised Vs Metastatic Prostate Cancer
|
p<0.001
|
Tissue
|
24519926
|
1347
|
Bone Alkaline Phosphatase [BAP]
|
Protein
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p<0.001
|
Serum
|
24565955
|
1348
|
C-terminal of type 1 collagen [CICP]
|
Protein
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p <0.001
|
Serum
|
24565955
|
1349
|
Pyridinoline [PYD]
|
Protein
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p <0.001
|
Serum
|
24565955
|
1350
|
N-telopeptides of type 1 collagen [NTx]
|
Protein
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p <0.001
|
Serum
|
24565955
|
1351
|
miR-221
|
miRNA
|
Humans
|
Downregulation in high-risk prostate cancer
|
Prognostic
|
Cancer Related Death Vs No Cancer Related Death
|
p<0.0001
|
Tissue
|
24607843
|
1352
|
ERG
|
Protein
|
Humans
|
NA
|
Prognostic
|
Histopathological Progression For ERG Positive Vs ERG Negative samples
|
p<0.0001
|
Tissue
|
24630684
|
1353
|
ERG
|
Protein
|
Humans
|
NA
|
Prognostic
|
Active Survillence (AS) Progression For ERG Positive Vs ERG Negative samples
|
p<0.0001
|
Tissue
|
24630684
|
1354
|
COMT [SNP: rs11705619: T>C]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.041
|
Blood
|
24682418
|
1355
|
COMT [SNP: rs165849: A>G]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.047
|
Blood
|
24682418
|
1356
|
COMT [SNP: rs9332377: C>T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.017
|
Blood
|
24682418
|
1357
|
CYP1B1 [SNP: rs1800440: A>G]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.016
|
Blood
|
24682418
|
1358
|
NQO1 [SNP: rs2917670: G>A]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.039
|
Blood
|
24682418
|
1359
|
NQO2 [SNP: rs10223369: C>T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.002
|
Blood
|
24682418
|
1360
|
NQO2 [SNP: rs1143684: T>C]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.030
|
Blood
|
24682418
|
1361
|
NQO2 [SNP: rs6920900 G>C]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.007
|
Blood
|
24682418
|
1362
|
SULT2B1 [SNP: rs12460535: G>A]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.017
|
Blood
|
24682418
|
1363
|
SULT2B1 [SNP: rs2665582: G>A]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.037
|
Blood
|
24682418
|
1364
|
COMT [ SNP: rs16982844: C>A]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.001
|
Blood
|
24682418
|
1365
|
CYP1B1: [SNP: rs1800440: A>G]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.0009
|
Blood
|
24682418
|
1366
|
SULT2B1: [SNP: rs10426628: G>A]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.025
|
Blood
|
24682418
|
1367
|
SULT2B1: [SNP: rs12460535: G>A]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.028
|
Blood
|
24682418
|
1368
|
SULT2B1: [SNP: rs2665582: G>A]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.07
|
Blood
|
24682418
|
1369
|
Hyaluronan-Mediated Motility Receptor (HMMR)
|
Metabolites
|
Humans
|
NA
|
Prognostic
|
Biochemical Failure Vs No Biochemical Faliure
|
Univariate: p=0.028; Multivariate: p=0.04
|
Tissue
|
24668563
|
1370
|
hsa-miR-337-3p; hsa-miR-330-3p; hsa-miR-339-3p; hsa-miR-124; hsa-miR-218; hsa-miR-128; hsa-miR-10a; hsa-miR-199b-5p; hsa-miR-200b; hsa-miR-15b;
|
miRNA
|
Humans
|
NA
|
Prognostic
|
High Vs Intermediate Vs Low risk
|
p<0.05
|
Blood
|
24661838
|
1371
|
CCND1
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical Failure Vs No Biochemical Faliure
|
p=0.042
|
Tissue
|
24708576
|
1372
|
HMMR
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical Failure Vs No Biochemical Faliure
|
Univariate: p=0.005 Multivariate; p=0.008
|
Tissue
|
24708576
|
1373
|
HOXC6
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical Failure Vs No Biochemical Faliure
|
p=0.05
|
Tissue
|
24708576
|
1374
|
IGF1
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical Failure Vs No Biochemical Faliure
|
Univariate: p=0.039 Multivariate; p=0.015
|
Tissue
|
24708576
|
1375
|
MAP4K4
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical Failure Vs No Biochemical Faliure
|
p=0.024
|
Tissue
|
24708576
|
1376
|
MKI67
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical Failure Vs No Biochemical Faliure
|
p=0.026
|
Tissue
|
24708576
|
1377
|
SIAH2
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical Failure Vs No Biochemical Faliure
|
p=0.016
|
Tissue
|
24708576
|
1378
|
SMAD4
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical Failure Vs No Biochemical Faliure
|
Univariate: p=0.01 Multivariate; p=0.016
|
Tissue
|
24708576
|
1379
|
HMMR+ SIAH2+ SMAD4
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical Failure Vs No Biochemical Faliure (3 years)
|
p=0.052
|
Tissue
|
24708576
|
1380
|
HMMR+ SIAH2+ SMAD4
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical Failure Vs No Biochemical Faliure (5 years)
|
p=0.024
|
Tissue
|
24708576
|
1381
|
BTG2; CDC37L1; COL15A1; COL3A1; EIF2D; FDPS; HIST1H1C; HIST1H2BG; IFT57; IGFBP3; ITPR1; LBH; LOC284801; MARCH5; MED4; MEMO1; MXI1; PTN; RPL23AP53; SACM1L; SIRT1; SNORA20; SRSF3; SYNM;
|
mRNA
|
Humans
|
Poor score with decreased BCR Survival
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p = 1.45E-21; Validation: p=2.85e-3
|
Tissue
|
24713434
|
1382
|
miR-598; miR-105; miR-767-5p; miR-24; miR-342-3p; miR-125a-5p; miR-27a; miR-194; miR-454; miR-26b; miR-146a miR-99b; miR-455-3p; miR-301a; miR-9; miR-200a; miR-1267 miR-205 miR-95 miR-200a-5p; miR-200b; miR-203; miR-34a; miR-375; miR-191; miR-100; miR-135b; miR-429
|
miRNA
|
Humans
|
Upregulated in docetaxel-resistant cell lines: [miR-598; miR-105; miR-767-5p; miR-24; miR-342-3p; miR-125a-5p; miR-27a; miR-194; miR-454; miR-26b; miR-146a miR-99b; miR-455-3p; miR-301a];Downreegulated in docetaxel-resistant cell lines: [miR-9; miR-200a; miR-1267 miR-205 miR-95 miR-200a-5p; miR-200b; miR-203; miR-34a; miR-375; miR-191; miR-100; miR-135b; miR-429]
|
Prognostic
|
PC3 Cell Line Vs PC3Rx Cell Line (docetaxel-resistant sublines)
|
p≤0.001
|
Cell Lines
|
24714754
|
1383
|
miR-30e-3p; miR-191-3p; miR-30a-5p; miR-152; miR-34b; miR-301b; miR-100; miR-301a; miR-99a; miR-151-3p; miR-30a-3p; miR-146b-5p; miR-210; miR-15a-3p; miR-135b; miR-200b; miR-590-3p; miR-429; miR-590-5p; miR-20b; miR-200c; miR-200a; miR-25; miR-146a; miR-196b; miR-489; miR-96; miR-486-5p;
|
miRNA
|
Humans
|
Upregulated in docetaxel-resistant cell lines: [miR-30e-3p; miR-191-3p; miR-30a-5p; miR-152; miR-34b; miR-301b; miR-100; miR-301a; miR-99a; miR-151-3p; miR-30a-3p; miR-146b-5p; miR-210; miR-15a-3p;]Downregulated in docetaxel-resistant cell lines: [miR-135b; miR-200b; miR-590-3p; miR-429; miR-590-5p; miR-20b; miR-200c; miR-200a; miR-25; miR-146a; miR-196b; miR-489; miR-96; miR-486-5p;]
|
Prognostic
|
DU145 Cell Line Vs DU145Rx Cell Line(docetaxel-resistant sublines)
|
p≤0.001
|
Cell Lines
|
24714754
|
1393
|
Testosterone
|
Hormone
|
Humans
|
Increased levels in patients with Higher overall Survival
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.018
|
Plasma
|
24722180
|
1399
|
Methylation status of GABRE + miR-224 +miR-452 (as continous value )
|
miRNA + Methylation
|
Humans
|
Hypermethylated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Cohort 1: Univariate: p<0.001; Multivariate: p= 0.019 Cohort 2: Univariate: p<0.001; Multivariate: p=0.008
|
Tissue
|
24737792
|
1400
|
Methylation status of GABRE + miR-224 +miR-452 (High vs. Low )
|
miRNA + Methylation
|
Humans
|
Hypermethylated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Cohort 1: Univariate: p<0.001; Multivariate: p= 0.019 Cohort 2: Univariate: p<0.001; Multivariate: p=0.008
|
Tissue
|
24737792
|
1401
|
GABRE + miR-224 +miR-452
|
mRNA + miRNA
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.001
|
Tissue
|
24737792
|
1402
|
GABRE
|
RNA
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.001
|
Tissue
|
24737792
|
1403
|
miR-224
|
miRNA
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.001
|
Tissue
|
24737792
|
1404
|
miR-452
|
miRNA
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.001
|
Tissue
|
24737792
|
1405
|
OAZ2
|
mRNA
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.001
|
Tissue
|
24737792
|
1406
|
GABRE + miR-224 +miR-452+OAZ2
|
mRNA + miRNA
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.001
|
Tissue
|
24737792
|
1407
|
MIR605 [SNP: rs2043556: GG]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: Cohort 1: p= 0.006 Cohort 1+2: p=0.01;Multivariate: Cohort 1:p = 0.005 Cohort 1+2: p=0.01
|
Blood
|
24740842
|
1408
|
MIR605 [SNP: rs2043556: AG/GG vs. AA]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: Cohort 1: p= 0.04 Cohort 1+2: p=0.02
|
Blood
|
24740842
|
1409
|
MIR605 [SNP: rs2043556: GG vs. AA/AG]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: Cohort 1: p= 0.02 Cohort 1+2: p=0.03;Multivariate: Cohort 1:p = 0.004 Cohort 1+2: p=0.01
|
Blood
|
24740842
|
1410
|
MTRR [SNP: rs9332: CT]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: Cohort 1: p= 0.008 Cohort 1+2: p=0.01
|
Blood
|
24740842
|
1411
|
MTRR [SNP: rs9332: CT/TT vs. CC]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: Cohort 1: p= 0.04 Cohort 1+2: p=0.05
|
Blood
|
24740842
|
1412
|
CDON [SNP: rs3737336: CC]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: Cohort 1: p= 0.05 Cohort 1+2: p=0.01;Multivariate: Cohort 1:p = 0.03 Cohort 2: p = 0.04 Cohort 1+2: p=0.003
|
Blood
|
24740842
|
1413
|
CDON [SNP: rs3737336: CC vs. TT/TC]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: Cohort 1+2: p=0.02;Multivariate: Cohort 1: p = 0.03; Cohort 1+2: p=0.007
|
Blood
|
24740842
|
1414
|
POSTN; ASPN; LAMB2; SERPH; CSPG2; ENTP1; SE1L1; ITAV; FOLH1; STIM1; PTK7; ICOSL; SPP2A; CD276; KLK3; ZA2G; FBN1; CD38; CNTP2; AMPN; FAM3B; RNT2; NAAA; PPAP; GSLG1; TSN1; DPP4; ST14;
|
Protein
|
Humans
|
Upregulated in Agressive PCa; Downregulated in Agressive PCa: []
|
Prognostic
|
Agressive Vs Non Agressive PCa
|
NA
|
Tissue
|
24741114
|
1415
|
TIMP1; CLUS; MFAP4; AOC3; CADM1; HYOU1; FSTL1; KLK11; NBL1; GOLM1; VTNC; CERU; A1AG2; LYVE1; A1AG1;
|
Protein
|
Humans
|
Upregulated in Metastatic PCa;Downregulated in Non Metastatic PCa: []
|
Prognostic
|
Metastatic Vs Non Metastatic Prostate Cancer
|
NA
|
Tissue
|
24741114
|
1417
|
NAAA
|
Protein
|
Humans
|
Downregulated in GS >7
|
Prognostic
|
Gleason Score ≤ 7 and Gleason Score >7
|
p <0.05
|
Tissue
|
24741114
|
1418
|
PTK7
|
Protein
|
Humans
|
Upregulated in GS >7
|
Prognostic
|
Gleason Score ≤ 7 and Gleason Score >7
|
p <0.01
|
Tissue
|
24741114
|
1419
|
NAAA+ PTK7
|
Protein
|
Humans
|
NAAA: Downregulated in GS >7; PTK7: Upregulated in GS >7
|
Prognostic
|
Gleason Score ≤ 7 and Gleason Score >7
|
p <0.05
|
Tissue
|
24741114
|
1424
|
miR-7; miR-221; miR-222
|
miRNA
|
Humans
|
Upregulated in PC-3 Cell Lines: [ miR-7(11.3 fold); miR-222 (8.6 fold); miR-221 (8.6 fold)]
|
Prognostic
|
LNCaP Cell Lines Vs PC-3 Cell Lines
|
p<0.05
|
Cell Lines
|
24760272
|
1425
|
miR-7; miR-221;
|
miRNA
|
Humans
|
Upregulated in Early Castration Resistant Acquisition
|
Prognostic
|
Early Vs Late Castration-resistant acquisition (≤20 months and ≥60 months)
|
miR-7: p=0.034; miR-221: p=0.036;
|
Blood
|
24760272
|
1428
|
DAB2IP
|
Protein
|
Humans
|
Reduced in lower FFBF (Freedom From Biochemical Faliure)
|
Prognostic
|
Freedom From Biochemical Failure Vs Biochemical Failure
|
p=0.04
|
Tissue
|
24867541
|
1429
|
miR-19a
|
miRNA
|
Humans
|
Upregulated in Cases
|
Prognostic
|
Gleason Score ≥7 or Gleason Score =6
|
p<0.05
|
Tissue
|
24893170
|
1430
|
miR-19b
|
miRNA
|
Humans
|
NA
|
Prognostic
|
Gleason Score ≥7 or Gleason Score =6
|
p<0.05
|
Tissue
|
24893170
|
1431
|
miR-345
|
miRNA
|
Humans
|
Downregulated in Cases
|
Prognostic
|
Gleason Score ≥7 or Gleason Score =6
|
p<0.05
|
Tissue
|
24893170
|
1432
|
miR-519c-5p
|
miRNA
|
Humans
|
Downregulated in Cases
|
Prognostic
|
Gleason Score ≥7 or Gleason Score =6
|
p<0.05
|
Tissue
|
24893170
|
1433
|
miR-19a
|
miRNA
|
Humans
|
Upregulated in Cases
|
Prognostic
|
Gleason Score ≥7 or Gleason Score =6
|
p<0.05
|
Tissue
|
24893170
|
1434
|
miR-19b
|
miRNA
|
Humans
|
Upregulated in Cases
|
Prognostic
|
Gleason Score ≥7 or Gleason Score =6
|
p<0.05
|
Tissue
|
24893170
|
1435
|
miR-345
|
miRNA
|
Humans
|
NA
|
Prognostic
|
Gleason Score ≥7 or Gleason Score =6
|
p<0.05
|
Tissue
|
24893170
|
1436
|
miR-519c-5p
|
miRNA
|
Humans
|
NA
|
Prognostic
|
Gleason Score ≥7 or Gleason Score =6
|
p<0.05
|
Tissue
|
24893170
|
1437
|
miR_19a+ miR_345+ miR_519c_5p
|
miRNA
|
Humans
|
NA
|
Prognostic
|
Gleason Score ≥7 or Gleason Score =6
|
p<0.05
|
Tissue
|
24893170
|
1438
|
miR_19b+miR_345+ miR_519c_5p
|
miRNA
|
Humans
|
NA
|
Prognostic
|
Gleason Score ≥7 or Gleason Score =6
|
p<0.05
|
Tissue
|
24893170
|
1439
|
miR_19a + miR_19b + miR_345 + miR_519c_5p
|
miRNA
|
Humans
|
NA
|
Prognostic
|
Gleason Score ≥7 or Gleason Score =6
|
p<0.05
|
Tissue
|
24893170
|
1440
|
MUC1
|
Protein
|
Humans
|
Increased with Increased mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.02
|
Tissue
|
24909936
|
1441
|
p53
|
Protein
|
Humans
|
Increased with Increased mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.005
|
Tissue
|
24909936
|
1442
|
AZGP1
|
Protein
|
Humans
|
Increased with Decreased mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.04
|
Tissue
|
24909936
|
1443
|
MUC1 + p53+ AZGP1
|
Protein
|
Humans
|
Increased with Increased mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
NA
|
Tissue
|
24909936
|
1445
|
miR-1
|
miRNA
|
Humans
|
Downregulated in Recurrent PCa
|
Prognostic
|
Recurrence Vs No Recurrence
|
p = 0.036
|
Tissue
|
24967583
|
1446
|
miR-133b
|
miRNA
|
Humans
|
Downregulated in Recurrent PCa
|
Prognostic
|
Recurrence Vs No Recurrence
|
p = 0.012
|
Tissue
|
24967583
|
1447
|
miR-1 + miR-133b
|
miRNA
|
Humans
|
Downregulated in Recurrent PCa
|
Prognostic
|
Recurrence Vs No Recurrence
|
p = 0.012
|
Tissue
|
24967583
|
1455
|
N-terminal telopeptide of type I collagen (NTx)
|
Protein
|
Humans
|
NA
|
Prognostic
|
Gleason Score
|
p< 0.001
|
Serum
|
24992524
|
1456
|
N-terminal telopeptide of type I collagen (NTx)
|
Protein
|
Humans
|
NA
|
Prognostic
|
Prostate Cancer Stage
|
p = 0.007
|
Serum
|
24992524
|
1457
|
Brachyury
|
Protein
|
Humans
|
Increases with increasing Gleason Score
|
Prognostic
|
Gleason Score GS <7 Vs GS = 7 Vs GS >7
|
p = 0.027
|
Tissue
|
25009296
|
1462
|
Receptor for advanced glycation end products (RAGE)
|
Protein
|
Humans
|
Upregulated in Stage T3-T4
|
Prognostic
|
stage T1-T2 Vs Stage T3-T4
|
p=0.004
|
Tissue
|
25057439
|
1463
|
High Mobility Group Box 1 (HMGB1)
|
Protein
|
Humans
|
Upregulated in Stage T3-T5
|
Prognostic
|
stage T1-T2 Vs Stage T3-T4
|
p=0.009
|
Tissue
|
25057439
|
1464
|
High Mobility Group Box 1 (HMGB1) + Receptor for advanced glycation end products (RAGE)
|
Protein
|
Humans
|
Upregulated in Stage T3-T6
|
Prognostic
|
stage T1-T2 Vs Stage T3-T4
|
p=0.007
|
Tissue
|
25057439
|
1465
|
Receptor for advanced glycation end products (RAGE)
|
Protein
|
Humans
|
Upregulated in Distant Metastases
|
Prognostic
|
Distant Metastases Vs No Distant Metastases
|
p=0.013
|
Tissue
|
25057439
|
1466
|
High Mobility Group Box 1 (HMGB1)
|
Protein
|
Humans
|
Upregulated in Distant Metastases
|
Prognostic
|
Distant Metastases Vs No Distant Metastases
|
p=0.019
|
Tissue
|
25057439
|
1467
|
High Mobility Group Box 1 (HMGB1) + Receptor for advanced glycation end products (RAGE)
|
Protein
|
Humans
|
Upregulated in Distant Metastases
|
Prognostic
|
Distant Metastases Vs No Distant Metastases
|
p=0.026
|
Tissue
|
25057439
|
1468
|
High Mobility Group Box 1 (HMGB1) + Receptor for advanced glycation end products (RAGE)
|
Protein
|
Humans
|
Increased Coexpression in patients with Decreased overall Survival
|
Prognostic
|
Overall Suvival Vs No Survival
|
p=0.047
|
Tissue
|
25057439
|
1470
|
miR-135a
|
miRNA
|
Humans
|
Downregulated in GS ≥ 8
|
Prognostic
|
Glesaon Score ≥ 8 and Gleason Score <8
|
p<0.01
|
Tissue
|
25065599
|
1471
|
miR-135a
|
miRNA
|
Humans
|
Downregulated in Stage pT3a
|
Prognostic
|
Stage pT3a Vs Stage pT2c
|
p<0.05
|
Tissue
|
25065599
|
1472
|
PTEN
|
Protein
|
Humans
|
NA
|
Prognostic
|
Lethal Outcome Vs No Lethal Outcome
|
p=0.0011
|
Tissue
|
25075204
|
1473
|
CCND1
|
Protein
|
Humans
|
NA
|
Prognostic
|
Lethal Outcome Vs No Lethal Outcome
|
p=0.036
|
Tissue
|
25075204
|
1474
|
SMAD4
|
Protein
|
Humans
|
NA
|
Prognostic
|
Lethal Outcome Vs No Lethal Outcome
|
p=0.0035
|
Tissue
|
25075204
|
1475
|
PTEN + CCND1 +SMAD4 + SSP1
|
Protein
|
Humans
|
NA
|
Prognostic
|
Lethal Outcome Vs No Lethal Outcome
|
p = 0.00000456
|
Tissue
|
25075204
|
1476
|
pS6
|
Protein
|
Humans
|
NA
|
Prognostic
|
Lethal Outcome Vs No Lethal Outcome
|
p=0.021
|
Tissue
|
25075204
|
1477
|
pPRAS40
|
Protein
|
Humans
|
NA
|
Prognostic
|
Lethal Outcome Vs No Lethal Outcome
|
p=0.019
|
Tissue
|
25075204
|
1478
|
CCND1 +SMAD4 + SSP1 + pS6 + pPRAS40
|
Protein
|
Humans
|
NA
|
Prognostic
|
Lethal Outcome Vs No Lethal Outcome
|
p = 0.000013
|
Tissue
|
25075204
|
1481
|
miR-21
|
miRNA
|
Humans
|
Downregulated in GS ≥ 8 (Benign: 0.636 ± 0.048; malignant: 0.521 ± 0.027)
|
Prognostic
|
Gleason Score ≥ 8 Vs Gleason Score < 8
|
p=0.004
|
Tissue
|
25075250
|
1482
|
miR-21
|
miRNA
|
Humans
|
Downregulated in Metastatis (No Metastasis: 0.667 ± 0.037; Metastatis: 0.463 ± 0.027)
|
Prognostic
|
Metastatic Vs Non Metastatic Prostate Cancer
|
p<0.0001
|
Tissue
|
25075250
|
1483
|
miR-30c
|
miRNA
|
Humans
|
Downregulated in Metastatis (No Metastasis: 0.514 ± 0.029; Metastatis: 0.354 ± 0.032)
|
Prognostic
|
Metastatic Vs Non Metastatic Prostate Cancer
|
p= 0.0003
|
Tissue
|
25075250
|
1484
|
miR-219
|
miRNA
|
Humans
|
Downregulated in Metastatis (No Metastasis: 0.532 ± 0.028; Metastatis: 0.448 ± 0.029)
|
Prognostic
|
Metastatic Vs Non Metastatic Prostate Cancer
|
p= 0.039
|
Tissue
|
25075250
|
1485
|
miR-21
|
miRNA
|
Humans
|
Downregulated in Patients who suvived (Survival : 0.636 ± 0.039; No Survival: 0.507 ± 0.03)
|
Prognostic
|
Survival Vs No Survival
|
p= 0.009
|
Tissue
|
25075250
|
1486
|
miR-30c
|
miRNA
|
Humans
|
Downregulated in Patients who suvived (Survival : 0.500 ± 0.031; No Survival: 0.406 ± 0.028)
|
Prognostic
|
Survival Vs No Survival
|
p= 0.024
|
Tissue
|
25075250
|
1487
|
miR-30c
|
miRNA
|
Humans
|
Downregulated in Patients With Recurrence (No Recurrence : 0.609 ± 0.036; recurrence: 0.415 ± 0.051)
|
Prognostic
|
PSA Recurrence Vs No Recurrence
|
p= 0.003
|
Tissue
|
25075250
|
1488
|
let-7c
|
miRNA
|
Humans
|
Downregulated in Patients With Recurrence (No Recurrence : 0.703 ± 0.098; recurrence: 0.963 ± 0.06)
|
Prognostic
|
PSA Recurrence Vs No Recurrence
|
p=0.0266
|
Tissue
|
25075250
|
1489
|
Interleukin-1β (IL-1β)
|
Protein
|
Humans
|
Increased in patients with Biochemical Recurrence
|
Prognostic
|
Recurrence Vs No Recurrence
|
p=0.02
|
Tissue
|
25075566
|
1490
|
Interferon β (IFNβ)
|
Protein
|
Humans
|
Decreased in patients with Biochemical Recurrence
|
Prognostic
|
Recurrence Vs No Recurrence
|
p=0.008
|
Tissue
|
25075566
|
1491
|
Interleukin-1β (IL-1β) + Interferon β (IFNβ)
|
Protein
|
Humans
|
Interleukin-1β (IL-1β): Increased in patients with Biochemical Recurrence; Interferon β (IFNβ): Decreased in patients with Biochemical Recurrence
|
Prognostic
|
Recurrence Vs No Recurrence
|
p=0.004
|
Tissue
|
25075566
|
1495
|
mir-27b
|
miRNA
|
Humans
|
Decreased in patients with shorter progression free interval
|
Prognostic
|
Progression Vs No Progression
|
p=0.0346
|
Tissue
|
25115396
|
1496
|
miR-1290
|
miRNA
|
Humans
|
NA
|
Prognostic
|
High Risk vs Low Risk (Survival)
|
p<0.0008
|
Plasma
|
25129854
|
1497
|
miR-1246
|
miRNA
|
Humans
|
NA
|
Prognostic
|
High Risk vs Low Risk (Survival)
|
p<0.0008
|
Plasma
|
25129854
|
1498
|
miR-375
|
miRNA
|
Humans
|
NA
|
Prognostic
|
High Risk vs Low Risk (Survival)
|
p<0.0008
|
Plasma
|
25129854
|
1499
|
miR-1290 + miR-375 + PSA + ADT
|
miRNA
|
Humans
|
NA
|
Prognostic
|
High Risk vs Low Risk (Survival)
|
p= 0.0016
|
Plasma
|
25129854
|
1500
|
miR-1290 + miR-375
|
miRNA
|
Humans
|
NA
|
Prognostic
|
High Risk vs Low Risk (Survival)
|
p<0.05
|
Plasma
|
25129854
|
1501
|
tPSA
|
Protein
|
Humans
|
Upregulated in patients with Grade pT3 or GS ≥ 7
|
Prognostic
|
Single adverse pathologic characteristic (pT3 disease or pathologic Gleason score I7)
|
p < 0.001
|
Serum
|
25139197
|
1502
|
p2PSA
|
Protein
|
Humans
|
Upregulated in patients with Grade pT3 or GS ≥ 7
|
Prognostic
|
Single adverse pathologic characteristic (pT3 disease or pathologic Gleason score I7)
|
p < 0.001
|
Serum
|
25139197
|
1503
|
%p2PSA
|
Protein
|
Humans
|
Upregulated in patients with Grade pT3 or GS ≥ 7
|
Prognostic
|
Single adverse pathologic characteristic (pT3 disease or pathologic Gleason score I7)
|
p < 0.001
|
Serum
|
25139197
|
1504
|
Prostate Health Index (PHI)
|
Protein
|
Humans
|
Upregulated in patients with Grade pT3 or GS ≥ 7
|
Prognostic
|
Single adverse pathologic characteristic (pT3 disease or pathologic Gleason score I7)
|
p < 0.001
|
Serum
|
25139197
|
1505
|
tPSA
|
Protein
|
Humans
|
Upregulated in patients with Grade pT3 or GS ≥ 7
|
Prognostic
|
Both adverse pathologic characteristics (pT3 disease and pathologic Gleason score I7)
|
p < 0.001
|
Serum
|
25139197
|
1506
|
p2PSA
|
Protein
|
Humans
|
Upregulated in patients with Grade pT3 or GS ≥ 7
|
Prognostic
|
Both adverse pathologic characteristics (pT3 disease and pathologic Gleason score I7)
|
p < 0.001
|
Serum
|
25139197
|
1507
|
%p2PSA
|
Protein
|
Humans
|
Upregulated in patients with Grade pT3 or GS ≥ 7
|
Prognostic
|
Both adverse pathologic characteristics (pT3 disease and pathologic Gleason score I7)
|
p < 0.001
|
Serum
|
25139197
|
1508
|
Prostate Health Index (PHI)
|
Protein
|
Humans
|
Upregulated in patients with Grade pT3 or GS ≥ 7
|
Prognostic
|
Both adverse pathologic characteristics (pT3 disease and pathologic Gleason score I7)
|
p < 0.001
|
Serum
|
25139197
|
1515
|
YWHAZ
|
Protein
|
Humans
|
NA
|
Prognostic
|
Gleason Score ≤ 6 Vs Gleason Score 7 (3+4) Vs Gleason Score 7 (4+3) Vs Gleason Score ≥ 8
|
p<0.001
|
Tissue
|
25156059
|
1516
|
YWHAZ
|
Protein
|
Humans
|
Increased expression in patients with PCa specific death
|
Prognostic
|
High Risk vs Low Risk (Survival)
|
Univariate: p=0.004; Multivariate: p = 0.015
|
Tissue
|
25156059
|
1517
|
YWHAZ
|
Protein
|
Humans
|
Increased expression in patients with Castration Resistant Prostate Cancer (CRPC)
|
Prognostic
|
Castration Resistant Prostate Cancer (CRPC) Vs No CRPC
|
Univariate: p=0.005; Multivariate: p = 0.008
|
Tissue
|
25156059
|
1518
|
YWHAZ
|
Protein
|
Humans
|
Increased expression in patients with PSA Relapse
|
Prognostic
|
High Risk vs. Low Risk (Relapse
|
Univariate: p=0.005; Multivariate: p = 0.019
|
Tissue
|
25156059
|
1523
|
Oligophrenin-1 (OPHN1)
|
Protein
|
Humans
|
Upregulated in Prostate Cancer (Tumor/nonneoplastic prostate (T/N ratio): > 3 fold)
|
Prognostic
|
Gleason Score 6-7 Vs Gleason Score 8-9-10
|
univariate: p=0.0011; Multivariate: 0.0038
|
Tissue
|
25170626
|
1524
|
Oligophrenin-1 (OPHN1)
|
Protein
|
Humans
|
Upregulated in Prostate Cancer (Tumor/nonneoplastic prostate (T/N ratio): > 3 fold)
|
Prognostic
|
Stage pT2 Vs Stage pT3
|
univariate: p=0.0099; Multivariate: 0.0104
|
Tissue
|
25170626
|
1527
|
Yin Yang 1 (YY1)
|
Protein
|
Humans
|
Downregulated in PCa
|
Prognostic
|
High Grade cancer Vs Low grade Cancer
|
P<0.0001
|
Tissue
|
25174820
|
1528
|
Death Receptor 5
|
Protein
|
Humans
|
Downregulated in PCa
|
Prognostic
|
High Grade cancer Vs Low grade Cancer
|
P<0.0001
|
Tissue
|
25174820
|
1532
|
cytoplasmic-nuclear factor erythroid 2-related factor 2 (c-Nrf-2)
|
Protein
|
Humans
|
Upregulated in Malignant Tissue
|
Prognostic
|
Biochemical Failure Free Survival Vs No Survival
|
Univariate: p=0.28; Multivariate: p=0.019
|
Tissue
|
25175169
|
1533
|
cytoplasmic-nuclear factor erythroid 2-related factor 2 (c-Nrf-2)
|
Protein
|
Humans
|
Upregulated in Malignant Tissue
|
Prognostic
|
Overall Survival Vs No Survival
|
Univariate: p=0.28; Multivariate: p=0.019
|
Tissue
|
25175169
|
1536
|
E Cadherin
|
Protein
|
Humans
|
Downregulated in patients with early relapse
|
Prognostic
|
Biochemical Relapse Vs No Biochemical Relapse for external beam radiotherapy treated (EBRT)
|
p=0.02
|
Tissue
|
25227682
|
1537
|
Ki-67
|
Protein
|
Humans
|
Upregulated in patients with early relapse
|
Prognostic
|
Early Relapse Vs No Relapse
|
EBRT cohort: p=0.0006; PADT Cohort: p=0.0004
|
Tissue
|
25227682
|
1553
|
miR-221
|
miRNA
|
Humans
|
Downregulated in Recurrent Cases (Recurrent Median: 0.25; Control Median: 0.46)
|
Prognostic
|
Recurrence Vs No Recurrence
|
Regulation: p=0.0002; Univariate: p=0.02; Multivariate: p=0.05
|
Tissue
|
25252191
|
1554
|
miR-21
|
miRNA
|
Humans
|
Downregulated in Recurrent Cases (Recurrent Median: 1.01; Control Median: 1.54)
|
Prognostic
|
Recurrence Vs No Recurrence
|
p=0.0149
|
Tissue
|
25252191
|
1555
|
miR-141
|
miRNA
|
Humans
|
Downregulated in Recurrent Cases (Recurrent Median: 0.39; Control Median: 0.81)
|
Prognostic
|
Recurrence Vs No Recurrence
|
p<0.0001
|
Tissue
|
25252191
|
1557
|
Chondroitin Sulfate
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Prognostic
|
Progression Vs No Progression
|
p=0.0001
|
Tissue
|
9815775
|
1560
|
Versican
|
Protein
|
Humans
|
Upregulated in Prostate Cancer
|
Prognostic
|
Progression Vs No Progression
|
p=0.0003
|
Tissue
|
9563891
|
1562
|
WISP1
|
Protein
|
Humans
|
Increased with decreased BCR survival
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Cohort 1: p = 0.028;Cohort 3: p= 0.042
|
Tissue
|
31069142
|
1563
|
WISP1
|
Protein
|
Humans
|
Upregulated with increasing Stage
|
Prognostic
|
pTNM 2 Vs pTNM 3 Vs pTNM 4
|
p<0.05
|
Tissue
|
31069142
|
1564
|
WISP1
|
mRNA
|
Humans
|
Upregulated in Metastatic PCa
|
Prognostic
|
Primary Vs Metastatis Prostate Cancer
|
p=0.03
|
Tissue
|
31069142
|
1566
|
TMEFF2
|
mRNA
|
Humans
|
Upregulated in PCa (Log 2 Median Centered Intensity)
|
Prognostic
|
Primary/Localised Vs Metastatic/CRPC Prostate Cancer
|
p<0.05
|
Tissue
|
31060542
|
1567
|
TMEFF2
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p<0.0001
|
Tissue
|
31060542
|
1569
|
BUB1B; CDC45; CDK1; CENPI; CLSPN; ERCC6L; EXO1; NCAPG; NUSAP1; RAD51; RRM2;
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
31060542
|
1570
|
BUB1B+CDC45+CDK1+CENPI+CLSPN+ERCC6L+EXO1+NCAPG+NUSAP1+RAD51+RRM2
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
31060542
|
1571
|
Osteopontin (OPN)
|
Protein
|
Humans
|
increased with decreased BRFS
|
Prognostic
|
Biochemical Recurrence Free Survival Vs No Biochemical Recurrence Free Survival
|
p < 0.036
|
Tissue
|
31059955
|
1572
|
Glucose Transporter 1 (GLUT1)
|
Protein
|
Humans
|
increased with decreased BRFS
|
Prognostic
|
Biochemical Recurrence Free Survival Vs No Biochemical Recurrence Free Survival
|
p < 0.001
|
Tissue
|
31059955
|
1573
|
Glucose Transporter 1 (GLUT1)
|
Protein
|
Humans
|
increased with decreased DMFS
|
Prognostic
|
Distant Metastasis Free Survival Vs Distant Metastasis Free Survival
|
p = 0.045
|
Tissue
|
31059955
|
1574
|
RNASEL (SNP: rs635261)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
PCa-specific mortality Vs No PCa-specific mortality
|
p= 0.002
|
Blood
|
25273821
|
1575
|
XRCC1 (SNP: rs915927)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
PCa-specific mortality Vs No PCa-specific mortality
|
p=0.009
|
Blood
|
25273821
|
1576
|
AKT1 (SNP: rs2494750)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
PCa-specific mortality Vs No PCa-specific mortality
|
p=0.016
|
Blood
|
25273821
|
1577
|
(Intergenic) KLK3–KLK2: [SNP: rs2735839]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Gleason Score ≤ 6 Vs Gleason Score ≥ 8
|
p=0.002
|
Blood
|
25274378
|
1578
|
JAZF1 [SNP: rs10486567]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Gleason Score ≤ 6 Vs Gleason Score ≥ 8
|
p=0.012
|
Blood
|
25274378
|
1579
|
(Intergenic) LILRB2–LILRA3 [SNP: rs103294]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Gleason Score ≤ 6 Vs Gleason Score ≥ 8
|
p=0.024
|
Blood
|
25274378
|
1580
|
(Intergenic) KLK3–KLK2: [SNP: rs2735839] (AG/GG)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Gleason Score 7 (3+4) Vs Gleason Score 7 (4+3)
|
p=0.0002
|
Blood
|
25274378
|
1581
|
(Intergenic) KLK3–KLK2: [SNP: rs2735839] (AG+AA/GG)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Gleason Score 7 (3+4) Vs Gleason Score 7 (4+3)
|
p=0.0005
|
Blood
|
25274378
|
1582
|
Ki-67
|
Protein
|
Humans
|
NA
|
Prognostic
|
Distant Metastatis Vs No Distant Metastatis
|
p<0.0001
|
Tissue
|
25294917
|
1583
|
Cox-2
|
Protein
|
Humans
|
Upregulation
|
Prognostic
|
Distant Metastatis Vs No Distant Metastatis
|
p=0.04
|
Tissue
|
25294917
|
1584
|
p16
|
Protein
|
Humans
|
NA
|
Prognostic
|
Distant Metastatis Vs No Distant Metastatis
|
p=0.0065
|
Tissue
|
25294917
|
1585
|
MDM2
|
Protein
|
Humans
|
NA
|
Prognostic
|
Distant Metastatis Vs No Distant Metastatis
|
p=0.036
|
Tissue
|
25294917
|
1594
|
Kallikrein-related peptidase 2 [hK2]+ intact PSA+ free PSA [fPSA]+total PSA [tPSA]
|
Protein
|
Humans
|
Upregulated in GS ≤ 7
|
Prognostic
|
Gleason Score <7 and Gleason Score ≤7
|
p<0.0001
|
Blood
|
25454615
|
1602
|
Vascular endothelial growth factor A (VEGF-A)
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.016
|
Tissue
|
26268996
|
1603
|
Vascular endothelial growth factor A (VEGF-A) + Vascular endothelial growth factor Receptor (VEGFR-2)
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.006
|
Tissue
|
26268996
|
1604
|
Full Length Androgen Receptor (AR-FL)
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Progression-free survival Vs No Progression-free survival
|
p=0.0003
|
Plasma
|
31055861
|
1610
|
mir-145
|
miRNA
|
Humans
|
Downregulated in Gleason Score Upgradation (Without Upgradation: -0.4831 Vs Upgradation: -1.1202)
|
Prognostic
|
Gleason Score Upgradation Vs No Upgradation
|
p=0.03
|
Tissue
|
31045265
|
1611
|
mir-221
|
miRNA
|
Humans
|
Downregulated in Recurrence (Recurrence: −1.7170 Vs No Recurrence: − 0.9129)
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.04
|
Tissue
|
31045265
|
1612
|
IL2RB [SNP: rs84460; C vs T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.006
|
Blood
|
31035590
|
1613
|
SMAD3 [SNP: rs7162912; G vs T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.0001
|
Blood
|
31035590
|
1614
|
FOXO3 [SNP: rs7762395 C Vs T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.002
|
Blood
|
31035590
|
1615
|
FOXO3 [SNP: rs2153960 C Vs T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.001
|
Blood
|
31035590
|
1616
|
SMAD3 [SNP: rs9302242; A vs G]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.005
|
Blood
|
31035590
|
1617
|
IL4R [SNP: rs1805011; A vs C]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.003
|
Blood
|
31035590
|
1618
|
IL4R [SNP: rs3024586; A vs G]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.003
|
Blood
|
31035590
|
1619
|
CCL5 [SNP: rs2280789 C Vs T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.001
|
Blood
|
31035590
|
1620
|
MMP9 [SNP: rs3918262; A Vs G]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Overall Survival
|
p=0.001
|
Blood
|
31035590
|
1621
|
VEGFR2 [SNP: rs7692791; C Vs T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Overall Survival
|
p=0.001
|
Blood
|
31035590
|
1622
|
VEGFR2 [SNP: rs2034967; C Vs T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Overall Survival
|
p=0.00000008
|
Blood
|
31035590
|
1624
|
KIF20A
|
mRNA
|
Humans
|
Upregulated in prostate cancer tissues compared with HR: 2.060 Pathways include: Kinesins, Aurora B signaling, Polo-like kinase 1 (PLK1) pathway, M phase pathway, MHC class II antigen presentation Prostate Cancer Vs No Prostate Cancer Diagnostic 498 cases from TCGA-PRAD were analysed along with 52 normal prostate controls were selected for the analysis NA NA 0.8406 (95% CI: 0.6603-0.8256) NA p < 0.0001 1623 NA No NA NA Not validated on independent patient dataset
31031850 2019 CDK1 NA Expression Based mRNA Tissue Humans normal tissues
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p < 0.0001
|
Tissue
|
31031850
|
1625
|
CCNB1
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.0166
|
Tissue
|
31031850
|
1626
|
BUB1
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p < 0.0001
|
Tissue
|
31031850
|
1627
|
CENPA
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p < 0.0001
|
Tissue
|
31031850
|
1628
|
AURKB
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p =0.0002662
|
Tissue
|
31031850
|
1629
|
CCNB2
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p < 0.001469
|
Tissue
|
31031850
|
1630
|
BIRC5
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p =0.0001304
|
Tissue
|
31031850
|
1631
|
AURKA
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p < 0.0001
|
Tissue
|
31031850
|
1632
|
BUB1B
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p < 0.0001
|
Tissue
|
31031850
|
1633
|
TTK
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p < 0.0001
|
Tissue
|
31031850
|
1634
|
KIF20A
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p < 0.0001
|
Tissue
|
31031850
|
1636
|
CDKN3
|
mRNA
|
Humans
|
Upregulated in prostate cancer tissues compared with HR: 2.451 Pathways include: T cell receptor regulation of apoptosis Biochemical recurrence Vs No Biochemical Recurrence Prognostic 498 cases from TCGA-PRAD were analysed along with 52 normal prostate controls were selected for the analysis NA NA 0.6493 NA p =0.0002558 1635 NA No NA NA Not validated on independent patient dataset
31031850 2019 KIF2C NA Expression Based mRNA Tissue Humans normal tissues
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p < 0.0001
|
Tissue
|
31031850
|
1637
|
NCAPG
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p < 0.0001
|
Tissue
|
31031850
|
1638
|
CDCA8
|
mRNA
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p =0.0001771
|
Tissue
|
31031850
|
1639
|
miR-3162-5p
|
miRNA
|
Humans
|
NA
|
Prognostic
|
Gleason grades 4+5 and 5 Vs Gleason grade 4
|
p=0.04
|
Tissue
|
31018918
|
1646
|
NLR (neutrophil to lymphocyte ratio)
|
Others
|
Humans
|
Upregulated in TRAMP
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.0
|
Blood
|
30962764
|
1647
|
PLR (Platelet to lymphocyte ratio)
|
Others
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.0
|
Blood
|
30962764
|
1648
|
LMR (lymphocyte to monocyte ratio)
|
Others
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.0
|
Blood
|
30962764
|
1649
|
Neutrophil
|
Others
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.006
|
Blood
|
30962764
|
1650
|
Monocyte
|
Others
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.006
|
Blood
|
30962764
|
1651
|
NLR (neutrophil to lymphocyte ratio)
|
Others
|
Humans
|
NA
|
Prognostic
|
Progression Free Survival Vs No Progression Free Survival
|
p=0.0
|
Blood
|
30962764
|
1652
|
NLR (neutrophil to lymphocyte ratio)
|
Others
|
Humans
|
NA
|
Prognostic
|
Recurrence Free Survival Vs No Recurrence Free Survival
|
p=0.002
|
Blood
|
30962764
|
1653
|
LMR (lymphocyte to monocyte ratio)
|
Others
|
Humans
|
NA
|
Prognostic
|
Progression Free Survival Vs No Progression Free Survival
|
p=0.0
|
Blood
|
30962764
|
1654
|
Monocyte
|
Others
|
Humans
|
NA
|
Prognostic
|
Progression Free Survival Vs No Progression Free Survival
|
p=0.006
|
Blood
|
30962764
|
1655
|
miRâ€28; miRâ€100; miRâ€942; miRâ€28â€3p
|
miRNA
|
Humans
|
NA
|
Prognostic
|
Low Grade Vs High Grade Prostate Cancer
|
miRâ€28: p=0.016; miRâ€100: p=0.025; miRâ€942: p=0.025; miRâ€28â€3p: p=0.038
|
Plasma
|
30958910
|
1656
|
miRâ€708; miRâ€1298; miRâ€886â€3p; miRâ€374; miRâ€376c; miRâ€202; miRâ€128a; miRâ€185
|
miRNA
|
Humans
|
NA
|
Prognostic
|
Low Grade Vs High Grade Prostate Cancer
|
miRâ€708: p<0.001; miRâ€1298: p=0.001; miRâ€886â€3p:p=0.01; miRâ€374:p=0.017; miRâ€376c: p=0.031; miRâ€202: p=0.035; miRâ€128a: p=0.039; miRâ€185: p=0.041
|
Plasma
|
30958910
|
1660
|
SNHG6 (small nucleolar RNA host gene 6)
|
LncRNA
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Normal Prostate Vs T2 PCa Vs T3+T4 PCa
|
p<0.001
|
Tissue
|
30911973
|
1661
|
SNHG6 (small nucleolar RNA host gene 6)
|
LncRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Normal Prostate Vs Gleason Score 6 Vs GS 7 VS GS 8 Vs GS 9+GS10
|
p<0.001
|
Tissue
|
30911973
|
1662
|
SNHG6 (small nucleolar RNA host gene 6)
|
LncRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Disease Free Survival Vs No Disease Free Survival
|
p=0.0365
|
Tissue
|
30911973
|
1676
|
tPSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1677
|
fPSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1678
|
p2PSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1679
|
%fPSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1680
|
%p2PSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1681
|
PHI
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1682
|
tPSA+ fPSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1683
|
tPSA+ %fPSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1684
|
fPSA + p2PSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1685
|
%fPSA + %p2PSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1686
|
PSA + %fPSA + %p2PSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1692
|
sE-Cadherin
|
Protein
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Gleason Pattern 3 Vs 4 Vs 5
|
p=0.02
|
Serum
|
25967040
|
1693
|
sE-Cadherin
|
Protein
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Gleason Upgrade Vs No Gleason Upgrade
|
p=0.03
|
Serum
|
25967040
|
1711
|
ERG
|
Protein
|
Humans
|
Upregulated in PCa (Tissue, Serum)
|
Prognostic
|
Recurrence Free Survival Vs No Recurrence Free Survival
|
p=0.04
|
Tissue
|
26172920
|
1712
|
SPINK1
|
Protein
|
Humans
|
Upregulated in PCa (Tissue, Urine)
|
Prognostic
|
Recurrence Free Survival Vs No Recurrence Free Survival
|
p=0.004
|
Tissue
|
26172920
|
1713
|
ERG; SPINK1
|
Protein
|
Humans
|
Upregulated in PCa (Tissue, Urine)
|
Prognostic
|
Recurrence Free Survival Vs No Recurrence Free Survival
|
p=0.003
|
Tissue
|
26172920
|
1716
|
TEP1 (Telomerase Associated Protein 1) [SNP: rs1760904 AA vs GG]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.032
|
Blood
|
26238235
|
1717
|
TEP1 (Telomerase Associated Protein 1) [SNP: rs1760904 AG/AA Vs GG]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.002
|
Blood
|
26238235
|
1718
|
TNKS2 (Tankyrase 2) [SNP: rs1539042 CG Vs GG]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.032
|
Blood
|
26238235
|
1719
|
TNKS2 (Tankyrase 2) [SNP: rs1539042 CG/CC Vs GG]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.02
|
Blood
|
26238235
|
1721
|
FOXM1 (Forkhead Box M1)
|
Protein
|
Humans
|
NA
|
Prognostic
|
Low & Intermediate Risk Vs High Risk
|
p<0.001
|
Tissue
|
30719174
|
1722
|
FOXM1 (Forkhead Box M1)
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: p=0.022; Multivariate: p=0.035
|
Tissue
|
30719174
|
1724
|
CRIP3
|
Methylation
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Reclassification (Progression Vs No Progression)
|
p=0.017
|
Urine
|
30777394
|
1725
|
miR-24+miR-30c+ Methylation Status of CRIP3
|
miRNA + DNA (Gene)
|
Humans
|
Increased in shorter BCR-free survival
|
Prognostic
|
Reclassification (Progression Vs No Progression)
|
Univariate: p=0.008; Multivariate: p=0.017
|
Urine
|
30777394
|
1727
|
HA: Hyaluronic acid
|
Metabolites
|
Humans
|
NA
|
Prognostic
|
High Risk Vs Intermediate Risk PCa
|
p=0.0214
|
Serum
|
30516927
|
1732
|
SERPINA5; MFSD2A; ACSL6; MCF2; EMX2; HOXB8; CLDN2; AKR1B1; SPINK2; CYP19A1;
|
mRNA
|
Humans
|
Differentially Expressed [Log Fold Change: SERPINA5: (-6.78954); MFSD2A (− 5.97025); ACSL6: (− 4.99597); MCF2: (−5.26855); EMX2: (− 6.79059); HOXB8: (− 6.24965); CLDN2: (−7.91887); AKR1B1: (− 3.87736); SPINK2: (−7.41992); CYP19A1: (−5.40444;]
|
Prognostic
|
High Risk Vs Low Risk PCa
|
p=0.00822
|
Tissue
|
30286759
|
1741
|
Methylation Status of cg12799885
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: p=0.025
|
Tissue
|
30866497
|
1742
|
Methylation Status of DOCK2
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: p < 0.001; Multivariate: p=0.004
|
Tissue
|
30866497
|
1743
|
Methylation Status of GRASP
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: p < 0.001; Multivariate: p=0.037
|
Tissue
|
30866497
|
1744
|
Methylation Status of HIF3A
|
Methylation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: p=0.005 Multivariate: p =0.027
|
Tissue
|
30866497
|
1745
|
Methylation Status of PFKP
|
Methylation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: p=0.001 Multivariate: p=0.028
|
Tissue
|
30866497
|
1746
|
Methylation Status of TPM4
|
Methylation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: p=0.038;
|
Tissue
|
30866497
|
1749
|
Neutrophil to Lymphocyte Ratio (NLR)
|
Others
|
Humans
|
NA
|
Prognostic
|
Cancer Specific Survival Vs No Survival
|
p=0.011
|
Blood
|
30800682
|
1750
|
Neutrophil to Lymphocyte Ratio (NLR)
|
Others
|
Humans
|
Upregulated in PCa: Fold change mean(BPH: 1.470; PCa: 54.384)
|
Prognostic
|
Overall Survival Vs No Overall Survival
|
p=0.017
|
Blood
|
30800682
|
1751
|
Tyrosine+Methylguanine+Isoleucine+Hypoxanthine+Maleic Acid +Xanthurenic acid 3+ LPC(18:0e)+LPC(22:3)+SM(d16:1/14:0)+DG(16:0/24:6)+SM(d16:1/24:3)+TG(15:0/16:1/18:2)+TG(16:0/18:1/18:2)+TG(18:1/18:1/18:1)+TG(18:0/18:1/22:5)+LPI(16:0) +Cer(d18:1/24:1) +Leucine+Glucose+Inosine
|
Lipid
|
Humans
|
Upregulated in PCa: Fold change mean(BPH: 1.365; PCa: 10.108)
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
NA
|
Serum
|
30758971
|
1752
|
Gleason score+age,+pre-operative PSA +pathological stage+Tyrosine+Methylguanine+Isoleucine+Hypoxanthine+Maleic Acid +Xanthurenic acid 3+ LPC(18:0e)+LPC(22:3)+SM(d16:1/14:0)+DG(16:0/24:6)+SM(d16:1/24:3)+TG(15:0/16:1/18:2)+TG(16:0/18:1/18:2)+TG(18:1/18:1/18:1)+TG(18:0/18:1/22:5)+LPI(16:0) +Cer(d18:1/24:1) +Leucine+Glucose+Inosine
|
Lipid
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
NA
|
Serum
|
30758971
|
1753
|
5-hmC (5-hydroxymethylcytosin)+ ERG negative
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: p=0.01; Multivariate: p=0.003
|
Tissue
|
30818754
|
1754
|
AZGP1; C0S; H3K18Ac; H3K4Me2; Ki67; p53; PML
|
Protein
|
Humans
|
NA
|
Prognostic
|
Biochemical Relapse Vs No Biochemical Relapse
|
AZGP1 p= 0.03; C0S: p=0.01; H3K18Ac: p=0.04; H3K4Me2: p=0.05; Ki67: p=0.02; p53: p=0.002; PML: p=0.03
|
Tissue
|
30288742
|
1755
|
AZGP1; Ki67; PML
|
Protein
|
Humans
|
NA
|
Prognostic
|
Metastatic Relapse Vs No Relapse
|
AZGP1: p=0.002; Ki67: p=0.04; PML:p=0.04
|
Tissue
|
30288742
|
1756
|
AZGP1
|
Protein
|
Humans
|
NA
|
Prognostic
|
Prostate Cancer Specific Death Vs No Death
|
p=0.002
|
Tissue
|
30288742
|
1757
|
AZGP1+Ki67
|
Protein
|
Humans
|
NA
|
Prognostic
|
Metastatic Relapse Vs No Relapse
|
Discovery: Univariate: p=0.03; Multivariate: p=0.04
|
Tissue
|
30288742
|
1758
|
AZGP1+Ki67
|
Protein
|
Humans
|
NA
|
Prognostic
|
Prostate Cancer Specific Death Vs No Death
|
Discovery: Univariate: p=0.005; Multivariate: p=0.03;Validation: Univariate: p=0.05
|
Tissue
|
30288742
|
1761
|
CGA (chromogranin A)
|
Protein
|
Humans
|
NA
|
Prognostic
|
Progression Free Survival Vs No Progression Free Survival
|
p=0.0416
|
Serum
|
30286478
|
1767
|
miR-1825
|
miRNA
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Stage T1-T2 Vs Stage T3-T4
|
p<0.05
|
Serum
|
30324582
|
1768
|
let-7b
|
miRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Stage T1-T2 Vs Stage T3-T4
|
p<0.05
|
Serum
|
30324582
|
1769
|
miR-205
|
miRNA
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Bone Metastasis Vs No Bone Metastasis
|
p<0.05
|
Serum
|
30324582
|
1822
|
BUB1
|
mRNA
|
Humans
|
Methylated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1823
|
TPX2
|
mRNA
|
Humans
|
Methylated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1824
|
NCAPG
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1825
|
UBE2C
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1826
|
MELK
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1827
|
CCNA2
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1828
|
CCNB1
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1829
|
CDK1
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1830
|
E2F2
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1831
|
DLGAP5
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1832
|
TMEM206
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1833
|
CDKN3
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1834
|
SHMT2
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1835
|
SRD5A2
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1836
|
CSRP1
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1837
|
PGM5
|
mRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1838
|
NFIB
|
mRNA
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p<0.05
|
Tissue
|
30616540
|
1842
|
MT1IP (Metallothionein 1I, pseudogene (MT1IP), transcript variant 1); TRPT1 (tRNA phosphotransferase 1 (TRPT1), transcript variant 6); CHFR (Checkpoint with forkhead and ring finger domains, E3 ubiquitin protein ligase (CHFR), transcript variant 2); ZNF830 (Zinc finger protein 830); REXO1L2P (RNA exonuclease one homolog (S. cerevisiae)-like 2); SLC25A21 (SLC25A21 antisense RNA 1);
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Tumor Stage T1C Vs T2
|
p<0.05
|
Tissue
|
30890858
|
1843
|
FXR2 (Fragile X mental retardation, autosomal homolog 2); GADD45GIP1 (Growth arrest and DNA-damage-inducible, gamma interacting protein 1); STX4 (Syntaxin 4, transcript variant 1); CALCOCO2 (Calcium binding and coiled-coil domain 2, transcript variant 1); BEST4 (Bestrophin 4); URI1 (Prefoldin-like chaperone, transcript variant 3); DCP2 (Decapping mRNA 2, transcript variant 3);
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Tumor Stage T2 Vs T2a
|
p<0.05
|
Tissue
|
30890858
|
1844
|
RASSF4 (Ras association (RalGDS/AF-6) domain family member 4); SIRPA (Signal-regulatory protein alpha (SIRPA), transcript variant 3); COMP (Cartilage oligomeric matrix protein); SOD3 (Superoxide dismutase 3, extracellular); DIDO1 (Death inducer-obliterator 1, transcript variant 3); PRELP (Proline/arginine-rich end leucine-rich repeat protein, transcript variant 1);
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Tumor Stage T2a Vs T2b
|
p<0.05
|
Tissue
|
30890858
|
1845
|
BGN (Homo sapiens biglycan); RASSF4 (Ras association (RalGDS/AF-6) domain family member 4); USP21 (Ubiquitin-specific peptidase 21, transcript variant 3); NR1D1 (Nuclear receptor subfamily 1 group D, member 1); ANGPTL2 (Angiopoietin-like 2);
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Tumor Stage T2b Vs T2c
|
p<0.05
|
Tissue
|
30890858
|
1846
|
SMAP2 (Small ArfGAP2 (SMAP2), transcript variant 2); TMSA (Prothymosin, alpha (PTMA), transcript variant 1); YY1AP1 (YY1 associated protein 1 (YY1AP1), transcript variant 6); DOCK9 (Dedicator of cytokinesis 9 (DOCK9), transcript variant 2); KITLG (KIT ligand (KITLG), transcript variant b);
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Tumor Stage T2c Vs T3a
|
p<0.05
|
Tissue
|
30890858
|
1847
|
FAM133DP (Family with sequence similarity 133 member D pseudogene); SAMM50 (Sorting and assembly machinery component 50 homolog, protein coding); OR4F13P (Olfactory receptor family 4 subfamily F member 13 pseudogene);
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Tumor Stage T3a Vs T3b
|
p<0.05
|
Tissue
|
30890858
|
1848
|
IKZF3 (IKAROS family zinc finger 3 (Aiolos), transcript variant 12); USP13 (Ubiquitin-specific peptidase 13 (isopeptidase T-3)); CLASP1 (Cytoplasmic linker associated protein 1, transcript variant 3); CEP112 (Centrosomal protein 112kDa, transcript variant 3); TSEN15 (tRNA splicing endonuclease subunit, transcript variant 1); FLVCR2 (Feline leukemia virus subgroup C cellular receptor family, member 2,transcript variant 2); GOLGA8B (Golgin A8 family, member B, transcript variant 1); ZNF438 (Zinc finger protein 438, transcript variant 1); SCARNA22 (Small Cajal body-specific RNA 22); LPPR1 (Lipid phosphate phosphatase-related protein type 1, transcript variant 2); PTGFR (Prostaglandin F receptor (FP), transcript variant 1); NREP (Neuronal regeneration related protein, transcript variant 1);
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Tumor Stage T2c Vs T3/4
|
p<0.05
|
Tissue
|
30890858
|
1854
|
miR-424
|
miRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p=0.043
|
Tissue
|
30345533
|
1855
|
miR-572
|
miRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p= 0.031
|
Tissue
|
30345533
|
1856
|
miR-572+ miR-424
|
miRNA
|
Humans
|
Upregulated in PC3 and DU145
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p= 0.031
|
Tissue
|
30345533
|
1857
|
miR-572+ miR-424+ miR-1 + miR133b
|
miRNA
|
Humans
|
Downregulated in Recurrent PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p= 0.031
|
Tissue
|
30345533
|
1865
|
Methlyation Status of APC
|
Methylation
|
Humans
|
Methylated in PCa
|
Prognostic
|
Gleason Grade 1 Vs Gleason Grade 2-5
|
p<0.01
|
Tissue
|
30373654
|
1866
|
Methlyation Status of GSTP1
|
Methylation
|
Humans
|
Methylated in PCa
|
Prognostic
|
Gleason Grade 1 Vs Gleason Grade 2-5
|
p<0.01
|
Tissue
|
30373654
|
1867
|
Methlyation Status of RARβ2
|
Methylation
|
Humans
|
Methylated in PCa
|
Prognostic
|
Gleason Grade 1 Vs Gleason Grade 2-5
|
p<0.01
|
Tissue
|
30373654
|
1868
|
Methlyation Status of miR-34b/c
|
Methylation
|
Humans
|
Methylated in Gleason Grade 2-5
|
Prognostic
|
Gleason Grade 1 Vs Gleason Grade 2-5
|
p<0.01
|
Tissue
|
30373654
|
1869
|
Methlyation Status of APC
|
Methylation
|
Humans
|
Methylated in Gleason Grade 2-5
|
Prognostic
|
Low & Intermediate Risk Vs High Risk
|
p<0.01
|
Tissue
|
30373654
|
1870
|
Methlyation Status of APC
|
Methylation
|
Humans
|
Methylated in Gleason Grade 2-5
|
Prognostic
|
Low & Intermediate Risk Vs High Risk
|
p<0.05
|
Tissue
|
30373654
|
1871
|
Promoter methylation of: miR-193b+ miR-34b/c
|
Methylation
|
Humans
|
Methylated in Gleason Grade 2-5
|
Prognostic
|
Prostate Cancer Specific Survival Vs No Survival
|
p=0.017
|
Tissue
|
30373654
|
1872
|
Methlyation Status of APC
|
Methylation
|
Humans
|
Methylated in High Risk
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p=0.044
|
Tissue
|
30373654
|
1873
|
Promoter methylation of: GSTP1
|
Methylation
|
Humans
|
Methylated in High Risk
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p=0.017
|
Tissue
|
30373654
|
1874
|
Methlyation Status of miR-34b/c
|
Methylation
|
Humans
|
Methylated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p=0.017
|
Tissue
|
30373654
|
1876
|
PD-L2 (Programmed death ligand 2)
|
mRNA
|
Humans
|
Methylated in PCa
|
Prognostic
|
Biochemical Recurrence Free Survival Vs No Biochemical Recurrence Free Survival
|
p=0.01
|
Tissue
|
30321406
|
1877
|
PD-L2 (Programmed death ligand 2)
|
mRNA
|
Humans
|
Methylated in PCa
|
Prognostic
|
Distant Metastatic Free Survival Vs No DMFS Survival
|
p=0.01
|
Tissue
|
30321406
|
1878
|
PD-L2 (Programmed death ligand 2)
|
mRNA
|
Humans
|
Upregulated in PCa: []; Downregulated in PCa: []
|
Prognostic
|
Prostate Cancer Specific Survival Vs No PCSS Survival
|
p<0.001
|
Tissue
|
30321406
|
1879
|
Testosterone
|
Protein
|
Humans
|
Decreased in Biochemical Recurrence Free Survival
|
Prognostic
|
Progression Free Survival Vs No Progression Free Survival
|
p=0.037
|
Serum
|
30446464
|
1880
|
Testosterone
|
Protein
|
Humans
|
Decreased in Biochemical Recurrence Free Survival
|
Prognostic
|
Progression Free Survival Vs No Progression Free Survival
|
p=0.0028
|
Serum
|
30446464
|
1881
|
Testosterone
|
Protein
|
Humans
|
Decreased in Biochemical Recurrence Free Survival
|
Prognostic
|
Overall Survival Vs No Overall Survival
|
p=0.043
|
Serum
|
30446464
|
1894
|
ASAP1
|
DNA (Copy Number variations)
|
Humans
|
NA
|
Prognostic
|
Gleason Grade 4 in Gleason Score 7
|
p<0.01
|
Tissue
|
30611450
|
1895
|
HDAC9
|
DNA (Copy Number variations)
|
Humans
|
NA
|
Prognostic
|
Gleason Grade 4 in Gleason Score 7
|
p<0.01
|
Tissue
|
30611450
|
1896
|
CHD1
|
DNA (Copy Number variations)
|
Humans
|
NA
|
Prognostic
|
Gleason Grade 4 in Gleason Score 7
|
p<0.01
|
Tissue
|
30611450
|
1897
|
RB1
|
DNA (Copy Number variations)
|
Humans
|
Upregulated in Agressive PCa
|
Prognostic
|
Gleason Grade 4 in Gleason Score 7
|
p<0.01
|
Tissue
|
30611450
|
1898
|
PTEN
|
DNA (Copy Number variations)
|
Humans
|
Upregulated in Agressive PCa
|
Prognostic
|
Gleason Grade 4 in Gleason Score 7
|
p<0.01
|
Tissue
|
30611450
|
1899
|
MYC
|
DNA (Copy Number variations)
|
Humans
|
Upregulated in Agressive PCa
|
Prognostic
|
Gleason Grade 4 in Gleason Score 7
|
p<0.01
|
Tissue
|
30611450
|
1900
|
ASAP1
|
DNA (Copy Number variations)
|
Humans
|
Upregulated in Agressive PCa
|
Prognostic
|
GP3 in GS7 Vs GP3 in GS6
|
p<0.01
|
Tissue
|
30611450
|
1901
|
HDAC9
|
DNA (Copy Number variations)
|
Humans
|
Upregulated in Agressive PCa
|
Prognostic
|
GP3 in GS7 Vs GP3 in GS6
|
p<0.01
|
Tissue
|
30611450
|
1902
|
CHD1
|
DNA (Copy Number variations)
|
Humans
|
Upregulated in Agressive PCa
|
Prognostic
|
GP3 in GS7 Vs GP3 in GS6
|
p<0.01
|
Tissue
|
30611450
|
1903
|
RB1
|
DNA (Copy Number variations)
|
Humans
|
Upregulated in Agressive PCa
|
Prognostic
|
GP3 in GS7 Vs GP3 in GS6
|
p<0.01
|
Tissue
|
30611450
|
1904
|
PTEN
|
DNA (Copy Number variations)
|
Humans
|
Upregulated in Agressive PCa
|
Prognostic
|
GP3 in GS7 Vs GP3 in GS6
|
p<0.01
|
Tissue
|
30611450
|
1905
|
MYC
|
DNA (Copy Number variations)
|
Humans
|
Upregulated in Agressive PCa
|
Prognostic
|
GP3 in GS7 Vs GP3 in GS6
|
p<0.01
|
Tissue
|
30611450
|
1906
|
AFP; AKR1C1; AKR1C3; AKR1C4; C1orf229; C5orf28; C5orf34; CCNE1; DNMT1; E2F3; ENSA; FBXO4; G6PD; KPNA2; LETM2; LGSN; MRPS30; OPLAH; OR4K15; OR4L1; PAIP1; SKP1; SPEF2; WDR70; ZNF124; ZNF280A; ZNF324B; ZNF669; ZNF695;
|
mRNA
|
Humans
|
Upregulated in Agressive PCa
|
Prognostic
|
Primary Prostate Cancer Vs Metastatic Prostate Cancer
|
p<0.05
|
Tissue
|
30401717
|
1907
|
ANO7; NSA2; BOK; PDE8B; CECR6; PER3; CNNM1; PPP1R7; CNTNAP3; SCAMP1; COX15; SEMA4G; DMGDH; SLC7A8; DUSP1; TMEM18; EPHA7; TRIM8; FAM20C; TSLP; FOXC1; WDR41; ZNF658; GABRG3; GLB1L3; GLOD4; KCNMB1; LOC100128239; LOXL4; MTERFD2; NCAM1; NDN;
|
mRNA
|
Humans
|
Upregulated in Agressive PCa
|
Prognostic
|
Primary Prostate Cancer Vs Metastatic Prostate Cancer
|
p<0.05
|
Tissue
|
30401717
|
1908
|
ADAM12; AURKA; AURKB; C7orf49; CDCA8; CENPF; CIT; DNMT3B; DYRK2; FANCD2; FGD1; GDAP1; GPI; GTSE1; HNRNPUL1; IPO9; KIF23; LIG1; NCAPH; NHSL1; PEG10; SKP2; TMEM65; TOP2A; TPX2; UBE2T;
|
mRNA
|
Humans
|
Upregulated in Agressive PCa
|
Prognostic
|
Primary Prostate Cancer Vs Metastatic Prostate Cancer
|
p<0.05
|
Tissue
|
30401717
|
1909
|
ALDH1A3; APH1B; ATAD1; CTBS; CTSO; DHRS7; ESR1; FOXC1; MEIS2; NR4A1; PDE8B; RPS27L; SEC62; SPCS3; ZMAT1;
|
mRNA
|
Humans
|
Upregulated in Metastatic PCa
|
Prognostic
|
Primary Prostate Cancer Vs Metastatic Prostate Cancer
|
p<0.05
|
Tissue
|
30401717
|
1911
|
HSP27
|
Protein
|
Humans
|
Upregulated in Metastatic PCa
|
Prognostic
|
Survival Vs No Survival
|
p=0.007
|
Tissue
|
30396985
|
1912
|
Prohibitin
|
Protein
|
Humans
|
Upregulated in Metastatic PCa
|
Prognostic
|
Survival Vs No Survival
|
p<0.001
|
Tissue
|
30396985
|
1913
|
ALDH6A1
|
Protein
|
Humans
|
Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);]
|
Prognostic
|
Survival Vs No Survival
|
p<0.001
|
Tissue
|
30396985
|
1914
|
Prohibitin+ HSP27+ALDH6A1
|
Protein
|
Humans
|
Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);]Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);]
|
Prognostic
|
Survival Vs No Survival
|
NA
|
Tissue
|
30396985
|
1915
|
Prohibitin+ HSP27
|
Protein
|
Humans
|
Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);] Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);]
|
Prognostic
|
Survival Vs No Survival
|
NA
|
Tissue
|
30396985
|
1916
|
Prohibitin+ALDH6A1
|
Protein
|
Humans
|
Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);]
|
Prognostic
|
Survival Vs No Survival
|
NA
|
Tissue
|
30396985
|
1918
|
CAV1; MAGEA11; CALM1; CALR; TP53; FHL2; EGFR; APP; JUN; SMAD3; SMAD2; ESR1; RB1; HIPK3; BRCA1; SMAD1; GNB2L1; XRCC6; UBE2I; HDAC1; CDC2; AES; STAT3; IL6ST; APPBP2; PCAF; REPS2; FLNA; RAF1; MYC; MAPK1; TRAF6; CCND1; SMARCA4; HLA-B; TRAF2; RANBP9; PIAS4; GSK3B; TRIM29; FOS; IDE; SRC; PXN; SLC25A4; SP1; NR5A1 YWHAG; AKT1; CCNE1;
|
Protein
|
Humans
|
Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);]Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);]
|
Prognostic
|
Prostate Cancer Vs Lymph Node Metastasis
|
NA
|
Tissue
|
22654636
|
1931
|
let-7a*
|
miRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Disseminated PCa VS Localised PCa
|
p=0.012
|
Serum
|
25786615
|
1932
|
miR-200b*
|
miRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Disseminated PCa VS Localised PCa
|
p=0.028
|
Serum
|
25786615
|
1933
|
miR-210
|
miRNA
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Disseminated PCa VS Localised PCa
|
p=0.01
|
Serum
|
25786615
|
1934
|
miR-297
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Prognostic
|
Disseminated PCa VS Localised PCa
|
p=0.038
|
Serum
|
25786615
|
1935
|
miR-375
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Prognostic
|
Disseminated PCa VS Localised PCa
|
p=0.014
|
Serum
|
25786615
|
1936
|
miR-501-3p
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Prognostic
|
Disseminated PCa VS Localised PCa
|
p=0.028
|
Serum
|
25786615
|
1937
|
miR-562
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Prognostic
|
Disseminated PCa VS Localised PCa
|
p=0.03
|
Serum
|
25786615
|
1938
|
miR-616
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Prognostic
|
Disseminated PCa VS Localised PCa
|
p=0.05
|
Serum
|
25786615
|
1939
|
let-7a*+ miR-210
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Prognostic
|
Disseminated PCa VS Localised PCa
|
NA
|
Serum
|
25786615
|
1940
|
let-7a*+ miR-210+ miR-562
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Prognostic
|
Disseminated PCa VS Localised PCa
|
NA
|
Serum
|
25786615
|
1941
|
let-7a*+ miR-210+ miR-562+ miR-616
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Prognostic
|
Disseminated PCa VS Localised PCa
|
NA
|
Serum
|
25786615
|
1942
|
let-7a*+ miR-210+ miR-562+ miR-616+ miR-297
|
miRNA
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Prognostic
|
Disseminated PCa VS Localised PCa
|
NA
|
Serum
|
25786615
|
1968
|
Methylation status of ACTL6B
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1969
|
Methylation status of AEBP1
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0021
|
Tissue
|
22589488
|
1970
|
Methylation status of AMID
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1971
|
Methylation status of CD8A
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1972
|
Methylation status of CRIP1
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0037
|
Tissue
|
22589488
|
1973
|
Methylation status of FLJ30934
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1974
|
Methylation status of FLNC
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1975
|
Methylation status of FMOD
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1976
|
Methylation status of FOXE3
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1977
|
Methylation status of GAS7
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1978
|
Methylation status of GDPD5
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1979
|
Methylation status of HS3ST2
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1980
|
Methylation status of LOC349136
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1981
|
Methylation status of NEUROG1
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1982
|
Methylation status of PLTP
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1983
|
Methylation status of PTGER2
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1984
|
Methylation status of RASGRF2
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1985
|
Methylation status of RUNX3
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1986
|
Methylation status of SIX6
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1987
|
Methylation status of SLC9A3
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1988
|
Methylation status of SPSB4
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0008
|
Tissue
|
22589488
|
1989
|
Methylation status of SRD5A2
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1990
|
Methylation status of SUSD3
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0014
|
Tissue
|
22589488
|
1991
|
Methylation status of SYT10
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
1992
|
Methylation status of TMEM74
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0005
|
Tissue
|
22589488
|
1993
|
Methylation status of CHST7
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Clinical recurrence vs. biochemical recurrence
|
<0.0050
|
Tissue
|
22589488
|
1994
|
Methylation status of LMX1B
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Clinical recurrence vs. biochemical recurrence
|
<0.0021
|
Tissue
|
22589488
|
1995
|
Methylation status of PHLDA 3
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Clinical recurrence vs. biochemical recurrence
|
<0.0772
|
Tissue
|
22589488
|
1996
|
Methylation status of RAFTLIN
|
Methylation
|
Humans
|
Differentially Methylated in Clinical recurrence
|
Prognostic
|
Clinical recurrence vs. biochemical recurrence
|
<0.0050
|
Tissue
|
22589488
|
1997
|
Methylation status of RASGRF2
|
Methylation
|
Humans
|
Differentially Methylated in Clinical recurrence
|
Prognostic
|
Clinical recurrence vs. biochemical recurrence
|
<0.0015
|
Tissue
|
22589488
|
1998
|
Methylation status of TNFRSF10D
|
Methylation
|
Humans
|
Differentially Methylated in Clinical recurrence
|
Prognostic
|
Clinical recurrence vs. biochemical recurrence
|
<0.0008
|
Tissue
|
22589488
|
1999
|
Methylation status of ZNF135
|
Methylation
|
Humans
|
Differentially Methylated in Clinical recurrence
|
Prognostic
|
Clinical recurrence vs. biochemical recurrence
|
<0.0061
|
Tissue
|
22589488
|
2000
|
Methylation status of ALPL
|
Methylation
|
Humans
|
Differentially Methylated in Clinical recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0182
|
Tissue
|
22589488
|
2001
|
Methylation status of AMPH
|
Methylation
|
Humans
|
Differentially Methylated in Clinical recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0021
|
Tissue
|
22589488
|
2002
|
Methylation status of BCDIN3
|
Methylation
|
Humans
|
Differentially Methylated in Clinical recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2003
|
Methylation status of BCL11B
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2004
|
Methylation status of BRD4
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0038
|
Tissue
|
22589488
|
2005
|
Methylation status of C18orf34
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2006
|
Methylation status of DCAMKL1
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2007
|
Methylation status of FGF5
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2008
|
Methylation status of FLJ42486
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2009
|
Methylation status of JAM2
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2010
|
Methylation status of LHX9
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2011
|
Methylation status of LOC283537
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2012
|
Methylation status of LRAT
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0034
|
Tissue
|
22589488
|
2013
|
Methylation status of PDE4B
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2014
|
Methylation status of POU3F3
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2015
|
Methylation status of PTGS2
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0153
|
Tissue
|
22589488
|
2016
|
Methylation status of RASGRF2
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0002
|
Tissue
|
22589488
|
2017
|
Methylation status of SLC27A6
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0017
|
Tissue
|
22589488
|
2018
|
Methylation status of SLC03A1
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2019
|
Methylation status of SPSB4
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2020
|
Methylation status of STAT3
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0017
|
Tissue
|
22589488
|
2021
|
Methylation status of SYN2
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
2022
|
Methylation status of TACR3
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0086
|
Tissue
|
22589488
|
2023
|
Methylation status of TIRAP
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0003
|
Tissue
|
22589488
|
2024
|
Methylation status of WNT11
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0011
|
Tissue
|
22589488
|